CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR
The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.
Latest CHONG KUN DANG PHARMACEUTICAL CORP. Patents:
- 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
- Composition for preventing or treating gastritis or peptic ulcer
- Stable pharmaceutical composition comprising testosterone undecanoate
- Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
- Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
This application is a national stage filing under section 371 of International Application No. PCT/KR2012/002739 filed Apr. 12, 2012 and published as WO 2012/141487, and claims priority to Korean Patent Application No. 10-2011-0033943 filed on Apr. 12, 2011, the entire disclosure of these applications being hereby incorporated herein by reference.
TECHNICAL FIELDThe present invention relates to novel cycloalkenyl aryl derivatives, and more particularly to novel cycloalkenyl aryl derivatives having CETP inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, the use thereof for preparing pharmaceutical compositions, pharmaceutical compositions containing the same, methods of treating disease using these compositions, and methods for preparing novel cycloalkenyl aryl derivatives.
BACKGROUND ARTHyperlipidemia refers to high blood cholesterol levels and is asymptomatic. However, hyperlipidemia is a very significant condition, because it causes angina pectoris, myocardial infarction and arteriosclerosis. Statins, drugs that are commonly used to treat hyperlipidemia, exhibit therapeutic effects mainly by lowering LDL-C, but their effects on the prevention of cardiovascular diseases are still very insufficient. A recent study reported that elevated concentration of high-density lipoprotein (HDL-C) is very effective in preventing cardiovascular diseases as effective as lower low-density lipoprotein cholesterol (LDL-C) (Goldbourt et al, 1997, 17, 107-113). Among drugs that are used to increase HDL-C, the most effective drug is Niacin. However, this drug needs to be taken in relatively large doses and causes side effects such as facial flushing (Taylor et al, Circulation, 2004, 110, 3512-3517).
Meanwhile, cholesterol ester transfer protein (CETP) is a protein that participates in reverse cholesterol transport (the reverse transport of cholesterol from peripheral tissue to the liver). When CETP is inhibited, HDL-C can be effectively increased, thus preventing cardiovascular diseases. Accordingly, the development of compounds capable of inhibiting CETP activity is very important (Barter et al., Arterioscler Thromb Vasc Biol, 2003, 23, 160-167).
CETP inhibitors known to date can be divided according to structure into Torcetrapib (WO 02/088085) and Anacetrapib (WO 2006/014357), which are 3,5-bis-trifluoromethyl-benzene derivatives, and Dalcetrapib (WO 98/35937) which is a benzenethiol derivative.
However, among these CETP inhibitors, Torcetrapib causes a increases in blood pressure and an increase in mortality, and thus clinical trials thereof were terminated. It was reported that such side effects occur because Torcetrapib increases the levels of hormones, such as aldosterone and cortisol, associated with a significant elevation in blood pressure, and increases the thickness of the vascular wall to cause inflammation, thus increasing mortality (Forrest et al, British Journal of Pharmacology, 2008, 1-9). The other CETP inhibitor Dalcetrapib has not been reported to cause such side effects, but is known to have insufficient rise in HDL-C (Hisashi Shinkai Expert Opinion on Therapeutic Patents, 2009, 19(9), 112-1237). Among such CETP inhibitors, Anacetrapib and Dalcetrapib are in clinical trials for the purpose of treating hyperlipidemia and cardiovascular diseases by increasing HDL-C and decreasing LDL-C (Niesor et al, Journal of lipid Research, 2010, 51, 3443-3453).
DISCLOSURE Technical ProblemIt is an object of the present invention to provide novel cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, and preparation methods thereof.
Another object of the present invention is to provide novel cycloalkenyl aryl derivatives, which have less side effects and can effectively inhibit CETP, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, and preparation methods thereof.
Still another object of the present invention is to provide methods for preparing novel cycloalkenyl aryl derivatives.
Technical SolutionTo achieve the above objects, the present invention provides cycloalkenyl aryl derivatives of the following formula 1, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, and preparation methods thereof:
wherein B1 and B2 are each independently N or C, with the proviso that both B1 and B2 cannot be N at the same time, and if one of B1 and B2 is N, R2 or R5 is absent;
R1 and R2 are each independently H, —F, —OH, —NH2, —C(═O)H, —CH2OH, —OC1-C6 alkyl, —SC1-C6 alkyl, —CH2OC1-C6 alkyl, —NH(C1-C6 alkyl), —NH(C═O)(C1-C6 alkyl), —N(C1-C6 alkyl)2, or
or
R1 and R2 together with the carbon atoms to which they are bonded may form a 5- or 6-membered heterocyclic aromatic or non-aromatic ring compound having 1 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(═O), wherein the heterocyclic aromatic or non-aromatic ring compound may optionally be substituted with R8;
R3 is —H, —F, —OH, —C1-C6 alkyl, or —OC1-C6 alkyl;
R4 is —H, halogen, —CN, —NO2, —C1-C6 alkyl, —C2-C6 alkenyl, —C3-C6 cycloalkyl.
—OR7, —CH2OR7, —CH2NR7R8, —SR7, —C(═O)R7, —CO2R7, —CHR7CO2R8, —C(═O)NR7R8,
R3 and R4 together with the carbon atoms to which they are bonded may form a 5- or 6-membered cycloalkyl or heterocyclic ring compound having 0 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(═O), wherein the cycloalkyl or heterocyclic ring compound may optionally be substituted with R8;
Ar is a C6 monocyclic aromatic compound, which is unsubstituted or optionally substituted with one or more selected from the group consisting of halogen, —OH, —NH2, —C1-C6 alkyl and —OC1-C6 alkyl; Het is a 5- or 6-membered heterocyclic ring compound containing 0 to 2 double bonds and having 1 to 4 hetero atoms selected independently from the group consisting of N, O, S, C(═O) and C(═S), and may be unsubstituted or may optionally be substituted with R8;
R5 is —H, —F, —OH, —CF3, —C1-C6alkyl, or —OC1-C6 alkyl;
R6 is —H or —C1-C6 alkyl;
R7 is —H, halogen, —C(═O)(C1-C3 alkyl), —C1-C6 alkyl, —OC1-C6 alkyl, —C3-C6 cycloalkyl, or —OC(═O)(C1-C3 alkyl);
R8 is —H, halogen, —OH, —CN, —NH2, —NH(C1-C3 alkyl), —C(═O)NH2, —CO2H,
—C1-C6 alkyl, —OC1-C6 alkyl, —C3-C6 cycloalkyl, -Ph or
R9 is —H, —CN, —C1-C6 alkyl, —OC1-C6 alkyl, or —C(═O)(C1-C3 alkyl);
R10 is —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, or —S(C1-C3 alkyl);
p is an integer ranging from 0 to 2;
A1 and A2 are each independently —O—, —(CR11R12)— or —NR13, wherein R11 and R12 are each independently —H, —F, or —C1-C6 alkyl, or R11 and R12 together form a 3- or 4-membered spirocyclic non-aromatic ring compound, and R13 is —H, —C1-C6 alkyl, —C(═O)(C1-C6 alkyl), —CO2 (C1-C6 alkyl), —SO2 (C1-C6 alkyl), or —C3-C6 cycloalkyl;
A3 is —(CH2)n—;
m is an integer ranging from 0 to 3;
n is an integer ranging from 0 to 2;
q is an integer ranging from 1 to 3;
wherein said —C1-C3 alkyl, —C3-C6 cycloalkyl —C1-C6 alkyl or —C2-C6 alkenyl is unsubstituted or substituted with one or more selected from the group consisting of halogen, —OH, —CF3, —CN, —CO2H, —C(═O)CH3, —OC(═O)CH3, —C1-C3alkyl, —OC1-C3alkyl, and -Ph.
Preferrably, the present invention provides cycloalkenyl aryl derivatives according to the above definition, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof:
wherein B1 and B2 are each independently N or C, with the proviso that both B1 and B2 cannot be N at the same time, and if any one of B1 and B2 is N, R2 or R5 is absent;
R1 is —F, —OH, —NH2, —C(═O)H, —CH2OH, —OCH3, —OCF3, —SCH3, —CH2OCH3, —NHCH3,
R1 and R2 together with the carbon atoms to which they are bonded may form a 5- or 6-membered heterocyclic aromatic or non-aromatic ring compound having 1 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(═O), wherein the heterocyclic aromatic or non-aromatic ring compound may optionally be substituted with R8;
R3 is —H, —F, —OH, —CH3, —CF3, —CH2CH3, or —OCH3;R4 is —H, —F, —Cl, —CN, —NO2, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CF3, —CH(CF3)29—CH(CH3)(CF3), —C(OCH3)(CF3)2, —CH(OH)CH3, —C(OH)(CH3)2, —C(OH)(CF3)2, —C(═CF2)CF3, -cyclopropyl,
—OCH3, —OCH2CH3, —OCH(CH3)2, —OC(CH3)3, —OCF3, —OCH2CF3, —CH2OH, —CH2OCH3, —CH2NR7R8, —SCH3, —C(═O)R7, —CO2R7, —CHR7CO2R8, —C(═O)NR7R8,
R3 and R4 together with the carbon atoms to which they are bonded may form a 5- or 6-membered cycloalkyl or heterocyclic ring compound having 0 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(═O), wherein the cycloalkyl or heterocyclic ring compound may optionally be substituted with R8;
Ar is a C6 monocyclic aromatic compound, which is unsubstituted or optionally substituted with one or more selected from the group consisting of —F, —Cl, —OH, —NH2, —CH3 and —OCH3;
Het is selected from
R7 is —H, halogen, —C(═O)(C1-C3 alkyl), —C1-C6 alkyl, —OC1-C6 alkyl, —C3-C6 cycloalkyl, or —OC(═O)(C1-C3 alkyl);
R8 is —H, halogen, —OH, —CN, —NH2, —NH(C1-C3 alkyl), —C(═O)NH2, —CO2H,
—C1-C6 alkyl, —OC1-C6 alkyl, —C3-C6 cycloalkyl, -Ph or
R9 is —H, —CN, —C1-C6 alkyl, —OC1-C6 alkyl, or —C(═O)(C1-C3 alkyl);
R10 is —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, or —S(C1-C3 alkyl);
p is 2;
A1 is —CH2—, —C(CH3)2—, or —NR13;A2 is —O—, —(CR11R12), or —NR13, wherein R11 and R12 are each independently —H, —F, —CH3, —CF3, —CH2CH3, —CH(CH3)2, or —C(CH3)3; or R11 and R12 together form a 3- or 4-membered spirocyclic non-aromatic ring compound, and R13 is —H, —CH3, —CF3, —CH2CH3, —CH(CH3)2, —CH2CF3, —C(═O)CH3, —C(═O)CF3, —CO2C(CH3)3, —SO2CH3, —SO2CF3, or
A3 is —(CH2)n—;
X is S or O;m is an integer ranging from 0 to 3;
n is an integer ranging from 0 to 2;
q is an integer ranging from 1 to 3;
wherein said —C1-C3 alkyl, —C3-C6 cycloalkyl, —C1-C6 alkyl or —C2-C6 alkenyl is unsubstituted or substituted with one or more selected from the group consisting of —F, —Cl, —Br, —OH, —CF3, —CN, —CO2H, —C(═O)CH3, —OC(═O)CH3, —C1-C3 alkyl, —OC1-C3 alkyl, and -Ph.
Specific examples of preferred compounds of formula 1 according to the present invention include:
Specific examples of more preferred compounds of formula 1 according to the present invetnion include:
The compounds of formula I according to the present invention can be prepared according to the methods described in various literatures (WO 2006/014357 A1). Methods for preparing the compounds of formula I will now be described in detail with reference to reaction schemes.
wherein A1, A2, A3, B1, B2, R1, R2, R3, R4, R5, R6, Ra, p and X are as defined above; Y is a leaving group, preferably a halide group (e.g., chloride or bromide); and Q may represent —B(OH)2 or
As shown in reaction scheme 1 above, the starting material compound II is allowed to react with phosphorus tribromide (PBr3) or phosphorus oxychloride (POCl3) in dimethylformamide (DMF), which is a Vilsmeier reaction, so as to introduce halogen into compound II.
In the reaction for preparing compound II, methylene chloride may be used as a solvent, and the reaction temperature is 0˜70° C., and preferably 0˜45° C.
Compound V can be prepared by subjecting compound 111 and compound IV to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093) or an Ullmann reaction (Martin G. Banwell et al. Org. Lett. 2004, 6, 2741). In addition, compound IV used in the synthesis process can be prepared according to the method described in the literature (WO 2006/014357 A1, Erin F. DiMauro et al., J. Med. Chem. 2006, 49, 5671).
In the reaction for preparing compound V, dimethoxyethane (DME), dimethylsulfoxide (DMSO), water or the like is used as a solvent, and the reaction temperature is 80˜150° C., and preferably 80˜100° C. The resulting compounds V and III may be subjected to reductive amination with amino alcohol compound VI, prepared according to the method described in the literature (WO 2006/014357 A1, Jingjun Yin et al., J. Org. Chem. 2006, 840), thereby synthesizing compounds VII and VIII, respectively.
The resulting compounds VII and VIII can be converted to the desired compounds I and IX, respectively, by reaction with thiophosgen or triphosgen. In addition, the resulting compound IX may also be converted to the desired compound I by a Suzuki reaction with the compound IV.
As described above, the compounds of formula I are generally prepared according to the method shown in reaction scheme 1. In addition, compounds of examples of the present invention may also be prepared according to the following reaction schemes 2, 3, 4 and 5.
Reaction scheme 2 above shows a general process for preparing compounds 15, 16, 17, 18, 36, 41, 51, 56, 97, 115 and 117 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 2. As shown in reaction scheme 2, dimethylformamide (DMF) and phosphorus tribromide (PBr3) are added dropwise to the starting material dimethylcyclohexanone to obtain compound 2 which is then subjected to a Suzuki reaction with commercially available boronic acid derivatives in the presence of a palladium catalyst, thus synthesizing compound 3. The obtained compound 3 is converted to compound 5 by reaction with compound 4, prepared according to the method described in the literature (2006/014357 A1, Jingjun Yin et al., J. Org. Chem. 2006, 840). The obtained compound 5 can be converted into the desired compound 6 by reaction with thiophosgen or triphosgen.
Reaction scheme 3 above shows a general process for synthesizing compounds 57, 60, 61 and 79 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 3 above. The starting material compound 7 is allowed to react with compound 4, acetic acid and sodium cyanoborohydride to synthesize compound 8 which is then allowed to react with triphosgen, thereby preparing compound 9. The obtained compound 9 can be subjected to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093) with various boronic acids, thereby preparing desired compounds.
Reaction scheme 4 above shows a general process for synthesizing compounds 133 and 134 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 4 above. As shown in reaction scheme 4, the starting material compound 10 is allowed to react with iodine (I2) and silver sulfate to synthesize compound 11 which is then allowed to react with bis(pinacolato)diboron in the presence of a palladium catalyst, thus preparing compound 12. Compound 9 and boronic acid may be added dropwise to the obtained compound 12, and then subjected to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093), thereby preparing compound 133. The obtained compound 133 can be converted into compound 134 by hydrolysis with lithium hydroxide (LiOH).
Reaction scheme 5 above shows a general process for synthesizing compounds 110, 112, 128, 136, 137, 138, 141, 163 and 177 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 5 above. As shown in reaction scheme 5 above, the starting material boronic acid compound 13 is subjected to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093) with compound 2 to prepare compound 14 which is then nitrated with nitric acid, thus synthesizing compound 15. The obtained compound 15 may be subjected to the reactions shown in reaction scheme 2, thus synthesizing compound 16 and compound 52. The obtained compound 52 may be treated with a nickel metal to reduce the nitro group thereof, and then allowed to react with various acyl chloride or sulfonyl chloride compounds, thus preparing various compounds. The resulting compounds 110, 136 and 137 may be allowed to react with iodomethane, thus obtaining compounds 112, 128, 138, 141 and 177.
Reaction scheme 6 above shows a general process for synthesizing compounds 286 and 311 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 6 above. As shown in reaction scheme 6, the staring material 4-methoxyphenethyl bromide or 4-methoxybenzyl chloride is subjected to the reaction described in the paper (Akio Baba et al., Tetrahedron 2009, 65, 5462), thus synthesizing compound 19. The obtained compound 19 is allowed to react with iodine (I2) and silver sulfate to synthesize compound 20 which is then allowed to react with bis(pinacolato)diboron in the presence of a palladium catalyst, thus preparing compound 21. Compound 2 is added dropwise to the obtained compound 21, and then subjected to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093), thus synthesizing compound 22. The obtained compound 22 is subjected to the reactions shown in reaction scheme 2 (reductive amination and cyclization) to synthesize compounds 285 and 310 which are then hydrolyzed with lithium hydroxide (LiOH), thus preparing the desired compounds 286 and 311.
Reaction scheme 7 above shows a general process for synthesizing compounds 349 and 350 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 7 above. As shown in reaction scheme 7, key intermediate compound 29 can be synthesized in the following manner with reference to the literature (US 2010/0081673 A1). The starting material 6-hydroxynicotinic acid is allowed to react with bromine (Br2) to obtain compound 24 which is then esterified, thus synthesizing compound 25. The obtained compound 25 is allowed to be reacted with Meerwein's salt (U.S. Pat. No. 5,929,094 A1) to synthesize compound 26. The obtained compound 26 is reduced with diisobutylaluminum hydride (DIBAL-H) to obtain compound 27 which is then chlorinated with titanium chloride (TiCl4), thus synthesizing compound 28. The resulting compound 28 is reacted with the reagents described in the paper (Akio Baba et al., Tetrahedron 2009, 65, 5462), thus synthesizing key intermediate compound 29. Then, compound 29 are subjected to the reactions shown in reaction schemes 4 and 6, thereby preparing the desired compounds 349 and 350.
Reaction scheme 8 above shows a general process for synthesizing compound 366 of the present invention, and other compounds of the present invention can also be synthesized according to reaction scheme 8 above. As shown in reaction scheme 8, the starting material 2-bromo-3-pyridinol is reacted with iodine (I2) to synthesize compound 33 which is then methylated, thus synthesizing compound 34. The resulting compound 34 is subjected to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093) to synthesize compound 35 which is then reacted with intermediate compound 36, thus synthesizing compound 37. Then, various reactions (hydroxylation, oxidation (N-oxide)/reduction (DIBAL-H), and oxidation (Dess-Martin)) are carried out to obtain intermediate compound 41. Then, the reactions shown in reaction scheme 6 are carried out to obtain compound 43. Indium (In) and a saturated ammonium chloride aqueous solution are added dropwise to and reacted with compound 43, thus preparing compound 366.
The cycloalkenyl aryl derivatives of formula I may contain one or more asymmetric carbon atoms, and may thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers. Such isomers can be resolved using the methods of prior arts. For example, isomers of the cycloalkenyl aryl derivatives of formula I can be resolved by column chromatography or HPLC. Alternatively, any enantiomer of a compound of formula I can be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
Some of the compounds of the present invention are observed as mixtures of atropisomers (rotamers) in the NMR spectra. The individual atropisomers as well as mixtures thereof are encompassed with the compounds of the present invention.
The compounds of formula I according to the present invention can be in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. Preferred examples of acids which can be used to form pharmaceutically acceptable acid addition salts include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid.
Hereinafter, the present invention will be described in further detail with reference to examples, preparation examples and experimental examples. It is to be understood, however, that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Advantageous EffectsThe present invention can provide novel cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, and preparation methods thereof.
In addition, the present invention can provide novel cycloalkenyl aryl derivatives, which have less side effects and can effectively inhibit CETP, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, and preparation methods thereof.
BEST MODE ExamplesHereinafter, the present invention will be described in further detail with reference to examples. It is to be understood, however, that these examples are illustrative purposes only and are not construed to limit the scope of the present invention.
Compound 15 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thioneAs shown in reaction scheme 2, intermediate 5 was synthesized. Thiophosgene (5 mL) and triethylamine (66 μl, 0.44 mmol) was added dropwise to the obtained intermediate 5 (53 mg, 0.095 mmol), and then the reaction mixture was refluxed with stirring overnight at 100° C. After the completion of the reaction, the reaction mixture was diluted with methylene chloride (CH2Cl2), washed with saturated sodium hydrogen carbonate solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO2, 5% Hex/EA), thus obtaining Compound 15 (10 mg, 18%).
1H NMR (400 MHz, CDCl3); 1:1.5 atropisomer mixture; δ 7.77 (s, 1H), 7.65 (s, 2H), 6.98-6.95 (m, 1H), 6.72-6.62 (m, 2H), 5.63-5.60 (m, 1H), 4.50 (bd, 1H), 4.14-4.11 (m, 0.6H), 4.01-3.97 (m, 0.4H), 3.66 (s, 1H), 3.61 (s, 2H), 2.75-2.67 (m, 1H), 2.46-2.42 (bm, 1H), 2.18-2.16 (bm, 1H), 2.01-1.77 (m, 3H), 1.45-1.36 (m, 2H), 1.11-1.04 (m, 6H), 0.94-0.92 (m, 6H), 0.31 (d, 1.2H, J=6.6), 0.19 (d, 1.8H, J=6.6). MS (ESI) m/z 600 (M++H).
Compound 16 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thioneCompound 16 (21 mg, 39%) as yellow solid was obtained according to the same method as the synthesis of compound 15. 1H NMR (400 MHz, CDCl3); 1:1.7 atropisomer mixture; δ 7.77 (s, 1H), 7.65 (s, 2H), 7.15 (m, 1H), 6.89-6.71 (m, 3H), 5.62 (d, 1H, J=8.3), 4.52 (s, 0.5H), 4.48 (s, 0.5H), 4.16-3.97 (m, 1H), 3.70 (bd, 0.7H), 3.69-3.64 (bd, 3H), 3.58 (bd, 0.4H), 2.19-2.14 (bm, 1H), 2.01-1.76 (m, 3H), 1.42-1.34 (m, 2H), 0.93 (m, 6H), 0.34 (d, 1.1H, J=6.6), 0.21 (d, 1.9H, J=6.6).
Compound 17 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thioneCompound 17 (38 mg, 70%) as yellow solid was obtained according to the same method as the synthesis of compound 15.
1H NMR (400 MHz, CDCl3); 1:1.5 atropisomer mixture; δ 7.78 (s, 1H), 7.65 (s, 2H), 6.89-6.67 (m, 1H), 6.43 (m, 1H), 5.63 (d, 1H, J=8.4), 4.52-4.46 (m, 1H), 4.11-4.07 (m, 0.5H), 4.01-3.97 (m, 0.4H), 3.66 (bd, 0.6H), 3.65 (s, 1H), 3.59 (s, 2H), 3.56 (bd, 0.4H), 3.05-2.99 (m, 1H), 2.20-2.00 (bm, 1H), 1.91-1.77 (m, 2H), 1.42-1.37 (m, 2H), 1.12 (d, 3H, J=6.9), 1.08 (d, 1.5H, J=6.9), 1.02 (d, 1.3H, J=6.9), 0.93 (m, 6H), 0.34 (d, 1.2H, J=6.6), 0.24 (d, 1.8H, J=6.6). MS (ESI) m/z 618 (M++H).
Compound 18 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAs shown in reaction scheme 2, intermediate 5 was synthesized. The obtained intermediate 5 (43 mg, 0.083 mmol) was dissolved in methylene chloride (3 mL). Triphosgene (13 mg, 0.04 mmol) and diisopropylethylamine (0.09 mL, 0.49 mmol) were added dropwise to the obtained reaction mixture, and then stirred at room temperature for 1 hour. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 18 (36 mg, 80%) as colorless oil.
1H NMR (400 MHz, CDCl3); 1:1.5 atropisomer mixture; δ 7.74 (s, 1H), 7.62 (s, 2H), 7.14-7.09 (m, 1H), 6.89-6.71 (m, 3H), 5.50-5.46 (m, 1H), 3.92-3.79 (m, 2H), 3.66 (s, 1.3H), 3.63 (s, 1.8H), 3.48 (bd, 0.6H), 3.33 (bd, 0.4H), 2.20-2.00 (m, 1H), 2.00-1.81 (m, 3H), 1.41-1.35 (m, 2H), 0.94 (d, 3H, J=6), 0.91 (s, 3H), 0.31 (d, 1.2H, J=6.6), 0.19 (d, 1.8H, J=6.5). MS (ESI) m/z 542 (M++H).
Compound 19 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 19 (37 mg, 100%) as white solid was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1.2 atropisomer mixture; δ 7.75 (s, 1H), 7.62 (s, 2H), 6.68 (dd, 1H, J=8.7, 10.9), 6.42 (dd, 1H, J=12, 17), 5.50 (t, 1H, J=6.8), 3.91-3.77 (m, 2H), 3.62 (s, 1.4H), 3.59 (s, 1.7H), 3.44 (bd, 0.6H), 3.31 (bd, 0.4H), 3.09-2.97 (m, 1H), 2.39-2.34 (bm, 0.5H), 2.12-2.01 (bm, 1H), 1.95-1.90 (bm, 0.6H), 1.82-1.80 (m, 2H), 1.43-1.32 (m, 2H), 1.11-1.01 (m, 6H), 0.94 (s, 3H), 0.90 (d, 3H, J=6.6), 0.31 (d, 1.4H, J=6.5), 0.22 (d, 1.6H, J=6.5). MS (ESI) m/z 602.0 (M++H)
Compound 25 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 25 (33 mg, 87%) as white solid was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.83 (s, 1H), 7.71 (s, 2H), 6.79-6.73 (m, 1H), 6.55-6.47 (m, 1H), 5.62-5.56 (m, 1H), 3.98-3.85 (m, 2H), 3.70 (s, 1.4H), 3.67 (d, 1.6H, J=3.9), 3.59-3.35 (m, 1H), 3.13-3.07 (m, 1H), 2.25-2.02 (m, 2H), 1.82-1.71 (m, 3H), 1.35-1.28 (m, 1H), 1.19-1.09 (m, 6H), 1.04-1.02 (m, 3H), 0.39 (dd, 1.38H, J=1.7, 6.5), 0.34 (d, 0.79H, J=6.5), 0.30 (d, 0.82H, J=6.5).
Compound 26 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thioneCompound 26 (22 mg, 73%) as yellow solid was obtained according to the same method as the synthesis of compound 15.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.88 (s, 1H), 7.76 (s, 2H), 6.82-6.78 (m, 1H), 6.59-6.49 (m, 1H), 5.78-5.73 (m, 1H), 4.75-4.25 (m, 1H), 4.40-4.07 (m, 1H), 3.82 (d, 0.3H), 3.75 (s, 1.5H), 3.71-3.58 (m, 0.7H), 3.69 (d, 1.5H, J=4.1), 3.15-3.10 (m, 1H), 2.60-2.05 (bm, 3H), 1.85-1.77 (bm, 3H), 1.43-1.33 (m, 1H), 1.19-1.08 (m, 6H), 1.06 (d, 3H, J=4.4), 0.46 (m, 1.1H), 0.40 (d, 0.7H, J=6.6), 0.34 (d, 0.8H, J=6.6).
Compound 27 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 27 (91 mg, 93%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1.1 atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.80 (dd, 1H, J=11.6, 8.7), 6.54 (dd, 1H, J=16.9, 12.2), 5.61 (d, 1H, J=8.1), 4.01-3.87 (m, 2H), 3.73 (s, 1.4H), 3.70 (s, 1.6H), 3.54 (d, 0.6H, J=14.5), 3.43 (d, 0.4H, J=14.9), 3.17-3.08 (m, 1H), 2.43-1.99 (bm, 4H), 1.81-1.73 (bm, 4H), 1.24-1.18 (m, 5H), 1.14 (d, 1H, J=6.9), 0.42 (d, 1.4H, J=6.5), 0.35 (d, 1.6H, J=6.5). MS (ESI) m/z 574 (M++H).
Compound 28 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thioneCompound 28 (75 mg, 82%) as yellow oil was obtained according to the same method as the synthesis of compound 15.
1H NMR (400 MHz, CDCl3); 1:1.3 atropisomer mixture; δ 7.87 (s, 1H), 7.76 (s, 2H), 6.81-6.54 (t, 1H, J=8.8), 6.54 (dd, 1H, J=12.2, 21.1), 5.77 (t, 1H, J=8.7), 4.64-4.56 (bm, 1H), 4.22-4.08 (m, 1H), 3.78-3.68 (m, 1H), 3.75 (s, 1.23H), 3.69 (s, 1.64H), 3.17-3.09 (m, 1H), 2.44-2.00 (bm, 4H), 1.79-1.71 (bm, 4H), 1.31-1.12 (m, 6H), 0.46 (d, 1.3H, J=6.6), 0.38 (d, 1.7H, J=6.6). MS (ESI) m/z 590 (M++H).
Compound 29 (4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohept-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 29 (99 mg, 62%) as white solid was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1.7 atropisomer mixture; δ 7.84 (s, 1H), 7.72 (s, 2H), 6.75 (2d, 1H, J=8.6), 6.52 (2d, 1H, J=12.2), 5.60 (dd, 1H, J=8.1, 12.5), 4.04-3.87 (m, 2H), 3.72 (s, 1H), 3.69 (s, 2H), 3.47 (dd, 1H, J=14.6), 3.15-3.05 (m, 1H), 2.47-2.24 (m, 4H), 1.84-1.80 (m, 2H), 1.72-1.48 (m, 4H), 1.21-1.11 (m, 6H), 0.40 (d, 1.1H, J=6.5), 0.27 (d, 1.9H, J=6.5). MS (ESI) m/z 588 (M++H).
Compound 30 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 30 (35 mg, 61%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.71 (s, 2H), 6.56-6.89 (m, 1H), 6.53-6.61 (m, 1H), 5.60 (d, J=8.0, 1H), 4.15 (s, 2H), 3.84-4.03 (m, 4H), 3.76 (s, 3H), 3.45-3.63 (m, 1H), 3.12-3.17 (m, 1H), 2.12-2.66 (m, 2H), 1.21-1.28 (m, 6H), 0.38-0.39 (m, 3H). MS (ESI) m/z 620 (M++H).
Compound 31 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclopent-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 31 (0.13 g, 81%) as white solid was obtained according to the same method as the synthesis of compound 18. 1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.71 (s, 2H), 6.88 (d, J=8.7, 1H), 6.57 (d, J=12.2, 1H), 5.46 (d, J=8.0, 1H), 4.20 (d, J=15.0, 1H), 3.76-3.95 (m, 1H), 3.65 (s, 3H), 3.11-3.17 (m, 1H), 2.53-2.80 (m, 4H), 1.21-1.28 (m, 6H), 0.40 (m, 3H). MS (ESI) m/z 604 (M++45).
Compound 32 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)cyclopent-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 32 (0.22 g, 89%) as white solid was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3) δ 7.85 (s, 1H), 7.69 (s, 2H), 7.08-7.10 (m, 1H), 6.90-6.91 (m, 1H), 6.81 (d, J=8.4, 1H), 5.36 (d, J=8.1, 1H), 4.23 (d, J=14.8, 1H), 3.87-3.94 (m, 1H), 3.68 (m, 3H), 2.54-2.87 (m, 5H), 1.97-2.05 (m, 2H), 1.20-1.22 (m, 6H), 0.40 (m, 3H). MS (ESI) m/z 587 (M++H).
Compound 34 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoic acidCompound 36 (20 mg, 0.035 mmol) was dissolved in tetrahydropuran/water (3 mL, volume/volume 1:1). Lithium hydroxide (an excess amount) was added dropwise to the obtained solution, and then the reaction mixture was refluxed with stirring at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure, thus obtaining Compound 34 (16 mg, 60%) as white solid.
1H NMR (400 MHz, benzene-d6); 1:1 atropisomer mixture; δ 8.19-8.14 (m, 1H), 8.03-8.01 (m, 1H), 7.63 (s, 1H), 7.41-7.15 (m, 2H), 6.39-6.35 (m, 1H), 4.78-4.76 (d, J=8.0, 0.5H), 4.72-4.70 (d, J=8.0, 0.5H), 4.19-4.16 (d, J=13.6, 0.5H), 4.04-4.00 (d, J=13.6, 0.5H), 3.49-3.31 (m, 2H), 3.14 (s, 1.5H), 3.11 (s, 1.5H), 2.38-1.98 (m, 4H), 1.67-1.56 (m, 5H), (−)0.09-(−) 0.11 (d, J=6.5, 1.5H), (−)0.15-(−)0.17 (d, J=6.5, 1.5H). MS (ESI) m/z 558 (M++H).
Compound 36 methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoateCompound 36 (40 mg, 63%) as white solid was obtained according to the same method as the synthesis of compound 18. 1H NMR (400 MHz, benzene-d6); 1:1 atropisomer mixture; δ 8.11-8.05 (m, 1H), 7.96-7.91 (d, J=2.2, 0.5H), 7.95-7.94 (d, J=2.2, 0.5H), 7.62 (s, 1H), 7.38-7.36 (d, J=6.4, 1H), 6.41-6.35 (dd, J=8.6, 8.6, 1H), 4.76-4.74 (d, J=8.0, 0.5H), 4.70-4.68 (d, J=8.0, 0.5H), 4.20-4.16 (d, J=15.6, 0.5H), 4.01-3.98 (d, J=15.6, 0.5H), 3.58 (s, 1.5H), 3.52 (s, 1.5H), 3.43-3.30 (m, 3H), 3.16 (s, 1.5H), 3.12 (s, 1.5H), 2.16-2.07 (m, 3H), 1.67-1.55 (m, 4H), (−)0.12-(−)0.13 (d, J=6.5, 1.5H), (−)0.17-(−)0.19 (d, J=6.5, 1.5H). MS (ESI) m/z 573 (M++H).
Compound 37 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzoic acidCompound 37 (19 mg, 80%) as white solid was obtained according to the same method as the synthesis of compound 34.
1H NMR (400 MHz, benzene-d6); 1:1 atropisomer mixture; δ 8.19-8.14 (m, 1H), 8.03-8.01 (m, 1H), 7.63 (s, 1H), 7.41-7.15 (d, 2H), 6.39-6.35 (m, 1H), 4.83-4.81 (d, J=8.4, 0.5H), 4.77-4.75 (d, J=8.4, 0.5H), 4.17-4.13 (d, J=15.2, 0.5H), 4.00-3.96 (d, J=15.2, 0.5H), 3.49-3.31 (m, 2H), 3.14 (s, 1.5H), 3.11 (s, 1.5H), 2.42-1.90 (m, 3H), 1.46-1.23 (m, 4H), 1.06-0.83 (m, 6H), (−)0.06-(−)0.08 (d, J=6.5, 1.5H), (−)0.13-(−)0.15 (d, J=6.5, 1.5H). MS (ESI) m/z 586 (M++H).
Compound 41 methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzoateCompound 41 (45 mg, 70%) as white solid was obtained according to the same method as the synthesis of compound 18. 1H NMR (400 MHz, benzene-d6); 1:1 atropisomer mixture; δ 8.11-8.05 (m, 1H), 7.96-7.91 (d, 0.5H), 7.95-7.94 (d, 0.5H), 7.62 (s, 1H), 7.38-7.36 (d, 1H), 6.41-6.35 (dd, J=8.6, 8.6, 1H), 4.80-4.78 (d, J=8.0, 0.5H), 4.76-4.74 (d, J=8.0, 0.5H), 4.16-4.13 (d, J=15.0, 0.5H), 3.98-3.94 (d, J=15.0, 0.5H), 3.58 (s, 1.5H), 3.52 (s, 1.5H), 3.43-3.30 (m, 2H), 3.16 (s, 1.5H), 3.12 (s, 1.5H), 2.04-1.93 (m, 3H), 1.42-1.22 (m, 4H), 1.02-0.86 (m, 6H), (−)0.09-(−)0.10 (d, J=6.5, 1.5H), (−)0.16-(−)0.18 (d, J=6.5, 1.5H). MS (ESI) m/z 600 (M++H).
Compound 42 (4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(5-isopropyl-2-methoxyphenyl)cyclohept-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 42 (0.11 g, 75%) as white solid was obtained according to the same method as the synthesis of compound 18. 1H NMR (400 MHz, CDCl3); 1:1.9 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 7.04 (dd, 1H, J=8.3, 2.0), 6.81-6.71 (m, 2H), 5.58 (2d, 1H, J=8.0), 4.05-3.90 (m, 2H), 3.73 (d, 3H, J=11.3), 3.51 (2d, 1H, J=14.2), 2.85-2.76 (m, 1H), 2.52-2.27 (m, 4H), 1.85-1.82 (m, 2H), 1.71-1.51 (m, 4H), 1.20-1.14 (m, 6H), 0.38 (d, 1H, J=6.5), 0.23 (d, 1.9H, J=6.5). MS (ESI) m/z 574 (M++H).
Compound 43 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-ethyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 43 (0.12 g, 80%) as white solid was obtained according to the same method as the synthesis of compound 18. 1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.74 (s, 2H), 6.76-6.81 (m, 1H), 6.49-6.58 (m, 1H), 3.92-4.14 (m, 2H), 3.69-3.75 (m, 3H), 3.37-3.59 (m, 1H), 3.10-3.15 (m, 1H), 1.82-2.22 (m, 4H), 1.40-1.43 (m, 2H), 0.87-1.00 (m, 6H), 0.40 (m, 3H). MS (ESI) m/z 647 (M++H).
Compound 44 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 44 (2 mg, 4%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1.3 atropisomer mixture; δ 7.81 (s, 1H), 7.68 (s, 2H), 7.03-7.00 (m, 1H), 6.76-6.69 (m, 2H), 5.56 (d, 1H, J=8.2), 3.96-3.83 (m, 2H), 3.69 (d, 3H, J=11.1), 3.51 (2d, 1H, J=14.6, 14.7), 2.61-2.74 (m, 1H), 2.18-2.12 (m, 2H), 1.98-1.82 (m, 2H), 1.50-1.45 (m, 5H), 1.18-1.11 (m, 6H), 0.99-0.94 (m, 6H), 0.37 (d, 1.3H, J=6.6), 0.28 (d, 1.7H, J=6.5). MS (ESI) m/z 584 (M++H).
Compound 46 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(hydroxymethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 36 (30 mg, 0.052 mmol) was dissolved in anhydrous tetrahydropuran (5 mL). Lithium hydroxide (5 mg, 0.08 mmol) was added dropwise to the obtained solution at −78° C., and then stirred at room temperature for 5 hours. After the completion of the reaction, the reaction was quenched with 1M HCl (hydrochloride) solution. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure, thus obtaining Compound 46 (20 mg, 60%) as white solid.
1H NMR (400 MHz, benzene-d6); 1:1 atropisomer mixture; δ 7.62 (s, 1H), 7.40-7.38 (d, J=10.7, 2H), 7.10-6.96 (m, 2H), 6.51-6.45 (m, 1H), 4.73-4.71 (d, J=7.9, 1H), 4.40-4.36 (m, 2H), 4.21-4.15 (m, 1H), 3.49-3.41 (m, 2H), 2.54-2.39 (m, 1H), 2.18-2.05 (m, 3H), 1.73-1.52 (m, 5H), −0.07-(−)0.08 (d, J=6.5, 1.5H), (−)0.16-(−)0.18 (d, J=6.5, 1.5H). MS (ESI) m/z 544 (M++H).
Compound 47 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methoxymethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 46 (6.8 mg, 0.013 mmol) was dissolved in anhydrous tetrahydropuran (2 mL). Sodium hydride (1 mg, 0.03 mmol) was added dropwise to the obtained solution at 0° C., and then stirred at room temperature for 30 minutes. Iodomethane (an excess amount) was added dropwise slowly to the reaction mixture at 0° C., and then stirred at room temperature for 3 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 47 (5 mg, 97%) as white solid.
1H NMR (400 MHz, benzene-d6); 1:1 atropisomer mixture; δ 7.61 (s, 1H), 7.39-7.38 (m, 2H), 7.13-7.10 (m, 0.5H), 7.06-7.04 (m, 1H), 6.99-6.98 (m, 0.5H), 6.51-6.44 (m, 1H), 4.75-4.68 (dd, J=7.9, 7.9, 1H), 4.22-4.13 (m, 3H), 3.53-3.44 (m, 2H), 3.25 (s, 1.5H), 3.23 (s, 1.5H), 3.19 (s, 1.5H), 3.10 (s, 1.5H), 2.51-2.47 (m, 1H), 2.22-2.09 (m, 3H), 1.71-1.61 (m, 4H), (−)0.07-(−)0.09 (d, J=6.5, 1.5H), (−)0.18-(−)0.20 (d, J=6.5, 1.5H). MS (ESI) m/z 558 (M++H).
Compound 48 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 48 (0.2 g, 79.5%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.76 (s, 1H), 7.63-7.61 (m, 2H), 7.15-6.64 (m, 1H), 6.49-6.40 (m, 1H), 5.57-5.47 (m, 1H), 3.91-3.77 (m, 2H), 3.63-3.59 (m, 3H), 3.56-3.29 (m, 1H), 3.05-3.00 (m, 1H), 2.35-1.97 (m, 6H), 1.80-1.50 (m, 1H), 1.15-1.00 (m, 6H), 0.34-0.21 (ddd, J=6.5, 3H). MS (ESI) m/z 642 (M++H).
Compound 49 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3′-chloro-4,6′-dimethoxybiphenyl-3-yl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 49 (2 mg, 33%) as a colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1.5 atropisomer mixture; δ 7.82 (s, 1H), 7.70 (s, 2H), 7.37-7.32 (m, 1H), 7.22-7.11 (m, 3H), 6.90-6.81 (m, 2H), 4.01-3.87 (m, 2H), 3.78-3.70 (m, 6H), 3.68-3.50 (m, 1H), 2.28-2.02 (m, 4H), 1.79-1.72 (m, 4H), 0.41 (d, 1.2H, J=6.5), 0.34 (d, 1.8H, J=6.5). MS (ESI) m/z 654 (M++H).
Compound 50 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 50 (84 mg, 94%) as white solid was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1.1 atropisomer mixture; δ 7.83 (s, 1H), 7.73 (d, 2H, J=4.9), 7.17-7.13 (m, 1H), 6.95 (t, 1H, J=2.4), 6.76 (dd, 1H, J=8.8, 16.3), 5.59 (2d, 1H, J=8.0), 3.98-3.88 (m, 2H), 3.73 (d, 3H, J=11.8), 3.47 (2d, 1H, J=14.7), 2.38-2.02 (m, 4H), 1.77-1.67 (m, 4H), 0.45 (d, 1.4H, J=6.5), 0.36 (d, 1.6H, J=6.5). MS (ESI) m/z 548 (M++H).
Compound 51 (4S,5R)-3-((2-(1H-indol-4-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 51 (95 mg, 38%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.29 (bs, 1H), 7.80 (d, 1H, J=7.4), 7.65 (d, 2H, J=17), 7.26 (d, 1H, J=8), 7.18-7.07 (m, 2H), 6.84 (dd, 1H, J=17, 7), 6.36-6.29 (bm, 1H), 5.48 (t, 1H, J=8.0), 4.00-3.43 (m, 3H), 2.65-2.24 (m, 2H), 2.02-1.94 (m, 2H), 1.07 (t, 6H, J=13), 0.25 (2d, 3H, J=6.5).
Compound 52 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAs shown in reaction scheme 5, intermediate 16 was reacted with triphosgene, thus obtaining Compound 52 (0.13 g, 62%) as yellow oil. 1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 8.16-8.20 (m, 1H), 7.90-7.92 (m, 1H), 7.87 (s, 1H), 7.74 (d, J=8.0, 1H), 6.95 (t, J=9.2, 1H), 5.67 (d, J=8.3, 0.51H), 5.58 (d, J=8.1, 0.43H), 3.91-4.04 (m, 2H), 3.54 (d, J=13.9, 0.45H), 3.32 (d, J=15.0, 0.54H), 2.10-2.27 (m, 2H), 1.89-2.00 (m, 2H), 1.49-1.54 (m, 2H), 1.03-1.10 (m, 6H), 0.42-0.48 (m, 3H). MS (ESI) m/z 633 (M+45)−.
Compound 55 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(2-methoxyphenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 55 (0.8 g, 99%) as yellow oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.71 (s, 2H), 7.27-7.29 (m, 1H), 6.86-7.05 (m, 3H), 5.58 (d, J=8.0, 1H), 4.26 (s, 2H), 3.86-4.15 (m, 4H), 3.86 (m, 3H), 3.65 (d, J=15.2, 0.58H), 3.49 (d, J=15.9, 0.42H), 2.13-2.71 (m, 2H), 0.4 (d, J=6.4, 1.3H), 0.28 (d, J=6.5, 1.3H). MS (ESI) m/z 560 (M+45)−.
Compound 56 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(dimethylamino)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 56 (50 mg, 62%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:2 atropisomer mixture; δ 7.85 (s, 1H), 7.73 (m, 2H), 6.81 (d, J=8.9, 0.35H), 6.74 (d, J=8.9, 0.65H), 6.60-6.66 (m, 1H), 6.44 (d, J=3.0, 0.35H), 6.41 (d, J=3.1, 0.65H), 5.57-5.59 (m, 1H), 3.89-4.08 (m, 2H), 3.67-3.70 (m, 3H), 3.51-3.67 (m, 1H), 2.81-2.86 (m, 6H), 2.06-2.51 (m, 2H) 1.93 (s, 2H), 1.43-1.55 (m, 2H), 1.01-1.05 (m, 6H), 0.47 (d, J=0.6, 1H), 0.32 (d, J=6.5, 2H). MS (ESI) m/z 630 (M+45)−.
Compound 57 2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-5-methoxybenzaldehydeAs shown in reaction scheme 3, intermediate 9 was synthesized. The obtained intermediate 9 (0.13 g, 0.20 mmol) was subjected to a Suzuki reaction with boronic acid (58 mg, 0.33 mmol), thus obtaining Compound 57 (0.11 g, 75%) as brown oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 10.05 (s, 0.49H), 10.00 (s, 0.47H), 7.86 (s, 1H), 7.73 (s, 2H), 7.37-7.42 (m, 1H), 7.70-7.17 (m, 2H), 5.62-5.64 (m, 1H), 3.83-4.03 (m, 2H), 3.86 (d, J=3.0, 3H), 2.15-2.39 (m, 4H), 1.72-1.88 (m, 4H), 3.82 (d, J=3.4, 3H), 2.03-2.38 (m, 4H), 1.75 (d, J=3.8, 4H), 0.37-0.42 (m, 3H). MS (ESI) m/z 542 (M++H).
Compound 58 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(hydroxymethyl)-4-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 57 (94 mg, 0.17 mmol) was dissolved in methanol (2 mL). Sodium borohydride (10 mg, 0.19 mmol) was added dropwise slowly to the obtained solution at room temperature, and then stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was diluted with ethyl acetate, washed with brine, dried with sodium sulfate anhydrous, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 58 (85 mg, 90%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.74 (d, J=12.0, 2H), 6.75-7.08 (m, 3H), 5.47-5.68 (m, 1H), 4.53-4.57 (m, 2H), 3.87-4.03 (m, 2H), 3.82 (d, J=5.4, 3H), 3.62 (d, J=15.1, 0.37H), 3.31 (d, J=14.7, 0.61H), 2.09-2.21 (m, 4H), 1.73-1.77 (m, 4H), 0.46-0.57 (m, 3H). MS (ESI) m/z 544 (M++H).
Compound 59 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-methoxy-2-(methoxymethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 59 (85 mg, 90%) as yellow oil was obtained according to the same method as the synthesis of compound 47.
1H NMR (400 MHz, CDCl3); 1:1.9 atropisomer mixture; δ 7.86 (s, 1H), 7.75 (d, J=5.9, 2H), 6.75-7.00 (m, 3H), 5.65 (d, J=8.0, 0.63H), 5.58 (d, J=8.0, 0.31H), 4.28 (d, J=5.6, 0.67H), 4.25 (d, J=3.9, 1.15H), 3.83-4.00 (m, 2H), 3.80-3.81 (m, 3H), 3.78 (d, J=12.7, 0.32H), 3.40-3.42 (m, 3H), 3.34 (d, J=14.7, 4H), 2.05-2.25 (m, 4H), 1.70-1.76 (m, 4H), 0.54 (d, J=6.5, 0.95H), 0.40 (d, J=6.5, 1.9H). MS (ESI) m/z 558 (M++H).
Compound 60 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(quinolin-8-yl)cyclohex-1-enyl)methyl)oxazolidin-2-oneCompound 60 (8 mg, 22%) as yellow oil was obtained according to the same method as the synthesis of compound 57.
1H NMR (400 MHz, CDCl3); 1:2 atropisomer mixture; δ 8.94-8.86 (m, 1H), 8.17-8.10 (m, 1H), 7.90 (bd, 1H, J=14), 7.75-7.72 (m, 1H), 7.67-7.62 (bm, 2H), 7.44-7.31 (m, 3H), 3.52-3.34 (m, 1H), 4.13-3.98 (m, 2H), 3.52-3.34 (m, 1H), 2.85-2.60 (m, 1H), 2.40-2.15 (m, 3H), 1.85-1.62 (m, 4H), 0.46 (d, 1H, J=6.6), (−)0.34 (d, 2H, J=6.4). MS (ESI) m/z 535 (M++H).
Compound 61 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(1-methyl-1H-indazol-4-yl)cyclohex-1-enyl)methyl)oxazolidin-2-oneCompound 61 (16 mg, 46%) as yellow oil was obtained according to the same method as the synthesis of compound 57.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.80 (d, 2H, J=11), 7.66 (s, 2H), 7.34-7.25 (m, 2H), 6.82 (d, 1H, J=6.7), 5.53 (d, 1H, J=15), 3.86 (bs, 1H), 3.8-3.4 (bm, 1H), 2.6-2.18 (brm, 2H), 2.15 (s, 2H), 1.76 (bs, 4H), 0.38-0.11 (brm, 3H).
Compound 62 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-isopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneHydroxyisobutylamidine (9 mg, 0.08 mol) was dissolved in tetrahydrofuran (0.5 mL). Sodium hydride (8 mg, 0.17 mmol) was added dropwise to the obtained solution at room temperature, and stirred at 50° C. for 2 hours. Compound 36 (25 mg, 0.044 mmol) was added dropwise to the solution, and was refluxed with stirring at 90° C. overnight. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 62 (17 mg, 63%) as white solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.03-8.00 (m, 1H), 7.85 (s, 1H), 7.78-7.73 (m, 3H), 6.98 (dd, 1H, J=11.9, 8.7), 5.63 (m, 1H), 4.05-3.97 (m, 2H), 3.87 (d, 3H, J=12.4), 3.48 (m, 1H), 3.17-3.05 (m, 1H), 2.25-2.05 (bm, 4H), 1.83-1.75 (bm, 4H), 1.40-1.25 (m, 6H), 0.44-0.39 (m, 3H). MS (ESI) m/z 624 (M++H).
Compound 63 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 19 (21 mg, 0.035 mmol) was dissolved in methylene chloride (1 mL). Boron tribromide (0.07 mL, 0.07 mmol) was added dropwise slowly to the obtained solution at −78° C., and stirred at room temperature for 3 hours. After the completion of the reaction, the reaction was quenched with saturated sodium carbonate solution. The reaction mixture was extracted with methylene chloride, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 63 (5 mg, 25%) as colorless oil.
1H NMR (400 MHz, CDCl3); 1:1.6 atropisomer mixture; δ 7.89 (d, J=7.4, 1H), 7.74 (s, 2H), 6.72-6.75 (m, 1H), 6.57-6.64 (m, 1H), 6.04-6.06 (m, 1H), 5.72 (d, J=8.0, 0.61H), 5.62 (d, J=8.3, 0.37H), 3.98-4.06 (m, 1.65H), 3.75 (d, J=14.7, 0.39H), 3.60 (s, 0.38H), 3.37 (d, J=14.8, 0.61H), 3.10-3.15 (m, 1H), 1.48-2.26 (m, 6H), 0.67 (d, J=6.5, 1.18H), 0.50 (d, J=6.6, 1.94H). MS (ESI) m/z 588 (M++H).
Compound 64 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 64 (24 mg, 52%) as colorless oil was obtained according to the same method as the synthesis of compound 63.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.89 (d, J=5.4, 1H), 7.74 (s, 2H), 6.72-6.78 (m, 1H), 6.56-6.64 (m, 1H), 5.65-5.75 (m, 0.8H), 3.94-4.06 (m, 1.46H), 3.69 (m, 0.73H), 3.37 (d, J=14.8, 0.5H), 3.10-3.13 (m, 1H), 1.29-2.28 (m, 7H), 1.04-1.28 (m, 6H), 0.89 (t, J=6.7, 1H), 0.67 (t, J=6.7, 0.99H), 0.47-0.52 (m, 1.5H). MS (ESI) m/z 574 (M++H).
Compound 65 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 65 (15 mg, 60%) as colorless oil was obtained according to the same method as the synthesis of compound 63.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.89 (s, 1H), 7.75 (d, J=9.3, 2H), 6.57-6.78 (m, 3H), 5.66-5.86 (m, 1H), 3.96-4.10 (m, 2H), 3.41-3.73 (m, 1H), 2.10-2.48 (m, 6H), 1.75 (m, 1H), 1.15-1.20 (m, 1H), 0.55-0.69 (m, 3H). MS (ESI) m/z 628 (M++H).
Compound 66 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-morpholinophenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 50 (40.0 mg, 0.073 mmol), palladium acetate (0.8 mg, 0.0037 mmol), biphenyl ligand (2.2 mg, 0.007 mmol), sodium tert-butoxide (10.5 mg, 0.11 mmol) and morpholine (10.9 mg, 0.13 mmol) were dissolved in toluene (1.0 mL). The obtained solution was refluxed in microwave-reactor with stirring at 100° C. for 20 minutes. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (4 g silica, 4:1=hexane:EtOAc), thus obtaining Compound 66 (12.8 mg, 29%) as brown solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87-7.73 (m, 3H), 6.84-6.60 (m, 3H), 5.62, 5.57 (2d, 1H, J=8.0), 4.05-3.81 (m, 7H), 3.74, 3.70 (2s, 3H), 3.07-2.99 (m, 4H), 2.25-2.03 (m, 4H), 1.84-1.74 (m, 4H), 0.48, 0.34 (2s, 3H). MS (ESI): 599 (M+).
Compound 67 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxy-N-methylbenzamideCompound 34 (20 mg, 0.036 mmol), methylamine (13.5 μl, 0.02 mmol) and 1-hydroxybenzotriazole (5.6 mg, 0.04 mmol) were dissolved in methylene chloride (0.5 mL). 1-Ethyl-3-(3-dimethylpropyl)carbodiimide (7.9 mg, 0.04 mmol) was added dropwise to the obtained solution at 0° C., and stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was neutralized with saturated sodium hydrogen carbonate solution. The reaction mixture was extracted with methylene chloride, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (silica, 1%˜3% DCM/MeOH, thus obtaining Compound 67 (3 mg, 15%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (d, 1H, J=5.0), 7.75-7.57 (m, 3H), 7.54-7.48 (m, 1H), 6.89 (dd, 1H, J=8.6, 6.5), 6.30-6.16 (m, 1H), 5.54 (m, 1H), 4.07-3.93 (m, 2H), 3.85 (d, 3H, J=16.0), 3.48-3.36 (m, 1H), 2.99 (dd, 3H, J=15.5, 4.8), 2.40-2.01 (bm, 4H), 1.84-1.75 (bm, 4H), 0.45 (t, 3H, J=6.9).
Compound 68 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-ethyl-4-methoxybenzamideCompound 68 (11 mg, 61%) as yellow solid was obtained according to the same method as the synthesis of compound 67.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (d, 1H, J=4.8), 7.75-7.58 (m, 3H), 7.51 (m, 1H), 6.89 (dd, 1H, J=8.5, 6.4), 6.27-6.12 (m, 1H), 5.54 (m, 1H), 4.07-4.02 (m, 2H), 3.83 (d, 3H, J=15.6), 3.52-3.37 (m, 3H), 2.17-2.05 (bm, 4H), 1.82-1.62 (bm, 4H), 1.28-1.20 (m, 2H), 0.47-0.43 (m, 3H).
Compound 69 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxy-N-(2,2,2-trifluoroethyl)benzamideCompound 69 (23 mg, 100%) as yellow oil was obtained according to the same method as the synthesis of compound 67.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (d, 1H, J=6.8), 7.73 (d, 2H, J=18.8), 7.67 (dd, 1H, J=8.5, 2.4), 7.58 (dd, 1H, J=8.3, 2.4), 6.93 (t, 1H, J=8.8), 6.88-6.55 (m, 1H), 5.65-5.42 (m, 1H), 4.24-3.94 (m, 4H), 3.85 (d, 3H, J=18.3), 3.39 (dd, 1H, J=18.0, 15.3), 2.42-2.05 (bm, 4H), 1.83-1.76 (bm, 4H), 0.51-0.46 (m, 3H). MS (ESI) m/z 639 (M++H).
Compound 70 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxybenzamideCompound 70 (24 mg, 100%) as yellow solid was obtained according to the same method as the synthesis of compound 67.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (d, 1H, J=4.0), 7.74 (d, 2H, J=9.4), 7.71-7.56 (m, 1H), 7.48 (m, 1H), 6.88 (m, 1H), 6.00 (m, 1H), 5.55 (m, 1H), 4.30-4.20 (m, 1H), 4.07-3.93 (m, 2H), 3.83 (d, 3H, J=15.6), 3.43 (q, 1H, J=15.0), 2.30-2.04 (bm, 4H), 1.82-1.74 (bm, 4H), 1.28-1.22 (m, 6H), 0.45 (dd, 3H, J=12.9, 6.5). MS (ESI) m/z 599 (M++H).
Compound 71 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamideAs shown in reaction scheme 5, (4S,5R)-3-((2-(5-amico-2-methoxyphenyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-oxooxazolidin-2-one (29 mg, 0.05 mmol) and diisopropylamine (0.01 mL, 0.08 mmol) were dissolved in tetrahydropuran (1 mL). Acetyl chloride (5 μl, 0.08 mmol) was added dropwise slowly to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was extracted with ethyl acetate, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 2:1=Hexane:EtOAc), thus obtaining Compound 71 (21 mg, 68%) as colorless oil.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.84 (d, J=9.8, 2H), 7.79 (s, 1H), 6.77-7.33 (m, 3H), 5.62 (d, J=7.9, 0.5H), 5.52 (d, J=8.0, 0.5H) 4.06-4.16 (m, 2H), 3.98 (t, J=15.0, 1H), 3.76 (d, J=7.8, 3H), 3.58 (d, J=14.9, 0.5H), 3.38 (d, J=14.8, 0.5H), 1.71-2.39 (m, 8H), 2.14 (d, J=15.9, 3H), 0.44 (d, J=6.5, 1.5H), 0.32 (d, J=6.4, 1.5H). MS (ESI) m/z 571 (M++H).
Compound 72 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)isobutyramideCompound 72 (24 mg, 79%) as colorless oil was obtained according to the same method as the synthesis of compound 71.
1H NMR (400 MHz, CDCl3); 1:1.1 atropisomer mixture; δ 7.84 (s, 1H), 7.78 (s, 2H), 7.58 (d, J=2.6, 0.5H), 7.25-7.27 (m, 0.5H), 7.22 (s, 0.5H), 7.13 (s, 0.5H), 7.03 (dd, J=8.6, 2.7, 0.5H), 6.80 (t, J=8.3, 1H), 5.63 (d, J=8.0, 0.44H), 5.51 (d, J=8.0, 0.54H), 4.04-4.15 (m, 2H), 3.76 (d, J=4.1, 3H), 3.54 (d, J=14.8, 0.6H), 3.41 (d, J=14.8, 0.4H), 2.44-2.53 (m, 1H), 1.71-2.34 (m, 4H), 1.15-1.30 (m, 6H), 0.44 (d, J=6.5, 1.6H), 0.36 (d, J=6.4, 1.4H). (ESI) m/z 599 (M++H).
Compound 76 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 76 (14 mg, 52%) as yellow oil was obtained according to the same method as the synthesis of compound 62.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.99-7.96 (m, 1H), 7.86 (s, 1H), 7.75-7.72 (m, 3H), 6.97 (dd, 1H, J=8.7, 11.7), 5.62 (2d, 1H, J=8.0, 8.0), 4.04-3.97 (m, 2H), 3.86 (d, 3H, J=12.3), 3.47 (2d, 1H, J=14.8, 14.9), 2.24-2.05 (m, 5H), 1.76-1.75 (m, 4H), 1.60-1.58 (m, 2H), 1.16-0.97 (m, 2H), 0.42-0.39 (m, 3H).
Compound 79 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzaldehydeAs shown in reaction scheme 4, a pinacolato compound was synthesized, and then subjected to a Suzuki reaction with Compound 9, thus obtaining Compound 79 (65 mg, 35%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 9.86 (s, 1H), 9.81 (s, 1H), 7.83 (s, 1H), 7.82-7.71 (m, 3H), 7.56-7.53 (dd, 1H), 7.00-6.95 (dd, 1H), 5.64-5.54 (dd, 1H), 4.00-3.92 (m, 1H), 3.87 (s, 1.5H), 3.84 (s, 1.5H), 3.52-3.49 (d, 0.5H), 3.35-3.31 (d, 0.5H), 2.20-2.19 (m, 1H), 1.80-1.72 (m, 5H), 0.40-0.37 (m, 3H). MS (ESI) m/z 406 (M++H).
Compound 80 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 79 (65 mg, 0.117 mmol) was dissolved in tetrahydropuran (3 mL). Methylmagnesium chloride (56 μL, 0.17 mmol) was added dropwise to the obtained solution at 0° C., and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with methylene chloride, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography (silica gel; Hexane/EtOAC=6:1˜3:1), thus obtaining Compound 80 (88 mg, 98%) as colorless oil.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.83 (s, 1H), 7.73-7.69 (m, 2H), 7.21-7.17 (m, 1H), 7.07 (m, 0.5H), 7.00-6.97 (m, 0.5H), 6.85-6.78 (dd, 1H), 5.59-5.56 (m, 0.5H), 5.50-5.44 (dd, 0.5H), 4.83-4.79 (m, 1H), 4.11-3.94 (m, 2H), 3.78-3.77 (d, 1.5H), 3.72 (s, 1.5H), 3.55-3.39 (m, 1H), 2.17-2.20 (m, 4H), 1.71 (brs, 4H), 1.46-1.39 (m, 3H), 0.43-0.33 (m, 3H). MS (ESI) m/z 557 (M++H).
Compound 81 (4S,5R)-3-((2-(5-acetyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 80 (88 mg, 0.158 mmol) was dissolved in methylene chloride (2 mL). Dess-Martin periodinane (0.17 mg, 0.35 mmol) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 1 hour. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography (silica gel; hexane/EtOAC=5:1˜3:1), thus obtaining Compound 81 (45 mg, 90%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (m, 0.5H), 7.78 (m, 0.5H), 7.75-7.72 (m, 0.5H), 7.64-7.58 (m, 1.5H), 7.43-7.41 (m, 2H), 6.42-6.39 (m, 1H), 4.83-4.17 (m, 1H), 4.17-4.02 (dd, 1H), 3.45-3.24 (m, 2H), 3.23 (s, 1.5H), 3.19 (s, 1.5H), 2.41-1.99 (m, 4H), 2.27 (s, 1.5H), 2.23 (s, 1.5H), 1.69-1.57 (m, 4H), (−)0.07-(−)0.12 (m, 3H). MS (ESI) m/z 556 (M++H).
Compound 82 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 82 (8.2 mg, 36%) as yellow oil was obtained according to the same method as the synthesis of compound 80.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.62-7.61 (m, 1H), 7.40-7.29 (m, 3H), 7.291-7.18 (m, 1H), 6.53-6.49 (m, 1H), 4.74-4.69 (m, 1H), 4.28-4.19 (m, 1H), 3.56-3.33 (m, 2H), 3.30 (s, 1.5H), 3.26 (s, 1.5H), 2.54-2.10 (m, 4H), 1.74-1.65 (m, 4H), 1.42-1.37 (m, 6H), (−)0.07-(−) 0.16 (m, 3H). MS (ESI) m/z 572 (M++H).
Compound 83 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(2-(trifluoromethoxy)phenyl)cyclohex-1-enyl)methyl)oxazolidin-2-oneCompound 83 (96 mg, 95%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.75 (s, 2H), 7.33-7.22 (m, 3H), 7.17-7.14 (m, 1H), 5.64 (dd, J=4.4, 8.0, 1H), 4.04-3.88 (m, 2H), 3.54, 3.42 (2d, J=15.0, 1H), 2.36-2.04 (m, 4H), 1.81-1.73 (m, 4H), 0.49, 0.43 (2d, J=6.5, 3H). MS (ESI) m/z 568 (M++H).
Compound 84 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-fluoro-5-(trifluoromethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 84 (0.14 g, 79%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.75 (s, 2H), 7.55-7.54 (m, 1H), 7.40-7.38 (m, 1H), 7.21-7.14 (m, 1H), 5.64 (d, J=7.9, 1H), 4.15-3.92 (m, 2H), 3.51-3.47 (m, 1H), 2.39-2.20 (m, 4H), 1.78 (bs, 4H), 0.46 (d, J=6.5, 3H). MS (ESI) m/z 570 (M++H).
Compound 85 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)ethyl acetateCompound 80 (65.0 mg, 0.117 mmol) was dissolved in tetrahydropuran (2 mL). Methylmagnesium chloride (56 μL, 0.16 mmol) was added dropwise to the obtained solution at 0° C., and stirred at room temperature for 5 hours. After the completion of the reaction, ethyl acetate was added dropwise to the reaction mixture. And then, the reaction mixture was washed with water and brine, and concentrated under reduced pressure. The residue was separated by MPLC (15% Hexane/EtOAc), thus obtaining Compound 85 (30 mg, 70%) as white foam.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.82 (s, 1H), 7.73 (d, J=7.3, 1H), 7.25-7.17 (m, 1H), 6.99-6.93 (m, 1H), 6.84-6.77 (m, 1H), 5.82-5.71 (m, 1H), 5.60-5.55 (m, 1H), 3.99-3.87 (m, 2H), 3.75 (s, 1.5H), 3.72 (d, J=9.4, 1.5H), 3.58-3.39 (m, 1H), 2.41-1.63 (m, 11H), 1.49-1.42 (m, 3H), 0.40-0.31 (m, 3H). MS (ESI) m/z 540.0 (M++H-OAc).
Compound 86 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramideCompound 86 (5 mg, 35%) as colorless oil was obtained according to the same method as the synthesis of compound 47.
1H NMR (400 MHz, CDCl3); 1:1.1 atropisomer mixture; δ 7.87 (s, 1H), 7.75 (d, J=7.2, 2H), 7.06-6.84 (m, 3H), 5.65-5.60 (m, 1H), 4.06-3.89 (m, 2H), 3.80 (d, J=13.7, 3H), 3.54-3.44 (m, 1H), 3.18 (d, J=24.4, 3H), 2.50-2.42 (m, 1H), 2.27-1.75 (m, 4H), 1.03-0.83 (m, 6H), 0.48 (d, J=6.5, 1.4H), 0.39 (d, J=6.4, 1.6H). MS (ESI) m/z 613 (M++H).
Compound 87 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxy-N-methylbenzamideCompound 87 (11 mg, 79%) as yellow solid was obtained according to the same method as the synthesis of compound 47.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.77 (d, J=6.7, 2H), 7.29-7.25 (m, 1H), 7.12, 7.07 (2d, J=2.0, 1H), 6.86 (dd, J=7.1, 8.4, 1H), 5.63-5.49 (m, 1H), 4.04-3.92 (m, 2H), 3.81 (d, J=9.4, 3H), 3.53, 3.41 (2d, J=15.0, 1H), 2.88-2.85 (m, 3H), 2.25-2.05 (m, 4H), 1.74 (bs, 4H), 1.20-1.15 (m, 6H), 0.44 (dd, J=6.5, 15.2, 3H). MS (ESI) m/z 613 (M++H).
Compound 96 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 96 (57 mg, 69%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.75-7.73 (m, 2H), 7.52-7.49 (m, 1H), 7.25-7.23 (m, 1H), 6.96-6.90 (m, 1H), 5.67, 5.65, 5.61, 5.49 (4d, J=7.8, 7.9, 8.1, 8.2, 1H), 4.05-3.89 (m, 2H), 4.05-3.89 (m, 2H), 3.84, 3.82, 3.80 (3s, 3H), 3.55, 3.47, 3.38, 3.32 (4d, J=15.0, 14.8, 14.9, 14.9, 1H), 2.29-2.19 (m, 3H), 1.87-1.71 (m, 3H), 1.45-1.26 (m, 1H), 1.08-1.06 (m, 3H), 0.42-0.37 (m, 3H). MS (ESI) m/z 596 (M++H).
Compound 97 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 97 (77.8 mg, 75%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.87 (s, 1H), 7.75, 7.73 (2s, 2H), 7.51 (dm, 1H), 7.23 (d, 1H), 6.94 (d, J=8.7, 0.5H), 6.91 (d, J=8.7, 0.5H), 5.65 (d, J=8.1, 0.5H), 5.55 (d, J=8.2, 0.5H), 3.99-3.89 (m, 2H), 3.50 (d, J=14.9, 0.5H), 3.33 (d, J=15.0, 0.5H), 3.84 (s, 1.5H), 3.81 (s, 1.5H), 2.49-2.15 (m, 2H), 1.99-1.88 (m, 2H), 1.55-1.43 (m, 2H), 1.06, 1.02 (2s, 6H3), 0.40 (d, J=6.6, 1.5H), 0.37 (d, J=6.5, 1.5H). MS (ESI) m/z 610 (M++H).
Compound 101 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-tert-butyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 101 (0.31 g, 89%) as yellow solid was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.90-7.73 (m, 3H), 6.81-6.75 (m, 1H), 6.58-6.49 (m, 1H), 5.65-5.55 (m, 1H), 4.14-3.91 (m, 2H), 3.74-3.69 (m, 3H), 3.65-3.40 (m, 1H), 3.20-3.10 (m, 1H), 2.58-2.12 (m, 4H), 1.91-1.87 (m, 3H), 1.22-1.18 (m, 6H), 0.95 (d, J=2.6, 9H), 0.41-0.28 (m, 3H). MS (ESI) m/z 630 (M++H).
Compound 103 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 103 (65 mg, 73%) as colorless oil was obtained according to the same method as the synthesis of compound 80.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.84 (s, 1H), 7.71 (m, 2H), 7.21-7.06 (m, 1H), 7.05-6.98 (m, 0.5H), 6.97-6.85 (m, 0.5H), 6.83-6.78 (m, 1H), 5.59-5.30 (m, 1H), 4.85-4.78 (m, 1H), 4.04-3.92 (m, 2H), 3.78-3.72 (m, 3H), 3.55-3.49 (m, 1H), 3.41-3.33 (m, 1H), 2.43-1.90 (m, 6H), 147-1.41 (m, 6H), 1.04-1.01 (m, 3H), 0.42-0.30 (m, 3H). MS (ESI) m/z 568.0 (M-OH).
Compound 104 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 104 (6 mg, 53%) as colorless oil was obtained according to the same method as the synthesis of compound 80.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.84 (s, 1H), 7.71 (d, J=8.3, 2H), 7.33-7.30 (m, 1H), 7.18-7.17 (m, 0.5H), 7.078-7.072 (m, 0.5H), 6.82 (d, J=8.5, 0.5H), 6.77 (d, J=8.5, 0.5H), 5.57 (d, J=8.1, 0.5H), 5.48 (d, J=8.1, 0.5H), 4.05-3.90 (m, 2H), 3.77 (s, 1.5H), 3.72 (s, 1.5H), 3.53 (d, J=14.5, 0.5H), 3.38 (d, J=14.5, 0.5H), 2.60-1.70 (m, 6H), 1.55-1.1.51 (m, 6H), 1.04-1.00 (m, 6H), 0.40 (d, J=6.6, 1.5H), 0.30 (d, J=6.6, 1.5H). MS (ESI) m/z 583 (M+-OH).
Compound 107 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 107 (34 mg, 48%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.72 (s, 2H), 7.06 (dd, J=8.4, 2.2, 1H), 6.82-6.72 (m, 2H), 5.60-5.57 (m, 1H), 4.01-3.89 (m, 2H), 3.73, 3.70 (2s, 3H), 3.58, 3.44 (2d, J=14.6, 1H), 2.86-2.75 (m, 1H), 2.53-1.86 (m, 4H), 1.54-1.42 (m, 2H), 1.20-1.14 (m, 6H), 1.06-1.01 (m, 6H), 0.38, 0.28 (2d, J=6.5, 3H). MS (ESI) m/z 584 (M++H).
Compound 108 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 108 (80 mg, 55%) as yellow oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.63 (m, 1H), 7.43-7.32 (m, 2H), 7.04-6.95 (m, 1H), 6.85-6.78 (m, 1H), 6.57-6.45 (m, 1H), 4.77-4.72 (m, 1H), 4.24-4.15 (m, 0.5H), 4.03-3.93 (m, 0.5H), 3.68-3.62 (m, 0.5H), 3.51-3.43 (m, 1.5H), 3.35-3.28 (m, 1.5H), 3.27-3.19 (m, 1.5H), 2.84-2.63 (m, 1H), 2.54-2.38 (m, 2H), 2.33-2.10 (m, 2H), 1.99-1.65 (m, 2H), 1.53-1.39 (m, 1H), 1.24-1.11 (m, 6H), (−)0.01-(−)0.27 (m, 3H). MS (ESI) m/z 625 (M++H).
Compound 109 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 109 (87 mg, 93%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.76 (dd, J=8.7, 3.6, 1H), 6.54, 6.50 (2d, J=12.2, 1H), 5.61 (d, J=8.1, 1H), 3.98-3.87 (m, 2H), 3.70 (d, J=11.7, 3H), 3.55, 3.46 (2d, J=14.7, 1H), 3.15-3.07 (m, 1H), 2.21-2.11 (m, 2H), 1.95-1.81 (m, 2H), 1.53-1.46 (m, 2H), 1.20-1.12 (m, 6H), 1.00-0.86 (m, 6H), 0.42, 0.35 (2d, J=6.5, 3H). MS (ESI) m/z 602 (M++H).
Compound 110 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetamideAs shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (48.0 mg, 0.078 mmol) and diisopropylamine (30.0 μl, 0.17 mmol) were dissolved in methylene chloride (1.5 mL). Acetyl chloride (12.3 μl, 0.17 mmol) was added dropwise slowly to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was extracted with ethyl acetate, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (4 g silica, 4:1=hexane/EtOAc), thus obtaining Compound 110 (21.6 mg, 42%) as white solid foam.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.85, 7.84 (2s, 1H), 7.82, 7.77 (2s, 2H), 7.49 (d, J=2.7, 0.5H), 7.35 (dd, J=8.8, 2.7, 0.5H), 7.13 (d, J=2.7, 0.5H), 7.12, 7.06 (2brs, 1H), 7.02 (dd, J=8.8, 2.7, 1H), 6.82-6.78 (m, 1H), 5.61, 5.52 (2d, J=8.0, 1H), 4.14-3.92 (m, 2H), 3.76, 3.74 (2s, 3H), 3.57, 3.39 (2d, J=14.8, 1H), 2.49-2.21 (m, 2H), 2.16-2.12 (2s, 3H3), 1.96-1.92 (br m, 2H), 1.54-1.41 (m, 2H), 1.04, 1.03, 1.02, 1.00 (4s, 0.41, 0.40, 0.35, 0.33 (4s, 3H, CH3, 6H). MS (ESI) m/z 600 (M++H).
Compound 111 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)isobutyramideCompound 111 (38.8 mg, 72%) as yellow solid foam was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.79, 7.77 (2s, 2H), 7.56 (d, J=2.7, 0.5H), 7.32 (dd, J=8.8, 2.7, 0.5H), 7.22 (d, J=2.7, 0.5H), 7.08 (brs, 0.5H), 7.04 (dd, J=8.8, 2.7, 0.5H), 7.02 (brs, 0.5H), 6.82-6.78 (m, 1H), 5.62, 5.51 (2s, 3H), 3.54, 3.41 (2d, J=14.8, 1H), 2.52-2.08 (m, 3H), 1.94-1.92 (br m, 2H), 1.54-1.41 (m, 2H), 1.24-1.18 (m, 6H), 1.04, 1.03, 1.02, 1.00 (4s, 6H), 0.41, 0.40, 0.38, 0.37 (4s, 3H). MS (ESI) m/z 627 (M++H).
Compound 112 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamideCompound 110 (18 mg, 0.03 mmol) was dissolved in anhydrous tetrahydropuran (1 mL). Sodium hydride (4 mg, 0.09 mmol) was added dropwise to the obtained solution at 0° C., and stirred at room temperature for 30 minutes. Iodomethane (9.4 μl, 0.15 mmol) was added dropwise slowly to the reaction mixture at 0° C., and then stirred at room temperature for 3 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 112 (14 mg, 76%) as white solid foam.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.88 (s, 1H), 7.74 (s, 2H), 7.08-7.05 (m, 1H), 6.90-6.82 (m, 2H), 5.64 (d, J=7.9, 1H), 4.05-3.91 (m, 2H), 3.81, 3.78 (2s, 3H), 3.53, 3.43 (2d, J=14.8, 1H), 3.23, 3.17 (2s, 3H), 2.54-2.19 (m, 2H), 1.85, 1.82 (2s, 3H), 1.57-1.43 (m, 2H), 1.07, 1.05, 1.03, 1.02 (4s, 6H), 0.48, 0.46, 0.36, 0.35 (4s, 3H). MS (ESI) m/z 613 (M++H).
Compound 113 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramideCompound 113 (28 mg, 86%) as yellow foam was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.88 (s, 1H), 7.75 (s, 2H), 7.07 (m, 1H), 6.90-6.82 (m, 2H), 5.63 (d, J=8.1, 1H), 4.06-3.92 (m, 2H), 3.81, 3.78 (2s, 3H), 3.53, 3.43 (2d, J=14.8, 1H), 3.21, 3.15 (2s, 3H), 2.52-2.15 (m, 3H), 1.99-1.87 (m, 2H), 1.56-1.40 (m, 2H), 1.06-0.94 (m, 12H), 0.47, 0.45, 0.37, 0.35 (4s, 3H). MS (ESI) m/z 641 (M++H).
Compound 114 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(methoxymethyl)-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 9 was subjected to a Suzuki reaction with 6-(trifluoromethyl)benzo[c][1,2]oxaborol-1(3H)-ol, and then, the obtained intermediate compound was used as the same method as the synthesis of Compound 47, to obtain Compound 114 (60 mg, 74%) as white solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 3H), 7.55-7.47 (m, 1H), 7.13 (d, J=7.8, 1H), 5.64, 5.57 (2d, J=8.1, 1H), 4.36-4.26 (m, 2H), 4.01-3.81 (m, 2H), 3.71-3.21 (m, 1H), 3.43 (d, J=4.1, 3H), 2.23-2.18 (m, 2H), 1.99-1.90 (m, 2H), 1.55-1.46 (m, 2H), 1.07-0.87 (m, 6H), 0.55, 0.38 (2d, J=6.5, 3H). MS (ESI) m/z 624 (M++H).
Compound 115 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-tert-butyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 115 (9 mg, 39%) as a gray solid was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.71 (s, 2H), 7.22-7.19 (m, 1H), 6.95 (dd, J=12.6, 2.5, 1H), 6.80-6.72 (m, 1H), 5.60-5.54 (m, 1H), 4.00-3.86 (m, 2H), 3.73 (d, J=9.9, 3H), 3.57, 3.43 (2d, J=14.7, 1H), 2.55-2.04 (m, 2H), 1.93-1.91 (m, 2H), 1.52-1.42 (m, 2H), 1.28-1.23 (m, 9H), 1.04-1.00 (m, 6H), 0.36, 0.26 (2d, J=6.5, 3H). MS (ESI) m/z 598 (M++H).
Compound 116 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)-N-(2,2,2-trifluoroethyl)acetamide3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzaldehyde (32 mg, 0.06 mmol), which is a starting material, and 2,2,2-trifluoroethane amine (5.4 μl, 0.067 mmol) were dissolved in methylene chloride (2 mL). The obtained solution was stirred at room temperature overnight. Sodium cyanoborohydride (4 mg, 0.056 mmol) and acetic acid (3.2 μl, 0.06 mmol) were added dropwise to the solution, and stirred at room temperature for 1 hour. After the completion of the reaction, the reaction mixture was neutralized with saturated sodium hydrogen carbonate solution, extracted with methylene chloride, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained intermediate compound (39 mg, 0.06 mmol) was dissolved in methylene chloride (2 mL). Diisopropylethylamine (26 μl, 0.15 mmol) and acetyl chloride (4.6 μl, 0.06 mmol) were added dropwise carefully to the obtained solution, and stirred at room temperature for 2 hours. The reaction was quenched with water. The reaction mixture was extracted with methylene chloride, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (silica, 20˜50% Hexane/EtOAc), thus obtaining Compound 116 (25 mg, 61%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (d, J=12.2, 2H), 7.08-6.98 (m, 1H), 6.88-6.75 (m, 2H), 5.62-5.54 (m, 1H), 4.67-4.53 (m, 2H), 4.03-3.90 (m, 4H), 3.78-3.69 (m, 3H), 3.50-3.31 (m, 1H), 2.21-2.15 (m, 2H), 2.04 (s, 3H), 1.92-1.88 (m, 2H), 1.52-1.45 (m, 2H), 1.05-1.00 (m, 6H), 0.43, 0.34 (dt, J=5.9, 6.5, 3H). MS (ESI) m/z 695 (M++H).
Compound 117 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 117 (27.8 mg, 67%) as colorless oil was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.74 (s, 2H), 7.11-7.08 (m, 1H), 6.89-6.81 (m, 2H), 4.01-3.89 (m, 2H), 3.79, 3.77 (2s, 3H), 3.56, 3.39 (2d, J=14.8, 1H), 2.50-2.04 (m, 2H), 1.99-1.89 (m, 2H), 1.54-1.45 (m, 2H), 1.05, 1.05, 1.02, 1.019 (4s, 6H), 0.40, 0.39, 0.37, 0.35 (4s, 3H). MS (ESI) m/z 626 (M++H).
Compound 118 N-acetyl-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetamideCompound 118 (0.15 g, 79%) as yellow solid was obtained according to the same method as the synthesis of compound 71.
MS (ESI) m/z 641 (M++H).
Compound 120 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluoro-N-methylacetamideAs shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (0.16 g, 0.29 mmol), a starting material, was reacted with di-tert-butyl carboxylate. The obtained intermediate compound was subjected to methylation, and then subjected to deprotection using hydrogen chloride, thus obtaining (4S,5R)-5-(bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxooxazolidin-2-one. The obtained compound (40 mg, 0.07 mmol), a starting material, was dissolved in methylene chloride (1.5 mL). Trifluoroacetic anhydride (TFAA) (20 μl, 0.14 mmol) was added dropwise to the obtained solution at room temperature diisopropylamine (37 μl, 0.21 mmol), and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with water. The reaction mixture was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by Prep TLC (silica, 25% hexane/EtOAc), thus obtaining Compound 120 (37 mg, 80%) as yellow oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 7.12-7.09 (m, 1H), 6.89-6.83 (m, 2H), 5.61 (d, J=8.0, 1H), 4.01-3.84 (m, 2H), 3.81, 3.78 (2s, 3H), 3.54-3.42 (m, 1H), 3.32 (s, 1.8H), 3.27 (s, 1.2H), 2.50-1.90 (m, 4H), 1.53-1.42 (m, 2H), 1.38, 1.29 (2d, J=6.5, 3H), 1.04-0.99 (m, 6H).
Compound 121 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopyrrolidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAs shown in reaction scheme 4,3-iodo-4-methoxyaniline, a starting material, was subjected to acylation using acyl chloride and then reacted with sodium methoxide, a base, to synthesize a compound forming a ring. The obtained compound was reacted with bis(pinacolato)diborane to synthesize a pinacolato intermediate compound. The obtained pinacolato compound (0.05 g, 0.16 mmol) was subjected to a Suzuki reaction with Compound 9 (0.09 g, 0.138 mmol), thus obtaining Compound 121 (29 mg, 30%) as brown oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (d, J=7.4, 2H), 7.77 (m, 1H), 7.09-7.60 (m, 2H), 6.84 (t, J=1.0, 1H), 5.62 (d, J=7.9, 0.5H), 5.52 (d, J=8.0, 0.5H) 3.70-4.12 (m, 4H), 3.80-3.82 (m, 3H), 2.12-2.60 (m, 6H), 2.05-2.11 (m, 2H), 1.45-2.11 (m, 2H), 1.01-1.04 (m, 6H), 0.31-0.42 (m, 3H). MS (ESI) m/z 626 (M++H).
Compound 122 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopiperidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 122 (18 mg, 21%) as brown oil was obtained according to the same method as the synthesis of compound 121.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.83 (s, 1H), 7.81 (s, 2H), 6.82-7.17 (m, 3H), 5.58 (d, J=8.0, 0.5H), 5.47 (d, J=7.9, 0.5H), 3.95-4.02 (m, 2H), 3.78 (d, J=4.6, 3H), 3.44-3.75 (m, 3H), 2.50-2.55 (m, 2H), 2.05-2.15 (m, 2H), 1.91-1.96 (m, 6H), 1.43-1.49 (m, 2H), 0.99-1.03 (m, 6H), 0.37-0.42 (m, 3H). MS (ESI) m/z 640 (M++H).
Compound 123 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,5-difluoro-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 123 (45 mg, 58%) as white solid was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.81-6.77 (m, 1H), 6.59-6.51 (m, 1H), 5.65-5.62 (m, 1H), 3.99-3.86 (m, 3H), 3.73 (s, 1.5H), 3.70 (s, 1.5H), 3.57 (d, J=14.8, 1H), 3.46 (d, J=14.8, 1H), 3.15-3.09 (m, 1H), 2.70-2.47 (m, 6H), 1.32-1.13 (m, 6H), 0.40 (d, J=6.5, 1.5H), 0.33 (d, J=6.5, 1.5H).
Compound 124 methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(methyl)carbamateCompound 124 (18 mg, 55%) as yellow oil was obtained according to the same method as the synthesis of compound 120.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.75 (s, 2H), 7.07-7.03 (m, 1H), 7.00-6.83 (m, 1H), 6.84-6.77 (m, 1H), 5.60-5.51 (m, 1H), 4.00-3.90 (m, 2H), 3.76 (d, J=5.4, 3H), 3.68-3.57 (m, 3H), 3.55-3.42 (m, 1H), 3.34, 3.25 (2s, 3H), 2.40-2.04 (m, 2H), 1.92-1.88 (m, 2H), 1.52-1.41 (m, 2H), 1.03-1.00 (m, 6H), 0.41, 0.36 (2d, J=6.0, 3H).
Compound 128 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylmethanesulfonamideCompound 128 (30 mg, 59%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (d, J=3.8, 1H), 7.76 (d, J=10.2, 2H), 7.02-7.24 (m, 2H), 6.83-6.88 (m, 1H), 5.58 (t, J=9.6, 1H), 3.92-4.02 (m, 2H), 3.82 (d, J=1.0, 3H), 3.38-3.57 (m, 1H), 3.28 (d, J=13.8, 3H), 2.81 (d, J=28.0, 3H), 2.10-2.47 (m, 2H), 1.94-2.02 (m, 2H), 1.44-1.51 (m, 2H), 1.02-1.06 (m, 6H), 1.36-1.48 (m, 3H). MS (ESI) m/z 650 (M++H).
Compound 130 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-N-methylpropanamideCompound 130 (17 mg, 43%) as yellow oil was obtained according to the same method as the synthesis of compound 120.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (d, J=5.0, 2H), 7.07-7.03 (m, 1H), 6.92-6.83 (m, 2H), 5.61 (t, J=8.0, 1H), 4.05-3.91 (m, 2H), 3.82, 3.78 (2s, 3H), 3.51-3.35 (m, 1H), 3.26, 3.19 (2s, 3H), 2.98-2.88 (m, 2H), 2.48-1.97 (m, 2H), 1.93-1.86 (m, 2H), 1.55-1.44 (m, 2H), 1.03-0.97 (m, 6H), 0.47, 0.39 (2d, J=6.0, 3H). MS (ESI) m/z 681, 682 (M++1, M++2).
Compound 132 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1,1,1-trifluoropropan-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one2-Fluoro-4-methoxyacetophenone, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was subjected to a Suzuki reaction with Compound 2, thus synthesizing an aldehyde compound. The obtained aldehyde compound was reacted with Compound 4 to synthesize an amino alcohol compound, as an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 132 (24 mg, 68%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.94-6.96 (m, 1H), 6.57-6.64 (m, 2H), 5.53-5.62 (m, 1H), 3.80-3.99 (m, 2H), 3.77-3.78 (m, 3H), 3.75-3.80 (m, 1H), 1.20-2.50 (m, 6H), 1.45-1.52 (m, 3H), 1.00-1.05 (m, 6H), 0.30-0.43 (m, 3H). MS (ESI) m/z 657 (M++H).
Compound 133 Methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetateAs shown in reaction scheme 4, pinacolato compound was synthesized. The obtained pinacolato compound (0.1 g, 0.33 mmol), Compound 9 (0.17 g, 0.167 mmol), palladium catalyst (10 mg, 0.02 mmol) and sodium carbonate (70 mg, 0.65 mmol) were dissolved in dimethoxyethane/water (5 mL). The obtained solution was refluxed with stirring in microvessel at 120° C. for 15 minutes. After the completion of the reaction, the reaction was quenched with saturated ammonium chloride solution. The reaction product was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 1:1=Hexane/EtOAc), thus obtaining Compound 133 (91 mg, 45%) as brown oil.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.76 (d, J=7.0, 2H), 7.09-7.13 (m, 1H), 6.76-6.93 (m, 2H), 5.61 (d, J=8.1, 0.5H), 5.55 (d, J=8.0, 0.5H), 3.90-4.03 (m, 2H), 3.75 (d, J=7.3, 3H), 3.64 (d, J=38.0, 3H), 3.41-3.68 (m, 2H), 3.41-3.68 (m, 1H), 2.04-2.53 (m, 2H), 1.89-1.98 (m, 2H), 1.42-1.54 (m, 2H), 1.01-1.04 (m, 6H), 0.33-0.37 (m, 3H). MS (ESI) m/z 615 (M++H).
Compound 134 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetic acidCompound 133 (0.08 g, 0.13 mmol) was dissolved in dioxan/water (5 mL V/V 2:1). Lithium hydroxide (0.06 g, 1.32 mmol) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 6 hours. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 1:1=Hexane/EtOAc), thus obtaining Compound 134 (60 mg, 76%) as brown oil.
1H NMR (400 MHz, CDCl3); 1:1.3 atropisomer mixture; δ 7.85 (s, 1H), 7.74 (d, J=5.4, 2H), 7.09-7.13 (m, 1H), 6.77-6.91 (m, 2H), 5.58 (t, J=7.7, 1H), 3.92-4.02 (m, 2H), 3.70-3.76 (m, 3H), 3.41-3.60 (m, 2H), 3.41-3.60 (m, 1H), 2.17-2.50 (m, 2H), 1.88-1.97 (m, 2H), 1.41-1.54 (m, 2H), 1.04-1.07 (m, 6H), 0.41 (d, J=6.5, 1.3H), 0.33 (d, J=6.5, 1.7H). MS (ESI) m/z 601 (M++H). Compound 136 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanesulfonamide
Compound 136 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanesulfonamideCompound 136 (37 mg, 63%) as yellow solid was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.74 (d, J=6.4, 2H), 7.16, 7.08 (2dd, J=8.7, 2.7, 1H), 7.04, 6.94 (2d, J=2.7, 1H), 6.83-6.78 (m, 1H), 6.35-6.28 (m, 1H), 5.59 (dd, J=4.5, 8.0, 1H), 4.04-3.92 (m, 2H), 3.76, 3.74 (2s, 3H), 3.54, 3.39 (2d, J=14.0, 1H), 2.46-2.01 (m, 3H), 1.92 (bs, 2H), 1.53-1.43 (m, 2H), 1.12-1.06 (m, 2H), 1.06-1.03 (m, 6H), 1.02-0.82 (m, 2H), 0.43, 0.38 (2d, J=6.5, 3H).
Compound 137 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoromethanesulfonamideCompound 137 (43 mg, 98%) as white solid was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (d, J=4.9, 2H), 7.29-7.25 (m, 1H), 7.21-6.99 (m, 1H), 6.96-6.81 (m, 1H), 5.63-5.51 (m, 1H), 3.98-3.87 (m, 2H), 3.84 (d, J=5.2, 2H), 3.77 (d, J=8.3, 1H), 3.56, 3.37 (2d, J=15.0, 1H), 2.46-1.99 (m, 2H), 1.95-1.91 (m, 2H), 1.55-1.40 (m, 2H), 1.04-0.95 (m, 6H), 0.37-0.33 (m, 3H). MS (ESI) m/z 689 (M++H).
Compound 138 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylcyclopropanesulfonamideCompound 138 (21 mg, 66%) as yellow solid was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.75 (d, J=4.6, 2H), 7.27-7.20 (m, 1H), 7.10, 7.04 (2d, J=2.7, 1H), 6.83 (dd, J=12.1, 8.8, 1H), 5.57 (dd, J=14.9, 8.0, 1H), 4.01-3.91 (m, 2H), 3.77 (d, J=7.1, 3H), 3.56, 3.41 (2d, J=14.6, 1H), 3.30, 3.25 (2s, 3H), 2.47-2.22 (m, 3H), 1.92 (bm, 2H), 1.51-1.44 (m, 2H), 1.11-0.84 (m, 4H), 1.02-1.00 (m, 6H), 0.39 (dd, J=6.5, 2.4, 3H). MS (ESI) m/z 675 (M++H).
Compound 140 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylthioureaAs shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (30 mg, 0.049 mmol) was dissolved in ethanol. Isothiocyanato methane (an excess amount) was added dropwise to the obtained solution, and then refluxed with stirring. After the completion of the reaction, the reaction mixture was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 15%˜35%=hexane/EtOAc), thus obtaining Compound 140 (20 mg, 59%) as white solid.
1H NMR (400 MHz, CDCl3); 1:2 atropisomer mixture; δ 7.86 (s, 1H), 7.75 (s, 1H), 7.72 (s, 1H), 7.08-6.96 (m, 1H), 6.92-6.87 (m, 2H), 5.63 (m, 0.5H), 5.42-5.40 (m, 0.5H), 4.32-4.29 (m, 0.5H), 4.18-4.10 (m, 1H), 3.96-3.92 (m, 0.5H), 3.87 (s, 2H), 3.76 (s, 1H), 3.18-3.10 (m, 3H), 2.45-2.39 (m, 1H), 2.2.08-1.87 (m, 2H), 1.80-1.71 (m, 3H), 1.03-1.00 (m, 6H), 0.62-0.60 (d, J=6.4, 2H), 0.52-0.51 (d, J=6.4, 1H). MS (ESI) 630 (M+H)+.
Compound 141 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoro-N-methylmethanesulfonamideCompound 141 (23 mg, 62%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (d, J=4.1, 2H), 7.24-7.17 (m, 1H), 7.03, 6.99 (2d, J=2.7, 1H), 6.86 (dd, J=13.4, 8.8, 1H), 5.58, 5.52 (2d, J=8.0, 1H), 3.97-3.81 (m, 2H), 3.79 (d, J=7.0, 3H), 3.56 (d, J=15.0, 0.5H), 3.42 (d, J=15.3, 3H), 3.36 (d, J=14.9, 0.5H), 2.46-2.04 (m, 2H), 1.99-1.94 (m, 2H), 1.55-1.42 (m, 2H), 1.02 (d, J=11.6, 6H), 0.37, 0.32 (2d, J=6.5, 3H). MS (ESI) m/z 703 (M++H).
Compound 142 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxoimidazolidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAs shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (50 mg, 0.081 mmol) was reacted with 2-bromoethane amine (20 mg, 0.10 mmol) to synthesize an intermediate compound. The obtained intermediate compound (0.1 g, 0.167 mmol), diisopropylethylamine (43 μl, 0.25 mmol) and triphosgene (25 mg, 0.08 mmol) were dissolved in methylene chloride (3 mL). The obtained solution was stirred at room temperature. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 10%˜20%=hexane/EtOAc), thus obtaining Compound 142 (61.6 mg, 59%) as white solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.83 (s, 1H), 7.73 (s, 2H), 7.54-7.53 (m, 0.5H), 7.32-7.25 (m, 0.5H), 7.10-7.07 (m, 0.5H), 6.88-6.83 (m, 1H), 5.59-5.51 (dd, J=8.2, 23.7, 1H), 5.50-5.48 (d, J=7.9, 0.5H), 4.09-3.86 (m, 2H), 3.74-3.67 (m, 3H), 3.57-3.53 (d, J=14.7, 0.5H), 3.41-3.37 (d, J=4.7, 0.5H), 2.45-2.41 (m, 0.5H), 2.24-2.22 (m, 1H), 2.17-2.13 (m, 0.5H), 1.93-1.91 (m, 3H), 1.61 (brs, 2H), 1.51-1.41 (m, 3H), 1.02-1.00 (m, 6H), 0.39-0.35 (m, 3H). MS (ESI) m/z 626 (M++H).
Compound 143 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxooxazolidin-3-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 143 (10 mg, 32%) as white solid was obtained according to the same method as the synthesis of compound 142.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.83 (s, 1H), 7.77-7.72 (m, 2H), 7.29 (m, 0.5H), 7.17-7.16 (m, 0.5H), 7.14-7.07 (m, 0.5H), 6.97-6.94 (0.5H), 6.80-6.75 (m, 1H), 6.49-6.44 (m, 1H), 5.61-5.59 (d, J=7.9, 0.5H), 5.50-5.48 (d, J=7.9, 0.5H), 4.09-3.86 (m, 2H), 3.74-3.67 (m, 3H), 3.57-3.53 (d, J=14.7, 0.5H), 3.41-3.37 (d, J=14.7, 0.5H), 2.45-2.41 (m, 0.5H), 2.24-2.22 (m, 1H), 2.17-2.13 (m, 0.5H), 1.93-1.91 (m, 3H), 1.61 (brs, 2H), 1.51-1.41 (m, 3H), 1.02-1.00 (m, 6H), 0.39-0.35 (m, 3H). MS (ESI) m/z 627 (M++H).
Compound 144 (4S,5R)-3-((2-(2-amino-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 144 (54 mg, 50%) as brown oil was obtained according to the same method as the synthesis of compound 132.
1H NMR (400 MHz, CDCl3); 1:2 atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.63-6.96 (m, 3H), 5.63 (d, J=8.0, 0.68H), 5.54 (d, J=8.1, 0.32H), 3.71-4.04 (m, 2H), 3.49 (d, J=14.6, 1H), 2.70-2.81 (m, 1H), 2.21-2.31 (m, 2H), 1.90-2.05 (m, 2H), 1.48-1.55 (m, 2H), 1.10-1.31 (m, 6H), 1.04-1.09 (m, 6H), 0.57 (d, J=6.5, 1H), 0.33 (d, J=6.5, 2H). MS (ESI) m/z 569 (M++H).
Compound 145 N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)-N-methylacetamideAccording to the same method as the synthesis of compound 110, compound 166 was synthesized and then reacted with iodomethane to obtain Compound 145 (10 mg, 45%) as yellow oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.90 (s, 1H), 7.79 (d, J=15.0, 2H), 6.90-7.20 (m, 3H), 5.70-5.73 (m, 1H), 3.94-4.13 (m, 2H), 3.13-3.41 (m, 1H), 2.87-3.24 (m, 3H), 2.82-3.00 (m, 1H), 1.62-2.30 (m, 4H), 1.44-1.49 (m, 2H), 1.17-1.29 (m, 6H), 1.00-1.29 (m, 6H), 0.42-0.72 (m, 3H). MS (ESI) m/z 625 (M++H).
Compound 146 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,1-dimethylureaCompound 146 (21 mg, 55%) as colorless oil was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.82 (s, 1H), 7.79 (d, J=6.2, 2H), 7.77-7.11 (m, 1H), 7.09-6.92 (m, 1H), 6.76 (t, J=9.0, 1H), 6.14 (d, J=14.4, 1H), 5.59, 5.44 (2d, J=7.9, 1H), 4.05-3.91 (m, 2H), 3.73 (s, 3H), 3.52-3.41 (m, 1H), 3.00 (d, J=15.4, 6H), 2.42-2.09 (m, 2H), 1.93-1.89 (m, 2H), 1.50-1.41 (m, 2H), 1.01-0.99 (m, 6H), 0.40, 0.36 (2d, J=6.5, 3H). MS (ESI) m/z 628 (M++H).
Compound 147 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methylthio)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAs shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (50 mg, 0.076 mmol), a starting material, was dissolved in chloroform (1.5 mL). Dimethyl sulfide (10 μl, 0.11 mmol) and tert-butyl nitrile (18 μl, 0.15 mmol) were added dropwise to the obtained solution at room temperature, stirred at room temperature for 30 minutes, and then refluxed with stirring and heating for 3 hours. After the completion of the reaction, the reaction mixture was cooled down to room temperature, diluted with n-hexane, and immediately purified by column chromatography (silica, 20% Hexane/EtOAc), thus obtaining Compound 147 (9 mg, 21%) as yellow oil.
(ESI) m/z (586.2 neg. (M+−H).
Compound 148 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,5-dimethyl-2-(2-(methylthio)-5-(trifluoromethoxy)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 148 (25 mg, 50%) as yellow solid was obtained according to the same method as the synthesis of compound 57.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 7.12-7.10 (m, 2H), 6.85-6.83 (m, 1H), 5.64, 5.61 (2d, J=8.0, 1H), 4.10-4.05 (m, 1H), 3.91-3.83 (m, 1H), 3.54, 3.28 (2d, J=15.0, 1H), 2.60-2.00 (m, 2H), 2.41 (s, 3H), 1.94 (bm, 2H), 1.56-1.46 (m, 2H), 1.08-1.03 (m, 6H), 0.50, 0.37 (2d, J=6.5, 3H).
Compound 151 (E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-3-methylguanidineAs shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (70 mg, 0.113 mmol), a starting material, was reacted with diphenyl cyanocarboimidate to synthesize an intermediate compound. The obtained intermediate compound (70 mg, 0.1 mmol) and methylamine (13 mg, 0.2 mmol) were dissolved in acetonitrile (3 mL). The obtained solution was refluxed with stirring at 80° C. After the completion of the reaction, the reaction mixture was diluted with methylene chloride, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 25%˜35%=Hexane/EtOAc), thus obtaining Compound 151 (30 mg, 47%) as white solid.
1H NMR (400 MHz, CDCl3); 1:2 atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 1H), 7.67 (s, 1H), 7.09-7.05 (m, 1H), 6.95-6.87 (m, 2H), 5.40-5.38 (m, 1H), 4.36-4.32 (m, 0.5H), 4.22-4.18 (m, 1H), 3.94-3.91 (m, 0.5H), 3.88 (s, 2H), 3.76 (s, 1H), 3.08-3.05 (m, 1H), 2.84-2.80 (m, 3H), 2.50-2.37 (m, 1H), 2.08-1.91 (m, 3H), 1.69 (brs, 2H), 1.56-1.42 (m, 2H), 1.03-0.97 (m, 6H), 0.64-0.62 (d, J=6.6, 2H), 0.57-0.56 (d, J=6.5, 1H). MS (ESI) 638 (M+H)+.
Compound 149 (Z)-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,1-dimethylguanidineCompound 149 (20 mg, 51%) as white solid was obtained according to the same method as the synthesis of compound 151.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.74-7.72 (m, 2H), 6.95-6.91 (m, 1H), 6.84-6.75 (m, 1H), 6.70-6.68 (m, 1H), 5.61-5.55 (dd, J=8.1, 17.2, 1H), 4.07-3.92 (m, 2H), 3.88 (s, 1.5H), 3.76 (s, 1.5H), 3.63-3.59 (d, J=14.6, 0.5H), 3.51-3.47 (d, J=14.6, 0.5H), 2.95-2.92 (m, 6H), 2.45-2.22 (m, 2H), 1.92 (s, 2H), 1.65 (brs, 2H), 1.49-1.43 (m, 1H), 1.03-0.94 (m, 6H), 0.52-0.50 (d, J=6.5, 1.5H), 0.42-0.41 (d, J=6.5, 1.5H). MS (ESI) m/z 652 (M++H).
Compound 153 (E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,3,3-trimethylguanidineCompound 153 (5 mg, 25%) as white solid was obtained according to the same method as the synthesis of compound 47.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.74-7.72 (m, 2H), 6.89-6.79 (m, 2H), 6.67-6.62 (m, 1H), 5.63-5.58 (m, 1H), 4.04-3.89 (m, 2H), 3.76-3.73 (m, 3H), 3.55-3.43 (m, 1H), 3.37-3.31 (m, 3H), 2.81-2.79 (m, 6H), 2.40-2.20 (m, 1H), 1.99 (s, 2H), 1.53-1.49 (m, 4H), 1.04-0.96 (m, 6H), 0.49-0.48 (d, J=6.5, 1.5H), 0.39-0.37 (d, J=6.5, 1.5H). MS (ESI) m/z 666 (M++H).
Compound 156 (Z)-methyl N-3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl-N′-methylcarbamimidothioateCompound 156 (16 mg, 64%) as colorless oil was obtained according to the same method as the synthesis of compound 47.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (d, J=9.1, 2H), 7.11-7.08 (m, 1H), 6.90-6.83 (m, 2H), 5.60, 5.53 (2d, J=8.0, 1H), 4.64-4.63 (m, 0.5H), 4.29-4.27 (m, 0.5H), 4.19-3.95 (m, 2H), 3.82, 3.75 (2s, 3H), 3.45, 3.21 (2d, J=15.0, 1H), 3.21, 3.16 (2s, 3H), 2.71 (dd, J=14.7, 4.7, 3H), 2.45-2.0 (m, 2H), 1.92 (s, 2H), 1.51-1.46 (m, 2H), 1.04-1.00 (m, 6H), 0.53, 0.41 (2 d, J=6.6 Hz, 3H).
Compound 157 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,3,3-trimethylureaCompound 157 (8 mg, 44%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 6.95-6.91 (m, 1H), 6.79, 6.77 (dd, J=8.8, 1H), 6.72 (dd, J=13.0, 2.7, 1H), 5.61 (dd, J=4.4, 8.0, 1H), 4.02-3.89 (m, 2H), 3.74 (d, J=8.9, 3H), 3.53, 3.44 (2d, J=14.0, 1H), 3.13, 3.06 (2s, 3H), 2.65 (d, J=12.3, 6H), 2.50-2.00 (m, 2H), 2.07-2.04 (m, 2H), 1.50-1.45 (m, 2H), 1.04-0.99 (m, 6H), 0.43, 0.33 (2d, J=6.5, 3H). MS (ESI) m/z 642 (M++H).
Compound 159 methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoateCompound 159 (30 mg, 32%) as brown oil was obtained according to the same method as the synthesis of compound 133.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73-7.75 (m, 2H), 7.13-7.16 (m, 1H), 6.77-6.96 (m, 2H), 5.31-5.61 (m, 1H), 3.89-4.00 (m, 2H), 3.73-3.75 (m, 3H), 3.53-3.68 (m, 3H), 3.53-3.68 (m, 1H), 3.37-3.68 (m, 1H), 1.94-2.47 (m, 6H), 1.44-1.59 (m, 3H), 1.01-1.25 (m, 6H), 0.27-0.38 (m, 3H). MS (ESI) m/z 628 (M++H).
Compound 160 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1,1,1-trifluoropropan-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAccording to the same method as the synthesis of Compound 133, 3-iodo-4-methoxyaniline, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was reacted with Compound 4 to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 160 (72 mg, 38%) as brown oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (m, 2H), 6.67-6.77 (m, 1H), 6.52-6.56 (m, 1H), 6.33-6.36 (m, 1H), 5.57-5.60 (m, 1H), 4.00-4.04 (m, 1H), 3.84-3.99 (m, 2H), 3.69 (d, J=8.2, 3H), 3.46-3.64 (m, 1H), 3.34 (br s, 1H), 1.43-2.50 (m, 6H), 1.33-1.41 (m, 3H), 0.97-1.04 (m, 6H), 0.32-0.46 (m, 3H), 1.01-1.04 (m, 6H), 0.33-0.37 (m, 3H). MS (ESI) m/z 653 (M++H).
Compound 161 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(1,1,1-trifluoropropan-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 161 (25 mg, 54%) as yellow oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.69-6.81 (m, 2H), 6.48-6.52 (m, 1H), 5.56-5.60 (m, 1H), 4.10-4.14 (m, 1H), 3.90-4.02 (m, 2H), 3.69-3.72 (m, 3H), 3.43-3.69 (m, 1H), 2.80 (d, J=15.6, 3H), 2.05-2.48 (m, 2H), 1.93 (s, 2H), 1.47-1.55 (m, 2H), 1.34-1.48 (m, 3H), 1.01-1.05 (m, 6H), 0.31-0.45 (m, 3H). MS (ESI) m/z 666 (M++H).
Compound 162 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluoroacetamideCompound 162 (0.21 mg, 92%) as yellow foam was obtained according to the same method as the synthesis of compound 18.
MS (ESI) m/z 653 (M++H).
Compound 163 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-bromoacetamideCompound 163 (44 mg, 100%) as yellow oil was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.11, 8.04 (2S, 1H), 7.84 (d, J=5.5, 1H), 7.79, 7.74 (2S, 1H), 7.43-7.36 (m, 1H), 7.15-7.09 (m, 1H), 6.82 (t, J=9.1, 1H), 5.60, 5.52 (2d, J=8.0, 1H), 4.08-3.90 (m, 4H), 3.75 (d, J=7.3, 3H), 3.57, 3.38 (2d, J=14.7, 1H), 2.24-2.03 (m, 2H), 1.93 (d, J=11.2, 2H), 1.51-1.41 (m, 2H), 1.01 (dd, J=10.0, 4.4, 6H), 0.39, 0.34 (2d, J=6.5, 3H). MS (ESI) m/z 676.0, 679.0 (M+−1, M++2).
Compound 166 N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)acetamideCompound 166 (25 mg, 44%) as colorless oil was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); 1:1.2 atropisomer mixture; δ 7.88 (s, 1H), 7.78 (s, 2H), 6.98-7.25 (m, 3H), 5.64-5.67 (m, 1H), 3.77-4.02 (m, 2H), 3.41-3.49 (m, 1H), 2.86-2.98 (m, 1H), 2.52 (s, 1H), 2.47 (s, 2H), 2.14-2.22 (m, 2H), 1.83-1.99 (m, 2H), 1.41-1.50 (m, 2H), 1.22-1.31 (m, 6H), 0.90-1.03 (m, 6H), 0.71 (d, J=6.4, 1H), 0.57 (d, J=6.5, 2H). MS (ESI) m/z 611 (M++H).
Compound 167 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-(methylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 167 (13 mg, 11%) as colorless oil was obtained according to the same method as the synthesis of compound 47.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.87 (d, J=5.2, 1H), 7.72 (d, J=7.4, 2H), 7.00-7.07 (m, 1H), 6.54-6.70 (m, 2H), 5.63 (d, J=8.1, 0.5H), 5.49 (d, J=8.2, 0.5H), 3.98 (d, J=14.7, 0.5H), 3.83-3.92 (m, 1H), 3.71-3.73 (m, 1H), 3.42 (d, J=14.6, 0.5H), 2.81 (d, J=8.4, 3H), 2.72-2.78 (m, 1H), 2.18-2.29 (m, 2H), 1.87-1.98 (m, 2H), 1.47-1.54 (m, 2H), 0.74-1.35 (m, 15H), 0.55 (d, J=6.5, 1.7H), 0.32 (d, J=6.5, 1.3H). MS (ESI) m/z 583 (M++H).
Compound 168 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(dimethylamino)-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 144 (34 mg, 0.06 mmol), paraformaldehyde (1 mL) and sodium cyanoborohydride (7 mg, 0.12 mmol) were dissolved in acetonitrile (2 mL). Acetic acid (7.4 μl, 0.12 mmol) was added dropwise slowly to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 4:1=Hexane/EtOAc), thus obtaining Compound 168 (30 mg, 85%) as colorless oil.
1H NMR (400 MHz, CDCl3); 1:3.2 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.99-7.02 (m, 1H), 6.80-6.86 (m, 2H), 5.59-5.61 (m, 1H), 3.40-3.82 (m, 3H), 2.75-2.78 (m, 1H), 2.67 (d, J=10.2, 3H), 2.15-2.25 (m, 2H), 1.88-2.05 (m, 2H), 1.52-1.56 (m, 2H), 1.27-1.33 (m, 6H), 1.12-1.19 (m, 6H), 1.04-1.07 (m, 6H), 0.61 (d, J=6.6, 0.7H), 0.16 (d, J=6.5, 2.3H). MS (ESI) m/z 597 (M++H).
Compound 170 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2,2,2-trifluoroacetyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzaldehyde (0.18 g, 0.32 mmol), a starting material, was dissolved in dimethoxyethane (5.0 mL). Cesium fluoride (5 mg, 0.03 mmol) and trimethylsilyl trifluoride (0.05 mL, 0.36 mmol) were added dropwise slowly to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with 1M HCl (hydrochloride) solution. The reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 4:1=Hexane/EtOAc), thus obtaining an intermediate compound (0.14 g, 68%) as colorless oil. The obtained intermediate compound (0.14 g, 0.22 mmol) and Dess-Martin periodinane (0.14 mg, 0.33 mmol) were dissolved in methylene chloride (5.0 mL), and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with water. The reaction mixture was extracted with methylene chloride. The obtained organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 3:1=hexane/EtOAc), thus obtaining Compound 170 (0.1 g, 70%), which is an intermediate compound, as colorless oil.
1H NMR (400 MHz, CDCl3); 1:1.2 atropisomer mixture; δ 8.03 (d, J=7.6, 1H), 7.87 (s, 1H), 7.73 (d, J=7.5, 3H), 6.99 (t, J=9.0, 1H), 5.66 (d, J=7.6, 0.55H), 5.55 (d, J=7.9, 0.45H), 3.91-4.03 (m, 2H), 3.90 (d, J=10.4, 3H), 3.54 (d, J=15.0, 0.45H), 3.31 (d, J=14.8, 0.55H), 2.21-2.26 (m, 2H), 1.52-1.53 (m, 2H), 1.48-1.51 (m, 2H), 1.02-1.06 (m, 6H), 0.39-0.43 (m, 3H). MS (ESI) m/z 638 (M++H).
Compound 171 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(perfluoroprop-1-en-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 170 (0.1 g, 0.149 mmol) was dissolved in dimethylformamide (5 mL). Triphenylphosphine (0.08 g, 0.3 mmol) and sodium chlorodifluoroacetate (0.05 g, 0.3 mmol) were added dropwise in sequence to the obtained solution at room temperature, and then refluxed with stirring at 135° C. for 6 hours. After the completion of the reaction, the reaction was quenched with water. The reaction mixture was extracted with ethyl acetate. The obtained organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (4 g silica, 3:1=hexane/EtOAc), thus obtaining the intermediate Compound 171 (17 mg, 20%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 7.18-7.22 (m, 1H), 6.86-6.96 (m, 2H), 5.55-5.62 (m, 1H), 3.84-3.99 (m, 2H), 3.80 (d, J=8.6, 3H), 3.58 (d, J=12.2, 0.5H), 3.39 (d, J=14.9, 0.5H), 2.08-2.51 (m, 2H), 1.88 (s, 2H), 1.49-1.55 (m, 6H), 1.01-1.05 (m, 6H), 0.31-0.34 (m, 3H). MS (ESI) m/z 672 (M++H).
Compound 172 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoropropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 172 (14 mg, 14%) as yellow oil was obtained according to the same method as the synthesis of compound 171.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 7.24-7.31 (m, 1H), 7.01-7.06 (m, 1H), 6.87-6.92 (m, 1H), 5.55-5.63 (m, 1H), 3.83-4.03 (m, 2H), 3.83-4.03 (m, 1H), 3.80 (d, J=7.2, 3H), 3.55 (d, J=14.7, 0.5H), 3.37 (d, J=14.8, 0.5H), 2.21-2.53 (m, 2H), 1.89-1.99 (m, 2H), 1.44-1.52 (m, 2H), 1.04 (d, J=13.4, 6H), 0.27-0.33 (m, 3H). MS (ESI) m/z 692 (M++H).
Compound 173 tert-butyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(isopropyl)carbamateCompound 173 (50 mg, 56%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); 1:1.2 atropisomer mixture; δ 7.84 (s, 1H), 7.72 (s, 2H), 6.92-6.90 (m, 1H), 6.81-6.74 (m, 1H), 6.68-6.66 (m, 1H), 5.62-5.56 (m, 1H), 4.47 (brs, 1H), 3.99-3.90 (m, 2H), 3.89-3.87 (m, 3H), 3.60-3.48 (m, 1H), 2.54-2.49 (m, 1H), 2.24-2.02 (m, 1H), 1.92 (s, 2H), 1.53-1.42 (m, 2H), 1.33-1.21 (m, 9H), 1.19-1.00 (m, 12H), 0.46 (d, J=6.6, 1H), 0.27 (d, J=6.3, 2H). MS (ESI) m/z 699 (M++H).
Compound 174 tert-butyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(ethyl)carbamateCompound 174 (45 mg, 52%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.79 (s, 2H), 6.95 (s, 1H), 6.81 (m, 2H), 5.57 (m, 1H), 3.99-3.85 (m, 2H), 3.75-3.74 (m, 3H), 3.63-3.41 (m, 3H), 2.47-1.86 (m, 4H), 1.58-1.23 (m, 11H), 1.16-0.88 (m, 9H), 0.44-0.22 (m, 4H). MS (ESI) m/z 684 (M++H).
Compound 177 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-ethylacetamideCompound 177 (15 mg, 79%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); 1:1.3 atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 7.03-7.01 (m, 1H), 6.99-6.77 (m, 2H), 5.62-5.60 (d, J=8.0, 1H), 4.06-3.87 (m, 2H), 3.79 (s, 1.2H), 3.76 (s, 1.8H), 3.74-3.61 (m, 2H), 3.54-3.34 (m, 1H), 2.51-2.47 (m, 0.5H), 2.29-2.08 (m, 1.5H), 2.06-2.01 (m, 1H), 1.93-1.79 (m, 3H), 1.79 (s, 1.5H), 1.75 (s, 1.5H), 1.55-1.43 (m, 2H), 1.17-0.92 (m, 6H), 0.46-0.44 (d, J=6.2, 1.3H), 0.34-0.32 (d, J=6.2, 1.7H). MS (ESI) m/z 627 (M++H).
Compound 178 (4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2,2,2-trifluoro-1-(methoxyimino)ethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 170 (0.1 g, 0.157 mmol) and methylamine (26 mg, 0.31 mmol) were dissolved in methanol (5 mL). Pyridine (25 μl, 0.31 mmol) was added dropwise slowly to the obtained solution at room temperature, and stirred at 60° C. for 12 hours. After the completion of the reaction, the reaction was quenched with water. The reaction mixture was extracted with methylene chloride. The obtained organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 3:1=hexane/EtOAc), thus obtaining Compound 178 (35 mg, 30%), which is an intermediate compound, as colorless oil.
1H NMR (400 MHz, CDCl3); 1:3.2 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.99-7.02 (m, 1H), 6.80-6.86 (m, 2H), 5.59-5.61 (m, 1H), 3.40-3.82 (m, 3H), 2.75-2.78 (m, 1H), 2.67 (d, J=10.2, 3H), 2.15-2.25 (m, 2H), 1.88-2.05 (m, 2H), 1.52-1.56 (m, 2H), 1.27-1.33 (m, 6H), 1.12-1.19 (m, 6H), 1.04-1.07 (m, 6H), 0.61 (d, J=6.6, 0.7H), 0.16 (d, J=6.5, 2.3H). MS (ESI) m/z 685 (M++H).
Compound 179 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-(2-hydroxy-2-methylpropyl)acetamideAs the same method as the synthesis of Compound 112, except using isobutylene oxide instead of iodomethane, Compound 179 (10 mg, 50%) as colorless oil was obtained.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.88 (s, 1H), 7.82-7.78 (m, 1H), 7.48-7.45 (m, 0.5H), 7.24-7.23 (m, 0.5H), 7.17-7.00 (m, 2H), 6.82-6.79 (m, 1H), 4.99-4.98 (d, J=5.5, 1H), 3.93-3.41 (m, 7H), 2.38-2.32 (m, 1H), 2.17-2.15 (m, 3H), 1.97-1.83 (m, 3H), 1.50-1.42 (m, 2H), 1.38-1.22 (m, 6H), 1.15-1.05 (m, 3H), 0.89-0.86 (m, 3H), 0.69-0.61 (m, 3H). MS (ESI) 671 (M++H).
Compound 180 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3,3-difluoroazetidine-1-carbonyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 180 (17 mg, 77%) as colorless oil was obtained according to the same method as the synthesis of compound 67.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 7.55-7.44 (m, 1H), 7.43-7.33 (m, 1H), 6.88 (dd, J=8.6, 3.9, 1H), 5.60, 5.53 (2d, J=8.0, 1H), 4.55-4.47 (m, 4H), 4.01-3.93 (m, 2H), 3.83, 3.80 (2s, 3H), 3.48, 3.35 (2d, J=14.9, 1H), 2.39-2.01 (m, 4H), 1.80-1.73 (m, 4H), 0.42 (dd, J=15.7, 6.5, 3H). MS (ESI) m/z 633, 634 (M++H, M++2).
Compound 181 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 181 (37 mg, 72%) as white solid was obtained according to the same method as the synthesis of compound 170.
1H NMR (400 MHz, CDCl3); 1:3.2 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.99-7.02 (m, 1H), 6.80-6.86 (m, 2H), 5.59-5.61 (m, 1H), 3.40-3.82 (m, 3H), 2.75-2.78 (m, 1H), 2.67 (d, J=10.2, 3H), 2.15-2.25 (m, 2H), 1.88-2.05 (m, 2H), 1.52-1.56 (m, 2H), 1.27-1.33 (m, 6H), 1.12-1.19 (m, 6H), 1.04-1.07 (m, 6H), 0.61 (d, J=6.6, 0.7H), 0.16 (d, J=6.5, 2.3H). MS (ESI) m/z 708 (M++H).
Compound 182 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 182 (12 mg, 47%) as white solid was obtained according to the same method as the synthesis of compound 47.
1H NMR (400 MHz, CDCl3); 1:3.2 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.99-7.02 (m, 1H), 6.80-6.86 (m, 2H), 5.59-5.61 (m, 1H), 3.40-3.82 (m, 3H), 2.75-2.78 (m, 1H), 2.67 (d, J=10.2, 3H), 2.15-2.25 (m, 2H), 1.88-2.05 (m, 2H), 1.52-1.56 (m, 2H), 1.27-1.33 (m, 6H), 1.12-1.19 (m, 6H), 1.04-1.07 (m, 6H), 0.61 (d, J=6.6, 0.7H), 0.16 (d, J=6.5, 2.3H). MS (ESI) m/z 722 (M++H).
Compound 183 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 183 (8 mg, 24%) as yellow oil was obtained according to the same method as the synthesis of compound 120.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.88 (s, 1H), 7.78 (s, 2H), 6.76-6.72 (m, 1H), 6.52-6.49 (m, 1H), 6.24 (dd, J=10.1, 2.9, 1H), 4.99-4.97 (m, 1H), 3.94-3.83 (m, 1H), 3.67-3.61 (2s, 3H), 3.70-3.53 (m, 2H), 2.79, 2.77 (2s, 3H), 2.39-1.91 (m, 4H), 1.86, 1.81 (2s, 1H), 1.60-1.52 (m, 2H), 1.53, 1.49 (2s, 1H), 1.47-1.25 (m, 6H), 1.04-0.97 (m, 6H), 0.79, 0.55 (2s, 3H).
Compound 184 (4S,5R)-3-((2-(5-acetyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneAs shown in reaction scheme 4, Compound 12 was synthesized. The obtained Compound 12 (0.24 g, 0.83 mmol) was subjected to a Suzuki reaction with Compound 9 (0.39 g, 0.756 mmol) to obtain Compound 184 (0.11 g, 25%) as brown oil.
MS (ESI) m/z 602 (M++H).
Compound 185 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzaldehyde (35 mg, 0.06 mmol), a starting material, was dissolved in tert-butyl alcohol (2 mL). Ethanolamine (4 μl, 0.07 mmol) was added dropwise to the obtained solution at room temperature, and stirred for 30 minutes at room temperature. Potassium carbonate (25 mg, 0.18 mmol) and iodine (31 mg, 0.12 mmol) were added dropwise to the obtained reaction mixture. The obtained reaction mixture was refluxed with stirring at 70° C. overnight. After the completion of the reaction, saturated sodium thiosulfate solution was added dropwise to the reaction mixture, to quench the reaction. The reaction mixture was extracted with ethyl acetate. The obtained organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining the intermediate Compound 185 (11 mg, 30%) as white solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.82-7.77 (m, 1H), 7.74, 7.71 (2s, 2H), 7.61 (dd, J=13.5, 2.1, 1H), 6.87 (dd, J=8.6, 11.3, 1H), 5.62, 5.49 (2d, J=8.1, 1H), 4.42-4.32 (m, 2H), 4.04-3.83 (m, 4H), 3.81, 3.79 (2s, 3H), 3.53, 3.35 (d, J=14.8, 1H), 2.41-2.04 (m, 2H), 1.91 (bs, 2H), 1.52-1.42 (m, 2H), 1.03-1.00 (m, 6H), 0.35 (dd, J=8.9, 6.5, 3H). MS (ESI) m/z 611 (M++H).
Compound 187 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-hydroxyazetidine-1-carbonyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 187 (16 mg, 52%) as white solid was obtained according to the same method as the synthesis of compound 67.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.74 (d, J=4.0, 2H), 7.54 (dd, J=8.5, 2.2, 0.5H), 7.47 (dd, J=8.5, 2.1, 0.5H), 7.41 (d, J=2.1, 0.5H), 7.30 (d, J=2.2, 0.5H), 6.86 (dd, J=8.6, 4.0, 1H), 5.61, 5.56 (2d, J=8.0, 1H), 4.69 (bm, 1H), 4.44 (bs, 2H), 4.15-3.93 (m, 3H), 3.82, 3.79 (2s, 3H), 3.52, 3.37 (2d, J=14.6, 1H), 3.13, 3.03 (2d, J=5.4, 1H), 2.47-2.08 (m, 2H), 1.92 (bs, 2H), 1.53-1.44 (m, 2H), 1.04-1.01 (m, 6H), 0.44, 0.37 (2d, J=6.5, 3H). MS (ESI) m/z 642, 663 ((M+H)+, (M+H)++21).
Compound 188 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 188 (14 mg, 40%) as white solid was obtained according to the same method as the synthesis of compound 185.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84-7.77 (m, 2H), 7.74, 7.71 (2s, 2H), 7.59 (dd, J=12.1, 2.1, 1H), 6.85 (dd, J=8.6, 12.4, 1H), 5.63, 5.50 (2d, J=8.0, 1H), 4.38-4.30 (m, 1H), 4.12-3.93 (m, 4H), 3.80, 3.78 (2s, 3H), 3.52, 3.36 (2d, J=14.8, 1H), 2.47-2.12 (m, 2H), 1.92 (bs, 2H), 1.87-1.71 (m, 1H), 1.50-1.45 (m, 2H), 1.06-1.01 (m, 7.5H), 0.91-0.89 (m, 3H), 0.80 (d, J=6.7, 1.5H), 0.36 (2d, J=6.5, 3H). MS (ESI) m/z 653 (M++H).
Compound 189 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarbonitrileAccording to the same method as the synthesis of Compound 12 in reaction scheme 4, a pinacolato compound was synthesized. And then the synthesis procedure was operated according to the same method as shown in reaction scheme 2, to obtain Compound 189 (0.25 g, 81%) as green foam.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.74 (d, J=5.7, 2H), 7.16 (dd, J=8.5, 2.5, 0.5H), 7.07 (d, J=2.4, 0.5H), 7.02 (dd, J=8.5, 2.5, 0.5H), 6.90 (d, J=2.5, 0.5H), 6.81 (dd, J=8.5, 11.4, 1H), 5.59 (dd, J=8.3, 10.4, 1H), 4.00-3.94 (m, 2H), 3.76, 3.73 (2s, 3H), 3.50, 3.35 (2d, J=14.7, 1H), 2.50-2.04 (m, 2H), 1.92 (bs, 2H), 1.68-1.56 (m, 2H), 1.50-1.47 (m, 2H), 1.34-1.23 (m, 2H), 1.04-1.00 (m, 6H), 0.43, 0.36 (2d, J=6.5, 3H). MS (ESI) m/z 607 (M++H).
Compound 190 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarboxamideCompound 189 (0.1 g, 0.165 mmol), 30% hydrogen peroxide (0.6 mL) and 7M potassium hydroxide (60 μl) were dissolved in ethanol (1 mL). The obtained solution was stirred at 85° C. for 4 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining intermediate compound (27 mg, 28%). The obtained intermediate compound (26 mg, 0.04 mmol) was dissolved in anhydrous methylene chloride (1 mL). Diisopropylamine (45 μl, 0.26 mmol) and triphosgene (6 mg, 0.02 mmol) were added dropwise to the obtained solution at 0° C., and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 190 (19 mg, 70%) as white solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (d, J=7.6, 2H), 7.30-7.27 (m, 1H), 7.07, 7.03 (2d, J=2.3, 1H), 6.86, 6.81 (2d, J=8.4, 1H), 5.88 (bs, 0.5H), 5.61, 5.54 (2d, J=8.3, 1H), 5.52-5.42 (bm, 1.5H), 4.20-3.93 (m, 2H), 3.81 (s, 1.7H), 3.74 (s, 1.3H), 3.44, 3.20 (2d, J=14.5, 1H), 2.50-2.03 (m, 2H), 1.93 (bs, 2H), 1.59-1.46 (m, 4H), 1.04-1.02 (m, 6H), 1.00-0.94 (m, 2H), 0.53, 0.38 (2d, J=6.5, 3H). MS (ESI) m/z 625 (M++H).
Compound 191 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroacetyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 191 (33 mg, 55%) as yellow oil was obtained according to the same method as the synthesis of compound 170.
MS (ESI) m/z 656 (M++H).
Compound 192 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(cyclopropanecarbonyl)-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAccording to the same method as the synthesis of Compound 133, 2-bromo-4-fluorophenol, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was reacted with Compound 4, to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene to obtain Compound 192 (4 mg, 48%) as brown oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.76-6.79 (m, 1H), 6.50-6.57 (m, 1H), 5.59-5.62 (m, 1H), 3.90-3.98 (m, 2H), 3.73 (s, 3H), 3.53-3.73 (m, 1H), 3.10-3.16 (m, 1H), 2.02-2.45 (m, 2H), 1.91-1.93 (m, 2H), 1.50-1.54 (m, 2H), 1.01-1.05 (m, 6H), 0.32-0.42 (m, 3H). MS (ESI) m/z 628 (M++H).
Compound 193 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 193 (1 g, 99%) as yellow solid was obtained according to the same method as the synthesis of compound 18.
MS (ESI) m/z 560 (M++H).
Compound 194 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 194 (0.1 g, 80%) as white solid was obtained according to the same method as the synthesis of compound 52.
MS (ESI) m/z 627 (M++H).
Compound 195 (4S,5R)-3-((2-(5-amino-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 194 (0.1 g, 0.16 mmol) was dissolved in methanol (3 mL). Raney-nickel (3 mL) was added dropwise to the obtained solution at room temperature, and stirred at room temperature under hydrogen balloon. After the completion of the reaction, the reaction mixture was filtered with celite, and concentrated under reduced pressure. The reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 1:1=hexane/EtOAc), thus obtaining Compound 195 (35 g, 35%) as yellow solid.
MS (ESI) m/z 597 (M++H).
Compound 196 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(trifluoromethyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamideCompound 196 (40 mg, 70%) as yellow oil was obtained according to the same method as the synthesis of compound 110.
MS (ESI) m/z 640 (M++H).
Compound 197 methyl 5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxybenzoateAccording to the same method as the synthesis of Compound 133, 2-fluoro-4-methoxybenzoic acid, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was reacted with Compound 4 to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 197 (0.21 g, 88%) as yellow oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.74 (s, 1H), 7.71 (s, 1H), 7.57 (dd, J=8.3, 10.2, 1H), 6.61 (dd, J=8.8, 12.6, 1H), 5.64, 5.55 (2d, J=8.1, 1H), 3.98-3.89 (m, 2H), 3.84, 3.82 (2s, 3H), 3.80, 3.79 (2s, 3H), 3.53, 3.33 (2d, J=14.6, 1H), 2.41-2.01 (m, 2H), 1.92-1.87 (bm, 2H), 1.51-1.42 (m, 2H), 1.02 (dd, 13.0, 2.0, 6H), 0.43, 0.39 (2d, J=6.5, 3H). MS (ESI) m/z 618 (M++H).
Compound 204 5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxybenzoic acidCompound 204 (83 mg, 45%) as white solid was obtained according to the same method as the synthesis of compound 34.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (d, J=8.2, 2H), 7.63 (dd, J=8.4, 3.9, 1H), 6.65 (dd, J=9.0, 12.6, 1H), 5.65, 5.56 (2d, J=8.0, 1H), 4.00-3.92 (m, 2H), 3.83 (d, J=11.2, 3H), 3.53, 3.31 (2d, J=14.8, 1H), 2.41-2.04 (m, 2H), 1.97-1.84 (m, 2H), 1.50-1.44 (m, 2H), 1.04-1.00 (m, 6H), 0.43 (t, J=6.8, 3H). MS (ESI) m/z 604 (M++H).
Compound 206 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitro-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAs shown in reaction scheme 1,4-methoxy-1-nitro-2-(trifluoromethyl)benzene, a starting material, was subjected to iodination using iodine. The obtained compound was subjected to Ullmann reaction using Compound 2 (Martin G. Banwell et al. Org. Lett. 2004, 6, 2741), to synthesize a compound, and then according to the same method as the synthesis of compound 52, Compound 206 (0.65 g, 83%) as yellow foam was obtained.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.74 (d, J=4.9, 2H), 7.69 (d, J=2.4, 1H), 7.22 (d, J=11.4, 1H), 5.66, 5.77 (2d, J=8.2, 1H), 4.03-3.93 (m, 2H), 3.94, 3.93 (2s, 3H), 3.50, 3.31 (2d, J=14.9, 1H), 2.40-2.03 (m, 2H), 1.95 (bs, 2H), 1.53-1.47 (m, 2H), 1.05-1.01 (m, 6H), 0.50 (t, J=6.8, 3H).
Compound 207 (4S,5R)-3-((2-(5-amino-2-methoxy-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 207 (0.33 mg, 56%) as white foam was obtained according to the same method as the synthesis of compound 195.
MS (ESI) m/z 625 (M++H).
Compound 209 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)trifluoro-N-methylmethanesulfonamideCompound 209 (27 mg, 56%) as yellow solid was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (d, J=9.6, 1H), 7.74-7.70 (m, 2H), 7.17-7.13 (m, 1H), 7.06 (d, J=4.8, 1H), 5.65-5.46 (m, 1H), 4.03-3.53 (m, 6H), 3.41-3.29 (m, 3H), 2.22-2.06 (m, 2H), 2.02-1.87 (m, 2H), 1.52-1.46 (m, 2H), 1.04-0.99 (m, 2H), 1.50-0.47 (m, 1H), 0.38 (d, J=6.5, 1H), 0.32 (d, J=6.5, 1H). MS (ESI) m/z 771 (M++H).
Compound 210 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylacetamideAccording to the same method as the synthesis of Compound 112, Compound 210 (31 mg, 84%) as white solid was obtained.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 7.16-7.13 (m, 1H), 6.95 (d, J=6.2, 1H), 5.63 (dd, J=4.4, 8.0, 1H), 4.03-3.91 (m, 2H), 3.86, 3.83 (2s, 3H), 3.45-3.26 (m, 1H), 3.17-3.05 (m, 3H), 2.46-2.03 (m, 2H), 1.97-1.90 (bm, 2H), 1.76-1.71 (m, 3H), 1.53-1.45 (m, 2H), 1.04-0.96 (m, 6H), 0.50-0.36 (m, 3H). MS (ESI) m/z 681 (M++H).
Compound 212 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(4-(trifluoromethyl)thiazol-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 212 (58.2 mg, 40.3%) as white solid was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73, 7.72 (2s, 2H), 7.22, 7.19 (2dd, J=2.8, 0.9, 1H), 7.02, 7.00 (2d, J=2.7, 1H), 6.92, 6.89 (2d, J=8.8, 1H), 6.84, 6.79 (2t, J=1.0, 1H), 5.61 (d, J=8.1, 1H), 4.01 (m, 2H), 3.81, 3.78 (2s, 3H), 3.59, 3.47 (2d, J=14.6, 15.0, 1H), 3.50, 3.44 (2s, 3H), 2.55-1.86 (brm, 4H), 1.51 (m, 2H), 1.27 (m, 2H), 1.05, 1.03, 1.00 (3s, 6H). MS (ESI) m/z 766 (M+K)+.
Compound 213 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(4-(trifluoromethyl)thiazol-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAs shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (0.3 g, 0.486 mmol) was dissolved in chloroform/saturated sodium carbonate solution (10 mL, V/V 3:1). Thiophosgene (62.5 μl) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate. The obtained organic layer was washed with water and brine. The organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was dissolved in methanol (3 mL). Ammonia water (0.5 mL) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 5 hours. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was crystallized, thus obtaining the intermediate Compound (0.3 g, 87.2%) as white solid. The obtained intermediate compound (0.16 g, 0.27 mmol) was dissolved in ethanol (3 mL). 3-bromo-1,1,1-trifluoropropane-2-one (44.6 μl) was added dropwise to the obtained solution at room temperature, and then refluxed with stirring at 90° C. for 2 hours. After the completion of the reaction, the reaction mixture was cooled to room temperature. The reaction mixture was diluted with ethyl acetate. And then, the obtained organic layer was washed with saturated sodium hydrogen carbonate solution, water and brine. The organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure, thus obtaining Compound 213 (0.18 g, 93.1%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.23, 8.06 (2brs, 1H), 7.85, 7.84 (2s, 1H), 7.72 (s, 2H), 7.27-7.15 (m, 1.5H), 6.99-6.84 (m, 2.5H), 5.60 (d, J=8.1, 1H), 4.01 (m, 2H), 3.80, 3.78 (2s, 3H), 3.68, 3.42 (2d, J=14.2, 1H), 2.51-1.88 (brm, 6H), 1.50 (m, 2H), 1.04 (m, 6H), 0.42, 0.35 (2d, J=5.4, 6.5, 3H).
Compound 215 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-N-methylacetamideCompound 215 (21 mg, 31%) as white foam was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.73 (s, 2H), 6.86 (m, 1H), 6.68 (m, 1H), 5.64, 5.62 (2s, 1H), 3.97 (m, 2H), 3.79, 3.76 (2s, 3H), 3.51-3.33 (brm, 2H), 3.19, 3.18, 3.08 (3s, 3H), 2.46-1.62 (brm, 9H), 1.46 (m, 2), 1.00 (m, 6H), 0.49-0.36 (m, 3H). MS (ESI) m/z 631 (M++H).
Compound 216 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)acetamideCompound 216 (82 mg, 79%) as white solid foam was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.79-7.76 (m, 4H), 7.21, 7.18 (2s, 1H), 6.64, 6.61 (2d, J=7.4, 1H), 5.63, 5.46 (2d, J=7.9, 1H), 4.12 (m, 1H), 3.94 (m, 1H), 3.56, 3.30 (2d, J=15.0, 1H), 2.19, 2.14 (2s, 3H), 1.93, 1.90 (2s, 2H), 1.45 (m, 2H), 1.01, 1.00, 0.99, 0.98 (4s, 6H), 0.46, 0.32 (2d, J=6.5, 3H). MS (ESI) m/z 617 (M++H).
Compound 217 (4S,5R)-3-((2-(5-amino-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 217 (0.12 g, 99%) as yellow oil was obtained according to the same method as the synthesis of compound 195.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 6.58, 6.54 (2d, J=12.6, 1H), 6.44, 6.41 (2d, J=6.1, 1H), 5.60, 5.58 (2d, J=2.9, 1H), 4.0-3.89 (m, 2H), 3.67, 3.64 (2s, 3H), 3.58, 3.47 (2d, J=14.6, 1H), 3.37 (brs, 2H), 2.42-1.89 (brm, 6H), 1.45 (m, 2H), 0.99 (m, 6H), 0.48, 0.34 (2d, J=6.6, 6.5, 3H). MS (ESI) m/z 575 (M++H).
Compound 218 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 218 (0.3 g, 80%) as white solid was obtained according to the same method as the synthesis of compound 206.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.78, 7.77 (2d, J=4.4, 1H), 7.72, 7.71 (2s, 2H), 6.74, 6.71 (2d, J=7.6, 1H), 5.56, 5.59 (2d, J=5.4, 1H), 3.96 (m, 2H), 3.89, 3.86 (2s, 3H), 3.52, 3.30 (2d, J=15.0, 1H), 2.38-1.87 (brm, 6H), 1.48 (m, 2H), 1.09, 1.08, 1.00, 0.99 (4s, 6H), 0.47 (t, J=6.7, 3H). MS (ESI) m/z 649 (M++K).
Compound 219 tert-butyl 3-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate1-tert-Butyl 3-ethyl 4-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1,3(2H)-dicarboxylate, a starting material, was synthesized, and then was subjected to a Suzuki reaction with boronic acid. The obtained compound was subjected to a reduction using lithium aluminium hydride, and then to the oxidation using Dess-Martin periodinane. The obtained compound was reacted with Compound 4 to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene to obtain Compound 219 (39 mg, 45%) as white foam.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.82 (m, 1H), 6.57, 6.53 (2d, J=12.1, 1H), 3.99 (m, 4H), 3.74, 3.70 (2s, 3H), 3.12 (m, 1H), 2.6-2.01 (m, 2H), 1.51 (s, 9H), 1.19 (m, 6H), 0.40, 0.30 (2d, J=6.5, 3H).
Compound 222 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAccording to the same method as the synthesis of Compound 133, 2-fluoro-4-methoxyphenol, a starting material, was subjected to several synthesis processes to obtain an iodobenzene compound. The obtained compound was subjected to Ullmann reaction using Compound 2, thus synthesizing an aldehyde compound. The obtained aldehyde compound was reacted with Compound 4 to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 222 (7 mg, 47%) as yellow solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 6.75 (dd, J=15.5, 9.2, 1H), 6.65 (dd, J=12.7, 11.4, 1H), 5.60 (dd, J=8.1, 3.0, 1H), 4.38-4.28 (m, 2H), 3.99-3.88 (m, 2H), 3.74, 3.70 (2s, 3H), 3.52, 3.39 (2d, J=14.6, 1H), 2.45-1.99 (m, 2H), 1.95-1.89 (m, 2H), 1.52-1.41 (m, 2H), 1.03-0.98 (m, 6H), 0.41 (2d, J=6.5, 3H). MS (ESI) m/z 658 (M++H).
Compound 223 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-methoxybenzo[d][1,3]dioxol-5-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAccording to the same method as the synthesis of Compound 133, benzo[d][1,3]dioxol-5-ol, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was subjected to a Suzuki reaction using Compound 2, thus synthesizing an aldehyde compound. The obtained aldehyde compound was reacted with Compound 4 to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 223 (4 mg, 49%) as colorless oil.
1H NMR (400 MHz, CDCl3); 1:1.5 atropisomer mixture; δ 7.86 (s, 1H), 7.74 (s, 2H), 6.45-6.52 (m, 2H), 5.87-5.92 (m, 2H), 5.62 (t, J=7.7, 1H), 3.90-4.03 (m, 2H), 3.70 (d, J=7.6, 3H), 3.65 (d, J=3.8, 0.6H), 3.50 (d, J=14.9, 0.4H), 2.01-2.45 (m, 2H), 1.89-1.91 (m, 2H), 1.44-1.49 (m, 2H), 1.00-1.04 (m, 6H), 0.49 (d, J=6.6, 1.2H), 0.38 (d, J=6.5, 1.8H). MS (ESI) m/z 586 (M++H).
Compound 224 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylisobutyramideCompound 224 (49 mg, 74%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (d, J=4.5, 2H), 7.17-7.13 (m, 1H), 6.95 (d, J=10.4, 1H), 5.64-5.62 (m, 1H), 4.04-3.91 (m, 2H), 3.86-3.81 (m, 3H), 3.46-3.30 (m, 1H), 3.15-3.03 (m, 3H), 2.45-2.03 (m, 3H), 1.97-1.90 (m, 2H), 1.51-1.45 (m, 2H), 1.04-0.87 (m, 12H), 0.56-0.37 (m, 3H). MS (ESI) m/z 709, 710 (M++H, M++2).
Compound 225 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylpropionamideCompound 225 (33 mg, 70%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (d, J=4.5, 2H), 7.15 (d, J=13.2, 1H), 6.92 (d, J=7.2, 1H), 5.64 (dd, J=8.0, 3.3, 1H), 4.03-3.91 (m, 2H), 3.85 (2d, J=12.6, 1.3, 3H), 3.45-3.32 (m, 1H), 3.16 (s, 1H), 3.04 (s, 1H), 2.45-2.02 (m, 2H), 1.97-1.86 (m, 4H), 1.53-1.45 (m, 2H), 1.04-0.96 (m, 9H), 0.50-0.37 (m, 3H). MS (ESI) m/z 695 (M++H).
Compound 226 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylmethanesulfonamideAccording to the same method as the synthesis of Compound 112, Compound 226 (20 mg, 39%) as white solid was obtained.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (m, 1H), 7.75 (d, J=12.1, 2H), 7.45-7.06 (m, 2H), 5.63-5.41 (m, 1H), 4.00-3.70 (m, 2H), 3.88-3.80 (m, 3H), 2.50-3.24 (m, 1H), 3.18-3.02 (m, 3H), 2.98, 2.87 (2s, 3H), 2.40-2.03 (m, 2H), 1.97-1.94 (m, 2H), 1.51-1.42 (m, 2H), 1.03-0.97 (m, 6H), 0.54-0.33 (m, 3H). MS (ESI) m/z 717 (M++H).
Compound 227 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-2,2,2-trifluoro-N-methylacetamideCompound 227 (8 mg, 73%) as yellow solid was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.76-7.72 (m, 2H), 7.17-7.13 (m, 1H), 7.02-6.95 (m, 1H), 5.66-5.60 (m, 1H), 4.03-3.81 (m, 2H), 3.88-3.84 (m, 3H), 3.52-3.33 (m, 1H), 3.31-3.19 (m, 3H), 2.45-1.99 (m, 2H), 1.97-1.90 (m, 2H), 1.53-1.42 (m, 2H), 1.05-0.89 (m, 6H), 0.53-0.32 (m, 3H). MS (ESI) m/z 735 (M+).
Compound 228 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)trifluoromethanesulfonamideCompound 228 (61 mg, 73%) as yellow oil was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (d, J=7.2, 2H), 7.32-7.27 (m, 1H), 7.10 (d, J=9.8, 1H), 5.62, 5.51 (2d, J=8.0, 1H), 4.00-3.88 (m, 2H), 3.84 (d, J=5.6, 3H), 3.57, 3.26 (2d, J=14.9, 1H), 2.40-2.07 (m, 2H), 1.93 (bs, 2H), 1.51-1.44 (m, 2H), 1.03-0.98 (m, 6H), 0.44, 0.33 (2d, J=6.5, 3H). MS (ESI) m/z 757, 758 (M+, M++H).
Compound 229 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2,4-dimethoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 229 (89 mg, 74%) as colorless oil was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); 1:1.7 atropisomer mixture; δ 7.87 (s, 1H), 7.69-7.78 (m, 2H), 6.49 (d, J=9.1, 1H), 5.67 (d, J=7.4, 0.7H), 5.55 (d, J=8.2, 0.4H), 3.95-4.07 (m, 2H), 4.00-3.97 (m, 3H) 3.86-3.90 (m, 3H), 3.58 (d, J=14.8, 0.5H), 3.34 (d, J=14.9, 0.5H), 2.18-2.38 (m, 2H), 1.87. MS (ESI) m/z 617 (M++H).
Compound 230 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2,4-dimethoxyphenyl)-N-methylacetamideCompound 230 (4 mg, 85%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.74 (s, 2H), 6.76-6.81 (m, 1H), 6.44-6.48 (m, 1H), 5.61-5.64 (m, 1H), 3.91-4.04 (m, 2H), 3.74-3.85 (m, 6H), 3.40-3.59 (m, 1H), 3.13 (s, 2H), 3.01 (s, 1H), 2.07-2.49 (m, 2H), 1.95-2.10 (m, 3H), 1.78-1.81 (m, 3H), 1.50-1.59 (m, 2H), 1.01-1.08 (m, 6H), 0.07-0.47 (m, 3H). MS (ESI) m/z 643 (M++H).
Compound 231 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 219 (0.45 g, 0.67 mmol) was dissolved in methylene chloride (3 mL). Trifluoroacetic acid (1 mL) was added dropwise to the obtained solution at 0° C., and then stirred at room temperature for 3 hours. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with methylene chloride, washed with saturated sodium hydrogen carbonate solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized, thus obtaining an intermediate compound (0.32 mg, 88%) as white solid. The obtained compound was subjected to reaction process according to the same method as the synthesis of compound 47, to obtain Compound 231 (1.0 mg, 10%) as colorless oil.
MS (ESI) m/z 589 (M++K).
Compound 232 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-hydroxy-2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 218 (0.12 g, 0.2 mmol) and 2-(methylsulfonylethanol) (32 mg) were dissolved in dimethylformamide (3 mL). Sodium hydride (15.3 mg) was added dropwise carefully to the obtained solution at room temperature, and stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with saturated ammonium chloride solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized, thus obtaining Compound 232 (91 mg, 77%) as yellow solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 10.98, 10.96 (2s, 1H), 7.86 (s, 1H), 7.79-7.71 (m, 3H), 6.53, 6.51 (2s, 1H), 5.63 (2d, J=8.1, 1H), 4.02-3.93 (m, 2H), 3.87, 3.86 (2s, 3H), 3.45 (2d, J=14.9, 1H), 2.39-1.86 (m, 4H), 1.52-1.43 (m, 2H), 1.01 (2d, J=3.8, 6H), 0.46 (2d, J=6.6, 3H). MS (ESI) m/z 603 (M++H).
Compound 233 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methylamino)-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 233 (46 mg, 85%) as yellow oil was obtained according to the same method as the synthesis of compound 120.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.96, 6.89 (2s, 1H), 6.37 (d, J=8.0, 1H), 5.61 (d, J=7.2, 1H), 4.03-3.92 (m, 2H), 3.70 (d, J=7.6, 3H), 3.60-3.49 (m, 1H), 2.84, 2.80 (2s, 3H), 2.49-2.02 (m, 2H), 1.92 (bs, 2H), 1.52-1.46 (m, 2H), 1.04-0.98 (m, 6H), 0.52, 0.36 (2d, J=0.3, 3H). MS (ESI) m/z 639 (M++H).
Compound 234 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-ethyl-4-methoxyphenyl)-N-methylacetamideCompound 234 (1.4 mg, 74%) as yellow oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); 1:1 atropisomer mixture; δ 7.86 (s, 1H), 7.63 (s, 2H), 6.77 (m, 2H), 5.62 (m, 1H), 4.04-3.90 (m, 2H), 3.80, 3.77, 3.76 (3s, 3H), 3.56-3.89 (m, 2H), 3.16, 3.15, 3.03 (3s, 3H), 2.51 (m, 2H), 2.50-1.25 (m, 4H), 1.22 (m, 4H), 1.03 (m, 6H), 0.45-0.33 (m, 3H). MS (ESI) m/z 641 (M++H).
Compound 235 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-methoxy-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 235 (7 mg, 39%) as yellow solid was obtained according to the same method as the synthesis of compound 120.
MS (ESI) m/z 639 (M++H).
Compound 237 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-cyclopropyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAccording to the same method as the synthesis of Compound 133, 3-fluoro-4-bromoanisole, a starting material, was subjected to several synthesis processes to obtain a boronic acid compound. The obtained compound was subjected to a Suzuki reaction with Compound 2. The obtained compound was reacted with Compound 4, to obtain an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 237 (2 mg, 22%) as white solid.
1H NMR (400 MHz, CDCl3); 1:1.3 atropisomer mixture; δ 7.85 (s, 1H), 7.73-7.72 (m, 2H), 6.57-6.44 (m, 2H), 5.60 (t, J=8.0, 1H), 3.98-3.88 (m, 2H), 3.71, 3.68 (2s, 3H), 3.50, 3.38 (2d, J=14.5, 1H), 2.45-1.87 (m, 4H), 1.49-1.40 (m, 2H), 1.02-0.92 (m, 6H), 0.91-0.82 (m, 4H), 0.63-0.59 (m, 1H), 0.40 (d, J=6.5, 1.3H), 0.32 (d, J=6.5, 1.7H). MS (ESI) m/z 600 (M++H).
Compound 240 1-((5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetateCompound 240 (28 mg, 53%) as white solid was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85-7.74 (m, 3H), 7.11-7.07 (m, 1H), 6.86-6.78 (m, 1H), 5.65, 5.44 (2d, J=7.6, 1H), 4.12-3.32 (m, 6H), 3.26 (d, J=9.4, 3H), 2.45-1.88 (m, 7H), 1.49-1.47 (m, 6H), 1.45-1.39 (m, 2H), 1.02-0.97 (m, 6H), 0.65-0.36 (m, 3H). MS (ESI) m/z 767 (M++H).
Compound 241 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropoxy-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAccording to the same method as the synthesis of Compound 133, 2-fluoro-4-methoxyphenol, a starting material, was subjected to several synthesis processes to obtain boronic acid compound. The obtained compound was subjected to a Suzuki reaction with Compound 2. And then the obtained compound was reacted with Compound 4, to obtain an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 241 (3 mg, 60%) as white solid.
1H NMR (400 MHz, CDCl3); 1:1.5 atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.66-6.58 (m, 2H), 5.61 (dd, J=8.0, 4.6, 1H), 4.39-4.21 (m, 1H), 4.02-3.88 (m, 2H), 3.70, 3.67 (2s, 3H), 3.56, 3.46 (2d, J=14.5, 1H), 2.47-1.99 (m, 2H), 1.94-1.88 (m, 2H), 1.51-1.40 (m, 2H), 1.31 (d, J=6.0, 3H), 1.21-1.17 (m, 3H), 1.03-0.98 (m, 6H), 0.44 (d, J=6.5, 1.2H), 0.33 (d, J=6.5, 1.8H). MS (ESI) m/z 618 (M++H).
Compound 243 1-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetateCompound 243 (32 mg, 50%) as yellow solid was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.83 (s, 1H), 7.75 (s, 2H), 7.05 (d, J=8.6, 1H), 6.85-6.78 (m, 2H), 5.62-5.57 (m, 1H), 4.02-3.90 (m, 2H), 3.77, 3.74 (2s, 3H), 3.52 (d, J=14.7, 0.6H), 3.40 (d, J=14.7, 0.4H), 3.38-3.00 (bm, 3H), 2.42-2.07 (m, 2H), 2.02-1.87 (m, 2H), 1.70-1.40 (bm, 9H), 1.02-0.98 (m, 6H), 0.44-0.38 (m, 3H). MS (ESI) m/z 699 (M++H).
Compound 244 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-hydroxy-N,2-dimethylpropanamideCompound 243 (19 mg, 0.027 mmol) was added to methanol (0.8 mL). The solution of potassium carbonate (4 mg, 0.029 mmol) in water (0.2 mL) was added dropwise to the obtained mixture, and stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure, diluted with methylene chloride, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by PTLC (silica, 70% Hexane/EtOAc), thus obtaining Compound 244 (11 mg, 65%) as white solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.74 (d, J=5.7, 2H), 7.12-7.09 (m, 1H), 6.91-6.84 (m, 2H), 5.61 (dd, J=8.0, 2.1, 1H), 4.36 (bs, 1H), 4.06-3.93 (m, 2H), 3.82, 3.79 (2s, 3H), 3.53, 3.42 (2d, J=14.6, 1H), 3.29, 3.22 (2s, 3H), 2.47-1.99 (m, 2H), 1.94-1.92 (m, 2H), 1.56-1.46 (m, 2H), 1.20-1.10 (bm, 6H), 1.06-1.02 (m, 6H), 0.50, 0.41 (2d, J=6.5, 3H). MS (ESI) m/z 657 (M++H).
Compound 245 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 219 (0.45 g, 0.67 mmol) was dissolved in methylene chloride (3 mL). Trifluoroacetic acid (1 mL) was added dropwise to the obtained solution at 0° C., and stirred at room temperature for 1 hour. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with methylene chloride, washed with saturated sodium hydrogen carbonate solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized, thus obtaining an intermediate compound (0.32 g, 88%) as white solid. The obtained compound was dissolved in tetrahydropuran (5 mL). Lithium diisopropyl silane (0.35 mL) was added to the obtained solution at −78° C., and stirred for 10 minutes. Carbon disulfide (24.6 μl) and iodomethane (34.3 μl) was added dropwise to the reaction mixture, and then stirred at room temperature for 30 minutes. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (silica, 12 g, 20%˜60%, Hexane/EtOAc), thus obtaining an intermediate compound (0.21 g, 85%) as colorless oil. The obtained intermediate compound (83.5 mg, 0.13 mmol) was dissolved in methylene chloride (5 mL). The solution of TBAH2F3 (0.19 g) and DBH (0.14 g) in methylene chloride (2 mL) was added dropwise slowly to the obtained solution at 0° C., and then stirred at 0° C. for 30 minutes. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure, to remove the solvent. The residue was separated by MPLC (4 g silica, 3:1, Hexane/EtOAc), thus obtaining Compound 245 (12.5 mg, 15%) as white foam.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 6.84-6.80 (m, 1H), 6.61-6.52 (m, 1H), 5.67-5.62 (m, 1H), 4.17-3.15 (m, 11H), 3.11 (m, 1H), 2.42-2.39 (m, 2H), 1.27-1.11 (m, 6H), 0.40-0.29 (m, 3H).
Compound 246 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-4-methyl-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 246 (0.13 g, 69.1%) as colorless oil was obtained according to the same method as the synthesis of compound 206.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.76 (d, J=8.0, 1H), 7.73 (d, J=7.3, 2H), 6.72 (d, J=10.5, 1H), 5.60 (dd, J=38.2, 8.1, 1H), 3.97 (m, 2H), 3.87, 3.83 (2s, 3H), 3.55, 3.34 (2d, J=14.9, 1H), 2.64, 2.63 (2s, 3H), 2.40-1.92 (m, 4H), 1.50 (m, 2H), 1.05, 1.04, 1.01 (3s, 6H), 0.47, 0.45, 0.44, 0.43 (4s, 3H). MS (ESI) m/z 601 (M++H).
Compound 247 (4S,5R)-3-((2-(5-amino-2-methoxy-4-methylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 247 (76.6 mg, 73%) as colorless oil was obtained according to the same method as the synthesis of compound 195.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.60, 6.54 (2s, 1H), 6.33, 6.31 (2s, 1H), 5.59, 5.57 (2d, J=8.0, 1H), 4.05-3.84 (m, 2H), 3.67-3.50 (m, 4H), 3.33 (brs, 2H), 2.49-1.90 (m, 7H), 1.50-1.41 (m, 2H), 1.03, 1.01, 0.99 (3s, 6H), 0.47, 0.31 (2d, J=6.6, 6.5, 3H). MS (ESI) m/z 571 (M++H).
Compound 248 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)acetamideCompound 248 (28.8 mg, 67.1%) as colorless oil was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.83-7.79 (m, 3H), 7.40, 7.21 (2s, 1H), 6.82, 6.76 (2s, 1H), 6.68, 6.65 (2s, 1H), 5.59, 5.46 (2d, J=8.0, 1H), 4.07 (m, 1H), 3.94 (m, 1H), 3.74, 3.73 (2s, 3H), 3.61, 3.39 (2d, J=14.7, 1H), 2.23-1.91 (m, 10H), 1.45 (m, 2H), 1.01, 1.00, 0.98 (3s, 6H), 0.44, 0.31 (2d, J=6.5, 3H). MS (ESI) m/z 613 (M++H).
Compound 249 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)-N-methylacetamideCompound 249 (9.2 mg, 45.8%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.77-6.70 (m, 2H), 5.61 (m, 1H), 4.03-3.91 (m, 2H), 3.78, 3.75, 3.74 (3s, 3H), 3.55-3.27 m, 1H), 3.15, 3.14, 3.03 (3s, 3H), 2.50-1.45 (m, 12H), 1.13-0.96 (m, 6H). 0.48-0.31 (m, 3H). MS (ESI) m/z 627 (M++H).
Compound 250 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)trifluoromethanesulfonamideCompound 250 (24.2 mg, 57.3%) as colorless oil was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (d, J=4.0, 1H), 7.72 (d, J=6.9, 2H), 7.01, 6.94 (2s, 1H), 6.72, 6.70 (2s, 1H), 5.60, 5.53 (2d, J=8.0, 1H), 3.93 (m, 2H), 3.77, 3.76 (2s, 3H), 3.57, 3.34 (2d, J=14.7, 1H), 2.43-1.91 (m, 7H), 1.47 (m, 2H), 1.02, 0.99, 0.98 (3s, 6H), 0.36, 0.29 (2d, J=6.5, 3H). MS (ESI) m/z 703 (M++H).
Compound 251 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)trifluoro-N-methylmethanesulfonamideCompound 251 (9.5 mg, 42.8%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.7.86, 7.84 (2s, 1H), 7.74, 7.71 (2s, 2H), 6.90-6.73 (m, 2H), 5.58-5.46 (m, 1H), 4.02-3.25 (m, 9H), 2.41-1.95 (m, 7H), 1.49 (m, 2H), 1.03, 1.01, 1.00 (3s, 6H), 0.44-0.32 (m, 3H). MS (ESI) m/z 717 (M++H).
Compound 259 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylethanethioamideCompound 112 (35 mg, 0.057 mmol) was dissolved in toluene (1.3 mL). Lawesson's reagent (23 mg, 0.06 mmol) was added dropwise to the solution, and then stirred at 80° C. overnight. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (10-20% hexane/EtOAc), thus obtaining Compound 259 (28 mg, 78%) as solid.
1H NMR (400 MHz, CDCl3): atropisomer mixture; δ 7.86 (s, 1H), 7.73 (d, 2H, J=4.6 Hz), 7.06-7.03 (m, 1H), 6.91-6.86 (m, 1H), 6.83 (q, 1H, J=2.7 Hz), 5.62 (dd, 1H, J=4.1, 8.4 Hz), 4.05-3.91 (m, 2H), 3.81, 3.78 (2s, 3H), 3.70, 3.64 (2s, 3H), 3.49, 3.39 (2d, 1H, J=14.5 Hz), 2.49-2.43 (m, 1H), 2.38, 2.34 (2s, 3H), 2.29-2.00 (m, 2H), 1.93-1.85 (m, 2H), 1.53-1.43 (m, 2H), 1.05-1.01 (m, 6H), 0.47, 0.36 (2d, 3H, J=6.6 Hz); MS (ESI) m/z 629.0 (M++H).
Compound 261 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(2,2,2-trifluoroacetyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 267 (0.05 g, 0.087 mmol) was dissolved in anhydrous methylene chloride (20 mL). Triethylamine (0.02 mL) and trifluoroacetic anhydride (0.02 g) were added dropwise to the obtained solution at room temperature, and stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was washed with saturated ammonium chloride solution and water, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (silica, 4:1=hexane:EtOAc), thus obtaining Compound 261 (0.04 g, 72%) as white solid foam.
1H NMR (400 MHz, MeOD); atropisomer mixture; δ 7.99 (s, 1H), 7.93 (m, 2H), 7.06 (m, 1H), 6.79 (m, 1H), 5.87 (m, 1H), 4.20-3.62 (m, 10H), 3.16 (m, 1H), 2.75-2.30 (m, 2H), 1.21 (m, 6H), 0.43 (m, 3H).
Compound 262 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(trifluoromethylsulfonyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 262 (37 mg, 60%) as white solid foam was obtained according to the same method as the synthesis of compound 261.
1H NMR (400 MHz, MeOD); atropisomer mixture; δ 7.99 (s, 1H), 7.90 (m, 2H), 7.06 (m, 1H), 7.79 (m, 1H), 5.87 (m, 1H), 4.86 (s, 2H), 4.29-3.57 (m, 10H), 3.16 (m, 1H), 2.7-2.25 (m, 2H), 1.2 (m, 6H), 0.43 (m, 3H).
Compound 263 (4S,5R)-3-((1-acetyl-4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 263 (42 mg, 78%) as white solid foam was obtained according to the same method as the synthesis of compound 261.
1H NMR (400 MHz, MeOD); atropisomer mixture; δ 7.98 (s, 1H), 7.93 (m, 2H), 7.03 (m, 1H), 6.78 (m, 1H), 5.86 (m, 1H), 4.20-3.52 (m, 10H), 3.15 (m, 1H), 2.70-2.30 (m, 2H), 2.20 (m, 3H), 1.21 (m, 6H), 0.43 (m, 3H); MS (ESI): 616.0 (M)+.
Compound 264 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(methylsulfonyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 264 (45 mg, 79%) as white solid foam was obtained according to the same method as the synthesis of compound 261.
1H NMR (400 MHz, MeOD); atropisomer mixture; δ 7.98 (s, 1H), 7.92 (s, 2H), 7.05, 6.98 (2d, 1H, J=8.64, 8.64 Hz), 6.78, 6.75 (2d, 1H, J=8.44, 8.40 Hz), 4.2-3.0 (m, 12H), 2.70-2.20 (m, 2H), 1.26 (m, 6H), 0.42 (m, 3H); MS (ESI): 652.0 (M)+.
Compound 265 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-isopropyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 267 (0.05 g, 0.087 mmol) was dissolved in methanol (20 mL). 2-Iodopropane (0.02 mL) was added dropwise to the obtained solution, and stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was separated by PTLC (SiO2, EA:DCM:MeOH=5:4:1, thus obtaining Compound 265 (3 mg, 6%) as white solid foam.
1H NMR (400 MHz, MeOD); atropisomer mixture; δ 8.00 (s, 1H), 7.92 (s, 2H), 7.05 (m, 1H), 6.78 (m, 1H), 5.90 (m, 1H), 4.30-2.20 (m, 11H), 1.26 (m, 6H), 0.42 (m, 3H); MS (ESI): 616.7 (M)+.
Compound 267 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 219 (1.65 g, 2.46 mmol) was dissolved in methylene chloride (10 mL). Trifluoroacetic acid (3 mL) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 1 hour. After the completion of the reaction, ethyl acetate was added dropwise to the reaction mixture. And then, the obtained reaction mixture washed with saturated sodium hydrogen carbonate solution, water and brine, and concentrated under reduced pressure. The obtained residue was separated by MPLC (SiO2, 5%-20% DCM/MeOH), thus obtaining Compound 267 (1.0 g, 71%) as white foam.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.72 (s, 2H), 6.89, 6.84 (2d, J=8.6, 8.5 Hz, 1H), 6.57, 6.53 (2d, J=12.1 Hz, 1H), 5.70, 5.67 (2d, J=8.0 Hz, 1H), 4.03-3.99 (m, 2H), 3.76, 3.71 (2s, 3H), 3.60-3.41 (m, 4H), 3.28-3.06 (m, 3H), 2.66-2.12 (m, 4H), 1.26-1.10 (m, 6H), 0.33, 0.29 (2d, J=6.5 Hz, 3H); MS (ESI): 575 (M++H).
Compound 268 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(2,2,2-trifluoroethyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-oneCompound 268 (14 mg, 25%) as white solid foam was obtained according to the same method as the synthesis of compound 265.
1H NMR (400 MHz, MeOD); atropisomer mixture; δ 7.87 (s, 1H), 7.72 (s, 2H), 6.91, 6.86 (2d, 1H, J=8.56, 8.60 Hz), 6.60, 6.56 (2d, 1H, J=12.12, 12.08 Hz), 5.60 (m, 1H), 4.0 (m, 2H), 3.80-2.80 (m, 11H), 2.70-2.30 (m, 2H), 1.21 (m, 6H), 0.40, 0.33 (2d, 3H, J=6.52, 6.56 Hz); MS (ESI): 656.7 (M)+.
Compound 271 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-thioxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamideCompound 112 (60 mg, 0.098 mmol) was dissolved in 2-propanol (0.6 mL). The solution of potassium hydroxide (28 mg) in water (0.1 mL) was added dropwise to the obtained solution at room temperature, and stirred at 80° C. overnight. After the completion of the reaction, the reaction mixture was cooled down to room temperature, and concentrated under reduced pressure to remove the solvent. Ethyl acetate was added dropwise to the residue. The obtained mixture was washed with water and brine, and concentrated under reduced pressure. The obtained residue was separated by MPLC (SiO2, 10%-70% Hexane/EtOAc), thus obtaining an amino alcohol compound (26 mg, 45%) as colorless oil. The obtained amino alcohol compound was dissolved in methylene chloride (1.5 mL). Thiophosgene (2 μL, 0.02 mmol) and diisopropylamine (0.05 mL, 0.27 mmol) were added dropwise to the obtained solution, and then stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with methylene, and washed with water and brine. The organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO2, 30%-90% hexane/EtOAc), thus obtaining Compound 271 (12 mg, 43%) as yellow solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.88 (s, 1H), 7.75 (s, 2H), 7.06 (dt, 1H, J=2.4, 8.6 Hz), 6.90-6.81 (m, 2H), 5.77-5.74 (m, 1H), 4.66-4.63 (m, 1H), 4.25-4.09 (m, 1H), 3.83, 3.79 (2s, 3H), 3.72, 3.66 (2d, 1H, J=14.8 Hz), 3.22, 3.14 (2s, 3H), 2.53-1.89 (m, 4H), 1.84, 1.79 (2s, 3H), 1.53-1.44 (m, 2H), 1.05-1.02 (m, 6H), 0.51, 0.37 (2d, 1H, J=6.7 Hz); MS (ESI) m/z 628.8 (M+).
Compound 272 methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoateCompound 272 (0.12 g, 95.9%) as white solid foam was obtained according to the same method as the synthesis of compound 133.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.75 (m, 2H), 7.27 (2d, 1H, J=2.12, 2.08 Hz), 6.83 (m, 2H), 5.60 (m, 1H), 4.05-3.41 (m, 9H), 2.89 (m, 2H), 2.6 (m, 2H), 2.50-2.00 (m, 2H), 1.89 (m, 2H), 1.50 (m, 2H), 1.05 (m, 6H), 0.40 (m, 3H).
Compound 273 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoic acidCompound 273 (2 mg, 1.9%) as colorless oil was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 7.05-7.07 (m, 1H), 6.74-6.85 (m, 2H), 5.56-5.61 (m, 1H), 3.72-3.89 (m, 3H), 3.42-3.58 (m, 1H), 2.83-2.90 (m, 2H), 2.61-2.66 (m, 2H), 2.26-2.59 (m, 2H), 1.87-1.93 (m, 2H), 1.44-1.53 (m, 2H), 1.01-1.05 (m, 6H), 0.30, 0.45 (2d, 3H, J=4.86, 4.92 Hz); MS (ESI) m/z 614.2 (M++H).
Compound 274 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-5-isopropyl-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-oneCompound 274 (0.12 g, 76.5%) as white solid was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (d, J=0.4 Hz, 2H), 6.84, 6.80 (2d, J=8.7 Hz, 1H), 6.56, 6.52 (2d, J=12.2 Hz, 1H), 5.59 (t, J=8.4 Hz, 1H), 4.01-3.88 (m, 2H), 3.73, 3.71 (2s, 3H), 3.59, 3.46 (2d, J=14.6 Hz, 1H), 3.13 (m, 1H), 2.44-1.13 (m, 16H), 0.44-0.34 (m, 7H); MS (ESI): 600 (M++H).
Compound 275 tert-butyl 6-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-5-methoxyindoline-1-carboxylatetert-Butyl 5-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)indoline-1-carboxylate was synthesized using 4-methoxyindoline as a starting material, and then Compound 275 (0.24 g, 72.1%) as white solid foam was obtained according to the similar method to the synthesis of compound 133.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84, 7.77, 7.73 (3s, 3H), 7.53-7.05 (brs, 1H), 6.70, 6.66 (2s, 1H), 5.65-5.58 (m, 1H), 4.10-3.88 (m, 4H), 3.71-3.39 (m, 4H), 3.07-3.02 (m, 2H), 2.45-1.85 (m, 4H), 1.51-1.18 (m, 16H), 1.02-0.94 (m, 6H), 0.85 (m, 3H), 0.43, 0.37 (2d, 3H, J=6.5, 6.3 Hz); MS (ESI): 683 (M++H).
Compound 276 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxyindolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 276 (0.13 g, 63.5%) as colorless oil was obtained according to the same method as the synthesis of compound 267.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.74, 6.67 (2s, 1H), 6.31, 6.29 (2s, 1H), 5.59, 5.58 (2s, 1H), 4.05-3.87 (m, 2H), 3.67-3.63 (m, 4H), 3.55-2.48 (m, 3H), 3.01-2.97 (m, 2H), 2.45-1.86 (m, 4H), 1.45 (m, 2H), 1.03, 1.01, 0.99 (3s, 6H), 0.48, 0.33 (2d, 3H, J=6.5 Hz); MS (ESI): 583 (M++H).
Compound 277 (4S,5R)-3-((2-(1-acetyl-5-methoxyindolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 277 (18 mg, 64.6%) as colorless oil was obtained according to the same method as the synthesis of compound 261.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.91-7.74 (m, 4H), 6.71 (d, 1H, J=12.7 Hz), 6.54, 5.50 (2d, 1H, J=8.08, 8.04 Hz), 4.12-3.91 (m, 4H), 3.73, 3.72 (2s, 3H), 3.59, 3.37 (2d, 1H, J=14.7 Hz), 3.17 (m, 2H), 2.37-1.91 (m, 6H), 1.46 (m, 2H), 1.02, 1.00, 0.99 (3s, 6H), 0.41, 0.38 (2d, 3H, J=6.5 Hz); MS (ESI): 625 (M++H).
Compound 278 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxy-1-(2,2,2-trifluoroethyl)indolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 278 (4 mg, 11.3%) as colorless oil was obtained according to the same method as the synthesis of compound 261.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 6.74, 6.68 (2s, 1H), 6.12 (s, 1H), 5.58, 5.56 (2d, 1H, J=4.2 Hz), 4.03-3.85 (m, 2H), 3.69, 3.67 (2s, 3H), 3.63-3.38 (m, 5H), 3.02-2.98 (m, 2H), 2.47-1.87 (m, 6H), 1.47 (m, 2H), 1.25 (m, 6H), 0.37, 0.35 (2d, 3H, J=6.5 Hz); MS (ESI): 665 (M++H).
Compound 280 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxy-1-(methylsulfonyl)indolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 280 (19 mg, 64.4%) as colorless oil was obtained according to the same method as the synthesis of compound 261.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.74 (s, 2H), 7.06 (d, 1H, J=16.2 Hz), 6.75 (d, 1H, J=13.6 Hz), 5.59 (2d, 1H, J=8.2 Hz), 3.99-3.87 (m, 4H), 3.75-3.72 (2s, 3H), 3.52, 3.33 (2d, 1H, J=14.9, 14.6 Hz), 3.14-3.09 (m, 2H), 2.84, 2.79 (2s, 3H), 2.38-1.91 (m, 4H), 1.45 (m, 2H), 1.03, 1.01, 1.00 (3s, 6H), 0.47, 0.41 (2d, 3H, J=6.5 Hz); MS (ESI): 661, 683 (M++H).
Compound 281 tert-butyl 4-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-3-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylateCompound 281 (0.38 g, 88%) as white solid foam was obtained according to the same method as the synthesis of compound 219.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.71 (s, 2H), 6.87 (dd, 1H, J=13.4, 8.7 Hz), 6.57 (dd, 1H, J=14.8, 12.0 Hz), 5.61 (d, 1H, J=7.9 Hz), 4.25-3.83 (m, 4H), 3.71, 3.68 (2s, 3H), 3.47-3.44 (m, 1H), 3.15-3.10 (m, 1H), 2.30-2.25 (m, 2H), 1.48 (s, 9H), 1.24-1.12 (m, 6H), 0.42, 0.37 (2d, 3H, J=6.5 Hz).
Compound 282 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((3-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1,2,5,6-tetrahydropyridin-4-yl)methyl)-4-methyloxazolidin-2-oneCompound 282 (0.19 g, 61%) as white solid foam was obtained according to the same method as the synthesis of compound 267.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.82 (s, 1H), 7.74 (d, 2H, J=5.5 Hz), 6.92, 6.83 (2d, 1H, J=8.4 Hz), 6.55 (dd, 1H, J=18.5, 12.0 Hz), 5.69 (dd, 1H, J=13.5, 8.0 Hz), 5.44 (brs, 1H), 4.18-4.01 (m, 2H), 3.84 (d, 0.6; H, J=16.7 Hz), 3.73, 3.72 (2s, 3H), 3.69-3.35 (m, 3.4H), 3.20-3.07 (m, 2H), 2.62-2.52 (m, 1H), 2.33-2.27 (m, 1H), 1.24-1.09 (m, 6H), 0.38, 0.31 (2d, 1H, J=6.6 Hz).
Compound 283 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((3-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(2,2,2-trifluoro ethyl)-1,2,5,6-tetrahydropyridin-4-yl)methyl)-4-methyloxazolidin-2-oneCompound 283 (40 mg, 88%) as brown oil was obtained according to the same method as the synthesis of compound 265.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.85 (t, 1H, J=9.0 Hz), 6.55 (dd, 1H, J=16.5, 12.0 Hz), 5.62 (dd, 1H, J=7.9, 6.0 Hz), 4.05-3.95 (m, 2H), 3.74, 3.71 (2s, 3H), 3.56-3.22 (m, 2.5H), 3.19-3.06 (m, 3.5; H), 3.03-2.98 (m, 1H), 2.94-2.87 (m, 1H), 2.39-2.25 (m, 2H), 1.25-1.12 (m, 6H), 0.43, 0.35 (2d, 1H, J=6.6 Hz).
Compound 284 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((3-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(trifluoromethylsulfonyl)-1,2,5,6-tetrahydropyridin-4-yl)methyl)-4-methyloxazolidin-2-oneCompound 284 (27 mg, 54%) as brown oil was obtained according to the same method as the synthesis of compound 261.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.72 (s, 2H), 6.84 (t, 1H, J=8.4 Hz), 5.63 (t, 1H, J=9.1 Hz), 4.41 (brd, 0.5; H, J=16.6 Hz), 4.12-3.80 (m, 5H), 3.74, 3.73 (2s, 3H), 3.58 (brd, 1.5; H, J=14.8 Hz), 3.17-3.08 (m, 1H), 2.53-2.34 (m, 2H), 1.25-1.09 (m, 6H), 0.49, 0.37 (2d, 1H, J=6.6 Hz); MS (ESI) m/z 706.8 (M+).
Compound 285 methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoateAs shown in reaction scheme 6, Compound 22, an intermediate compound, was synthesized, and then subjected to reductive amination using Compound 4, which is an amino alcohol compound, to synthesize Compound 23. The obtained Compound 23 (0.21 g, 0.34 mmol) was dissolved in methylene chloride (3 mL). Diisopropylamine (0.36 mL) and triphosgene (0.15 g) were added dropwise in sequence to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (12 g silica, 3:1=n-hexane:EtOAc), thus obtaining Compound 285 (0.1 g, 45%) as white solid foam.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (d, 1H, J=9.4 Hz), 6.92-6.95 (m, 1H), 6.67-6.77 (m, 2H), 5.58-5.61 (m, 1H), 3.87-4.01 (m, 2H), 3.71, 3.73 (2s, 3H), 3.63, 3.64 (2s, 3H), 3.50, 3.59 (2d, 1H, J=11.25, 10.86 Hz), 2.73-2.77 (m, 2H), 2.15-2.50 (m, 2H), 1.90-2.05 (m, 2H), 1.45-1.50 (m, 2H), 1.12-1.15 (m, 6H), 0.90-1.04 (m, 6H), 0.28, 0.41 (2d, 3H, J=4.86, 4.92 Hz); MS (ESI) m/z 656 (M++H).
Compound 286 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoic acidCompound 286 (27 mg, 42.4%) as white solid foam was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.85 (s, 1H), 7.73-7.75 (m, 2H), 6.99-7.02 (m, 1H), 6.72-6.81 (m, 2H), 5.61 (d, 1H, J=8.1 Hz), 3.88-4.02 (m, 2H), 3.71-3.74 (m, 3H), 3.52, 3.58 (2d, 1H, J=14.96, 14.52 Hz), 2.72-2.87 (m, 2H), 2.00-2.50 (m, 2H), 1.93 (m, 2H), 1.14-1.17 (m, 6H), 0.99-1.04 (m, 6H), 0.28, 0.44 (d, 3H, J=6.52, 6.56 Hz); MS (ESI) m/z 656, 547 (M++H).
Compound 291 (R)—N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylprop anamideCompound 291 (53 mg, 76%) as white solid foam was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.55, 8.53 (2s, 1H), 7.87-6.81 (m, 11H, ArH), 5.60 (d, 0.5H, J=8.2), 5.53 (d, 0.5H, J=8.1), 4.08-3.93 (m, 2H), 3.77, 3.76 (2s, 3H), 3.52-3.56 (m, 4H), 2.48-2.08 (m, 3H), 1.92 (broad signal, 2H), 1.55-1.39 (m, 2H), 1.04, 1.01 (2s, 6H), 0.40 (d, 1.5H, J=6.5), 0.36 (d, 1.5H, J=6.5); MS (ESI) m/z 773.2 (M++H).
Compound 292 (S)—N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylprop anamideCompound 292 (54 mg, 78%) as white solid foam was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.54, 8.50 (2s, 1H), 7.87-6.80 (m, 11H, ArH), 5.59 (d, 0.5H, J=8.1), 5.55 (d, 0.5H, J=8.1), 4.06-3.94 (m, 2H), 3.77, 3.76 (2s, 3H), 3.55-3.37 (m, 4H), 2.48-2.06 (m, 3H), 1.91 (broad signal, 2H), 1.54-1.40 (m, 2H), 1.04, 1.03, 1.01 (3s, 6H), 0.39 (d, 1.5H, J=6.5), 0.33 (d, 1.5H, J=6.5); MS (ESI) m/z 773.2 (M++H).
Compound 293 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-oneCompound 293 (0.73 g, 71%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 7.25-7.20 (m, 1H), 7.04-6.83 (m, 3H), 5.58 (t, 1H, J=8.5 Hz), 4.03-3.90 (m, 2H), 3.75, 3.74 (2s, 3H), 3.59, 3.48 (2d, 1H, J=15.0, 14.6 Hz), 2.47-1.21 (m, 10H), 0.44-0.31 (m, 7H); MS (ESI): 542 (M++H).
Compound 294 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(2-methoxy-5-nitrophenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-oneCompound 294 (0.73 g, 71%) as white solid foam was obtained according to the same method as the synthesis of compound 52.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.18-8.14 (m, 1H), 7.94 (dd, 1H, J=9.8, 2.8 Hz), 7.85 (s, 1H), 7.71 (d, 2H, J=4.7 Hz), 6.95 (t, 1H, J=9.4 Hz), 5.63, 5.58 (2d, 1H, J=8.1 Hz), 4.01-3.94 (m, 2H), 3.91, 3.88 (2s, 3H), 3.53, 3.36 (2d, 1H, J=15.0 Hz), 2.39-1.31 (m, 7H), 0.46-0.35 (m, 7H); MS (ESI) m/z 585 (M++H).
Compound 295 (4S,5R)-3-((6-(5-amino-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 294 (0.21 g, 0.36 mmol) was dissolved in methanol (3 mL). Raney-nickel (3 mL) was added dropwise to the obtained solution at room temperature, and stirred under hydrogen gas overnight. After the completion of the reaction, the reaction mixture was filtered with celite, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (25%-60% n-hexane/EtOAc), thus obtaining Compound 295 (0.12 g, 60%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.71 (d, 2H, J=4.1 Hz), 6.73-6.46 (m, 2H), 5.59, 5.53 (2d, 1H, J=8.0 Hz), 4.09-3.89 (m, 2H), 3.74, 3.70 (2s, 3H), 3.70-3.49 (m, 1H), 2.47-1.23 (m, 7H), 0.50-0.35 (m, 7H); MS (ESI) m/z 555 (M++H).
Compound 296 (R)—N-(3-(5-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamideCompound 296 (15 mg, 15%) as white solid was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.56 (s, 1H), 7.97-7.94 (m, 1H), 7.85-7.69 (m, 3H), 7.51 (m, 2H), 7.44-7.34 (m, 4H), 6.84 (t, 1H, J=8.6 Hz), 5.56, 5.52 (2d, 1H, J=8.2 Hz), 4.11-3.89 (m, 3H), 3.77, 3.76 (2s, 3H), 3.56-3.34 (m, 4H), 2.44-1.24 (m, 11H), 0.46-0.29 (m, 9H); MS (ESI) m/z 771 (M++H).
Compound 297 (S)—N-(3-(5-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamideCompound 297 (17 mg, 21%) as white solid was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.55, 8.53 (2s, 1H), 7.84 (s, 1H), 7.72-7.65 (m, 3H), 7.56 (m, 1H), 7.43-7.40 (m, 3H), 7.33-7.17 (m, 3H), 6.84, 6.81 (2d, 1H, J=8.9 Hz), 5.54 (d, 1H, J=8.1 Hz), 4.04-3.89 (m, 3H), 3.77, 3.76 (2s, 3H), 3.57-3.39 (m, 4H), 2.45-1.23 (m, 9H), 0.46-0.34 (m, 8H); MS (ESI) m/z 771 (M++H).
Compound 298 (R)—N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-N-methyl-2-phenylprop anamideCompound 298 (30 mg, 82%) as white solid was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (m, 1H), 7.72-7.78 (m, 2H), 7.59-7.60 (m, 1H), 7.41-7.45 (m, 2H), 7.30-7.36 (m, 2H), 7.01-7.04 (m, 1H), 6.84-6.90 (m, 2 h), 5.57-5.59 (m, 1H), 3.90-4.10 (m, 2H), 3.82-3.85 (m, 3H), 3.47-3.65 (m, 3H), 3.47-3.65 (m, 3H), 2.91-3.29 (m, 3H), 2.10-2.50 (m, 2H), 1.80-2.00 (m, 2H), 1.46-1.50 (m, 2H), 0.94-1.04 (m, 6H), 0.29-0.50 (m, 3H); MS (ESI) m/z 787 (M++H).
Compound 299 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyppropanamideCompound 273 (0.48 g, 0.78 mmol) was dissolved in methylene chloride (5 mL). Thionyl chloride (0.1 mL) and dimethylformamide (1 drop) were added dropwise to the obtained solution, and stirred for 5 hours. After the completion of the reaction, the reaction mixture was cooled down to room temperature, and concentrated under reduced pressure to remove the solvent. The residue was dissolved in tetrahydropuran (10 mL). Ammonia water (2 mL) was added dropwise to the obtained solution, and stirred for 1 hour at room temperature. Ethyl acetate was added dropwise to the reaction mixture. And then, the obtained reaction mixture was washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO2, 4:1 hexane/EtOAc), thus obtaining Compound 299 (0.39 g, 84%) as colorless oil.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (d, 1H, J=4.6 Hz), 7.04-7.08 (m, 1H), 6.73-6.87 (m, 2H), 5.47-5.62 (m, 3H), 3.93-3.97 (m, 2H), 3.71, 3.77 (2s, 3H), 3.38, 3.55 (2d, 1H, J=11.25, 10.89 Hz), 2.85-2.91 (m, 2H), 2.44-2.51 (m, 2H), 1.90-2.30 (m, 4H), 1.45-1.48 (m, 2H), 1.01-1.05 (m, 6H), 0.33, 0.47 (2d, 3H, J=4.89, 4.92 Hz); MS (ESI) m/z 613.2 (M++H).
Compound 300 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyppropanenitrileCompound 299 (0.19 g, 0.32 mmol) was dissolved in pyridine (5 mL). Phosphoryl chloride (0.12 mL) and imidazole (40 mg) were added dropwise to the obtained solution, and stirred at −20° C. for 1 hour. The reaction was quenched with 1M HCl (hydrochloride) solution. The reaction mixture was extracted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO2, 4:1 hexane/EtOAc), thus obtaining Compound 300 (0.14 g, 74%) as white oil.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.85 (s, 1H), 7.74 (s, 2H), 7.06-7.12 (m, 1H), 6.79-6.93 (m, 2H), 5.58, 5.61 (2d, 1H, J=6.18, 6.09 Hz), 3.89-4.00 (m, 2H), 3.74, 3.77 (2s, 3H), 3.46, 3.60 (2d, 1H, J=11.28, 10.98 Hz), 2.82-2.90 (m, 2H), 2.60-2.62 (m, 2H), 2.20-2.59 (m, 2H), 1.94 (m, 2H), 1.47-1.51 (m, 2H), 1.01-1.05 (m, 6H), 0.35, 0.42 (2d, 3H, J=4.86, 4.92 Hz); MS (ESI) m/z 595.2 (M++H).
Compound 301 (4S,5R)-3-((2-((5-(2-(2H-tetrazol-5-yl)ethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-oneCompound 300 (0.1 g, 0.16 mmol) was dissolved in dimethylformamide (5 mL). Sodium azide (0.04 g) and ammonium chloride (0.04 g, 0.82 mmol) were added dropwise to the obtained solution, and stirred at 120° C. overnight. After the reaction was quenched with 1M HCl (hydrochloride) solution, the reaction mixture was extracted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO2, 20:1 DCM/MeOH), thus obtaining Compound 301 (11 mg, 11%) as white oil.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.88 (s, 1H), 7.69-7.77 (m, 2H), 6.73-6.83 (m, 2H), 6.60-6.67 (m, 1H), 5.41, 5.74 (2d, 1H, J=6.42, 5.97 Hz), 4.49-4.95 (m, 1H), 4.15-4.33 (m, 1H), 3.70, 3.84 (2s, 3H), 2.90-3.36 (m, 4H), 1.98-2.50 (m, 2H), 1.90-1.98 (m, 2H), 1.46-1.50 (m, 2H), 1.00-1.05 (m, 6H), 0.60-0.70 (2d, 3H, J=4.92, 4.98 Hz); MS (ESI) m/z 638.2 (M++H).
Compound 302 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 302 (0.12 g, 88.4%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (d, 1H, J=3.6 Hz), 6.86, 6.83 (2d, 1H, J=8.7 Hz), 6.53, 6.49 (2d, 1H, J=12.2 Hz), 5.60 (t, 1H, J=7.5 Hz), 3.99-3.89 (m, 2H), 3.72, 3.68 (2s, 3H), 3.51, 3.39 (2d, 1H, J=14.6 Hz), 2.42-1.89 (m, 4H), 1.45 (m, 2H), 1.29-1.23 (m, 6H), 1.03-0.85 (m, 8H), 0.73-0.60 (m, 4H), 0.38, 0.31 (2d, 3H, J=6.5 Hz); MS (ESI): 614 (M++H).
Compound 303 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)spiro[2.5]oct-5-en-5-yl) methyl)-4-methyloxazolidin-2-oneCompound 303 (80 mg, 54.7%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.92, 6.88 (2d, 1H, J=8.8, 8.7 Hz), 6.55, 6.51 (2d, 1H, J=12.2, 12.1 Hz), 5.59 (t, 1H, J=7.8 Hz), 4.00-3.95 (m, 2H), 3.73, 3.70 (2s, 3H), 3.54, 3.44 (2d, 1H, J=14.9, 14.6 Hz), 2.42-1.24 (m, 10H), 0.74-0.61 (m, 4H), 0.44-0.37 (m, 7H); MS (ESI): 612 (M++H).
Compound 304 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3′,5′-difluoro-4-methoxy-4′-(methoxymethoxy)biphenyl-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one3′-(2-(Bromomethyl)-4,4-dicyclohex-1-enyl)-3,5-difluoro-4′-methoxy-4-(methoxy methoxy)biphenyl, which is an intermediate compound, was dissolved in dimethylformamide (DMF). (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-oxazolidin-2-one and sodium hydride were added dropwise to the obtained solution at room temperature. After the completion of the reaction, the reaction mixture was extracted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO2, 5:1 n-hexane:EtOAc), thus obtaining Compound 304 (60 mg, 46%) as white oil.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.86 (s, 1H), 7.79 (s, 2H), 7.36-7.39 (m, 1H), 6.88-6.95 (m, 3H), 5.57-5.62 (m, 1H), 5.17 (d, 1H, J=9.9 Hz), 3.96-4.04 (m, 2H), 3.79-3.82 (2s, 3H), 3.58-3.62 (m, 3H), 3.44-3.58 (m, 1H), 2.00-2.50 (m, 2H), 1.93-1.95 (m, 2H), 1.50-1.55 (m, 2H), 1.02-1.07 (m, 6H), 0.37, 0.43 (2d, 3H, J=6.6, 6.5 Hz); MS (ESI) m/z 714 (M++H).
Compound 305 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3′,5′-difluoro-4′-hydroxy-4-methoxybiphenyl-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 304 (0.03 g, 0.04 mmol), a starting material, was dissolved in methanol (2 mL). The solution (0.5 mL) of hydrogen chloride in methanol was added dropwise to the obtained solution, and stirred at room temperature for 3 hours. After the completion of the reaction, the reaction mixture was extracted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO2, 5:1 n-hexane:EtOAc), thus obtaining Compound 305 (20 mg, 71%) as white solid.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 7.34-7.37 (m, 1H), 6.99-7.12 (m, 3H), 6.89, 6.94 (2d, 1H, J=8.60, 8.60 Hz), 5.95 (br s, 1H), 5.61 (t, 1H, J=7.8 Hz), 3.93-4.05 (m, 2H), 3.78, 3.81 (2s, 3H), 3.49, 3.63 (2d, 1H, J=15.04, 14.64 Hz), 2.10-2.54 (m, 2H), 1.95 (m, 2H), 1.47-1.55 (m, 2H), 1.02-1.06 (m, 6H), 0.37, 0.43 (2d, 3H, J=6.48, 6.56 Hz); MS (ESI) m/z 670 (M++H).
Compound 306 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanamideCompound 306 (42 mg, 56%) as white solid foam was obtained according to the same method as the synthesis of compound 299.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.85 (s, 1H), 7.73-7.74 (m, 2H), 7.00-7.03 (m, 1H), 6.70-6.81 (m, 1H), 5.52-5.60 (m, 3H), 3.88-4.03 (m, 2H), 3.71, 3.75 (2s, 3H), 3.39, 3.58 (2d, 1H, J=14.84, 14.48 Hz), 2.65-2.82 (m, 2H), 2.00-2.50 (m, 2H), 1.92 (m, 2H), 1.45-1.50 (m, 2H), 1.14-1.18 (m, 6H), 1.01-1.64 (m, 6H), 0.29, 0.46 (2d, 3H, J=6.48, 6.56 Hz); MS (ESI) m/z 641 (M++H).
Compound 307 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanenitrileCompound 307 (12 mg, 48%) as white solid foam was obtained according to the same method as the synthesis of compound 300.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.73-7.93 (m, 3H), 6.82-7.16 (m, 3H), 5.58-5.60 (m, 1H), 3.89-4.02 (m, 2H), 3.75-3.77 (m, 3H), 3.43-3.67 (m, 1H), 2.57-2.86 (m, 2H), 1.85-2.47 (m, 4H), 1.94 (m, 2H), 1.21-1.78 (m, 6H), 0.85-0.89 (m, 6H), 0.30-0.40 (m, 3H); MS (ESI) m/z 623.3 (M++H).
Compound 308 methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoateMethyl 3-(4-methoxyphenyl)-3-methylbutanoate, an intermediate compound, was synthesized, and then Compound 308 (0.9 g, 66.5%) as white solid foam was obtained according to the same method as the synthesis of compound 285.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 7.18-7.21 (m, 1H), 6.92-6.96 (m, 1H), 6.74-6.81 (m, 1H), 5.58-5.61 (m, 1H), 3.87-4.00 (m, 2H), 3.73, 3.74 (2s, 3H), 3.47, 3.60 (2d, 1H, J=11.22 10.89 Hz), 3.49, 3.50 (2s, 3H), 2.54-2.59 (m, 2H), 2.00-2.30 (m, 2H), 1.93-1.94 (m, 2H), 1.46-1.48 (m, 2H), 1.38-1.41 (m, 6H), 1.01-1.05 (m, 6H), 0.28, 0.41 (2d, 3H, J=4.89, 4.92 Hz); MS (ESI) m/z 656.3 (M++H).
Compound 309 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutano ic acidCompound 309 (0.24 g, 32.7%) as white solid foam was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 7.20-7.23 (m, 1H), 6.94-6.98 (m, 1H), 6.75-6.82 (m, 1H), 5.57-5.60 (m, 1H), 3.85-4.01 (m, 2H), 3.73, 3.75 (2s, 3H), 3.49, 3.58 (2d, 1H, J=10.98, 10.83 Hz), 2.55-2.64 (m, 2H), 2.05-2.08 (m, 2H), 1.92-1.94 (m, 2H), 1.47-1.51 (m, 2H), 1.43-1.44 (m, 6H), 1.00-1.05 (m, 6H), 0.26, 0.43 (2d, 3H, J=4.95, 4.86 Hz); MS (ESI) m/z 642.2 (M++H).
Compound 310 methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutanoateCompound 310 (0.7 g, 96.1%) as white solid foam was obtained according to the same method as the synthesis of compound 285.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.86 (s, 1H), 7.73-7.75 (m, 2H), 6.99-7.02 (m, 1H), 6.71-6.79 (m, 2H), 5.59-5.62 (m, 1H), 3.91-4.02 (m, 2H), 3.71, 3.74 (2s, 3H), 3.63, 3.68 (2s, 3H), 3.47, 3.59 (2d, 1H, J=11.10, 10.95 Hz), 2.40-2.47 (m, 2H), 2.00-2.38 (m, 2H), 1.91-1.93 (m, 2H), 1.76-1.80 (m, 2H), 1.46-1.49 (m, 2H), 1.24-1.28 (m, 6H), 1.19 (d, 1H, J=3.4 Hz), 1.01-1.05 (m, 6H), 0.31, 0.43 (2d, 3H, J=4.86, 4.95 Hz); MS (ESI) m/z 670.2 (M++H).
Compound 311 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutanoic acidCompound 311 (0.11 g, 20%) as white solid foam was obtained according to the same method as the synthesis of compound 134
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.86 (s, 1H), 7.73-7.75 (m, 2H), 7.70-7.04 (m, 1H), 6.72-6.76 (m, 2H), 5.59-5.61 (m, 1H), 3.95-4.00 (m, 2H), 3.71-3.80 (m, 3H), 3.40-3.59 (m, 1H), 2.46-2.54 (m, 2H), 2.00-2.15 (m, 4H), 1.84-1.93 (m, 2H), 1.70-1.84 (m, 2H), 1.46-1.49 (m, 2H), 1.22-1.24 (m, 6H), 0.31, 0.44 (2d, 3H, J=5.01, 4.83 Hz); MS (ESI) m/z 656.3 (M++H).
Compound 312 ethyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylateCompound 312 (0.38 g, 85%) as white solid foam was obtained according to the same method as the synthesis of compound 285.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84, 7.77, 7.73 (3 brs, 3H), 7.70-6.95 (m, 1H), 6.76-6.69 (m, 2H), 5.58 (t, 1H, J=8.0 Hz), 4.13-4.05 (m, 2H), 3.99-3.85 (m, 2H), 3.72, 3.70 (2s, 3H), 3.56, 3.45 (2d, 1H, J=14.9, 14.5 Hz), 2.99-2.94 (m, 2H), 2.37-1.97 (m, 11H), 1.46 (m, 2H), 1.27-1.18 (m, 5H), 1.03-0.86 (m, 6H), 0.34, 0.25 (2d, 3H, J=6.5 Hz); MS (ESI): 726 (M++H).
Compound 313 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzypcyclobutanecarboxylic acidCompound 313 (0.15 g, 47.4%) as white solid foam was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84, 7.75, 7.72 (3s, 3H), 7.04-7.01 (m, 1H), 6.82-6.70 (m, 2H), 5.58 (d, 1H, J=8.1 Hz), 3.99-3.86 (m, 2H), 3.72, 3.70 (2s, 3H), 3.56, 3.46 (2d, 1H, J=14.9, 14.6 Hz), 3.04-2.96 (m, 2H), 2.47-1.81 (m, 12H), 1.46 (m, 2H), 1.03-0.98 (m, 6H), 0.38, 0.25 (2d, 3H, J=6.5 Hz); MS (ESI): 654 (M++H).
Compound 314 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzypcyclobutanecarboxamideCompound 314 (0.04 g, 59.5%) as colorless oil was obtained according to the same method as the synthesis of compound 299.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 7.06, 7.03 (2d, 1H, J=7.06, 7.04 Hz), 6.84, 6.79 (2d, 1H, J=6.84, 6.79 Hz), 6.77, 6.72 (2d, 1H, J=8.4 Hz), 5.58, 5.50 (2d, 1H, J=8.1, 8.0 Hz), 5.34-5.26 (brs, 2H), 4.12-3.85 (m, 2H), 3.77, 3.70 (2s, 3H), 3.54, 3.30 (2d, 1H, J=14.8, 14.5 Hz), 2.96 (d, 2H, J=10.6 Hz), 2.75-1.79 (m, 11H), 1.46 (m, 2H), 1.02-1.00 (m, 3H); MS (ESI): 697 (M++H).
Compound 315 methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoateMethyl 2-(4-methoxyphenyl)-2-methylpropanoate, an intermediate compound, was synthesized, and then Compound 315 (0.16 g, 76.8%) as colorless oil was obtained according to the same method as the synthesis of compound 285.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (d, 2H, J=4.4 Hz), 7.19, 7.17 (2t, 1H, J=2.7 Hz), 6.94, 6.90 (2d, 1H, J=2.5 Hz), 6.81, 6.76 (2d, 1H, J=8.7 Hz), 5.59, 5.55 (2d, 1H, J=8.2 Hz), 3.96-3.88 (m, 2H), 3.75, 3.73 (2s, 3H), 3.63, 3.55 (2s, 3H), 3.54, 3.40 (2d, 1H, J=14.8, 13.3 Hz), 2.52-1.93 (m, 5H), 1.55-1.44 (m, 10H), 1.04, 1.02, 1.00 (3s, 6H), 0.35, 0.27 (2d, 3H, J=6.7, 6.5 Hz); MS (ESI): 642 (M++H).
Compound 316 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyppyridin-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 316 (0.08 g, 30.6%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.37 (m, 1H), 7.88 (s, 1H), 7.74 (s, 2H), 7.49 (m, 1H), 5.64 (m, 1H), 4.02-3.94 (m, 5H), 3.47-3.36 (m, 1H), 2.60-2.00 (m, 2H), 1.94 (s, 2H), 1.55 (m, 2H), 1.10 (m, 6H), 0.40 (m, 3H); MS (ESI): 611.2 (M+H)+.
Compound 317 methyl 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetateCompound 317 (0.2 g, 77%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.76 (s, 2H), 6.67 (m, 1H), 6.50 (m, 1H), 5.95 (2d, 2H, J=1.04, 1.32 Hz), 5.57 (m, 1H), 4.09 (m, 1H), 3.95 (m, 1H), 3.64 (m, 4H), 3.50 (s, 2H), 2.40-2.20 (m, 2H), 1.95 (s, 2H), 1.51 (m, 2H), 1.03 (m, 6H), 0.41 (m, 3H); MS (ESI): 628.1 (M+H)+.
Compound 318 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetic acidCompound 318 (0.09 g, 76.7%) as colorless oil was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 6.65 (m, 1H), 6.46 (m, 1H), 5.93 (m, 2H), 5.59 (m, 1H), 4.09-3.91 (m, 2H), 3.66 (m, 1H), 3.49 (s, 2H), 2.40-2.18 (m, 2H), 1.93 (s, 2H), 1.50 (m, 2H), 1.03 (m, 6H), 0.42 (m, 3H); MS (ESI): 614.1 (M+H)+.
Compound 319 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)-N-methylacetamideCompound 318 (0.06 g, 0.1 mmol) was dissolved in methylene chloride (10 mL). Methylamine (0.02 g), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.04 g) and hydroxybenzotriazole (0.03 g) were added to the obtained solution at room temperature, and stirred at room temperature overnight. After the completion of the reaction, ethyl acetate was added dropwise to the reaction mixture. The obtained reaction mixture was washed with saturated sodium hydrogen carbonate solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO2, 4:1 hexane/EtOAc), thus obtaining Compound 319 (0.03 g, 49%) as white solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.75 (s, 2H), 6.64 (m, 1H), 6.49 (m, 1H), 5.96 (2d, 2H, J=1.16, 1.28 Hz), 5.69 (br s, 1H), 5.56 (m, 1H), 4.17 (m, 1H), 4.03 (m, 1H), 3.53 (m, 1H), 3.34 (s, 2H), 2.74 (m, 3H), 2.40-2.20 (m, 2H), 1.94 (s, 2H), 1.51 (m, 2H), 1.02 (m, 6H), 0.49 (m, 3H).
Compound 320 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoic acidCompound 320 (0.05 g, 31.4%) as white solid foam was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.71 (d, 2H, J=4.6 Hz), 7.24-7.21 (m, 1H), 6.97, 6.96 (2d, 1H, J=2.6 Hz), 6.82, 6.77 (2d, 1H, J=8.7 Hz), 5.55 (t, 2H, J=7.9 Hz), 3.98-3.85 (m, 2H), 3.75, 3.73 (2s, 3H), 3.54, 3.39 (2d, 1H, J=15.0, 14.6 Hz), 2.56-1.92 (m, 5H), 1.54-1.44 (m, 8H), 1.04, 1.01, 1.00 (3s, 6H), 0.38, 0.28 (2d, 3H, J=6.6, 6.5 Hz); MS (ESI): 628 (M++H).
Compound 321 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N,2,2-trimethylpropanamideCompound 321 (78 mg, 76.4%) as white solid foam was obtained according to the same method as the synthesis of compound 319.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.86 (s, 1H), 7.73-7.75 (m, 2H), 6.94-6.98 (m, 1H), 6.71-6.76 (m, 2H), 5.31-5.60 (m, 2H), 3.88-4.06 (m, 2H), 3.71, 3.76 (2s, 3H), 3.37, 3.56 (2d, 1H, J=14.92, 14.40 Hz), 2.47-2.84 (m, 2H), 2.67-2.76 (m, 3H), 2.00-2.50 (m, 2H), 1.93 (m, 2H), 1.44-1.57 (m, 6H), 1.11-1.14 (m, 6H), 1.01-1.05 (m, 6H), 0.29, 0.46 (2d, 3H, J=6.48, 6.56 Hz); MS (ESI) m/z 655 (M++H).
Compound 323 methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylateCompound 323 (81 mg, 51%) as white solid foam was obtained according to the same method as the synthesis of compound 285.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.77, 7.72 (2s, 2H), 6.94-6.90 (m, 1H), 6.74-6.66 (m, 2H), 5.59 (t, 1H, J=8.0 Hz), 3.99-3.84 (m, 2H), 3.75, 3.70 (2s, 3H), 3.63, 3.59 (2s, 3H), 3.57, 3.46 (2d, 1H, J=14.5 Hz), 2.85, 2.81 (2d, 1H, J=3.7 Hz), 2.53-2.42 (m, 1H), 2.24-2.16 (m, 1H), 2.02-1.93 (m, 5H), 1.64-1.44 (m, 7H), 1.03-0.99 (m, 6H), 0.38, 0.26 (2d, 3H, J=6.6 Hz); MS (ESI) m/z 682.2, 704.1 (M++H, M++Na).
Compound 324 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzypcyclopentanecarboxylic acidCompound 324 (6 mg, 9.4%) as white solid foam was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 7.03-6.99 (m, 1H), 6.84 (dd, 1H, J=9.9, 2.2 Hz), 6.73 (dd, 1H, J=16.4, 8.4 Hz), 5.62-5.58 (m, 1H), 3.99-3.89 (m, 2H), 3.73, 3.70 (2s, 3H), 3.54-3.50 (m, 1H), 2.99-2.77 (m, 2H), 2.17-1.88 (m, 7H), 1.66-1.32 (m, 7H), 1.03-0.98 (m, 6H), 0.47, 0.32 (2d, 3H, J=6.6 Hz); MS (ESI) m/z 668.1, 690.1 (M++H, M++Na).
Compound 325 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylprop anoic acidCompound 325 (1.07 g, 90%) as white solid foam was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.74 (d, 2H, J=7.0 Hz), 6.92 (t, 0H, J=58.5 Hz), 6.57-6.51 (m, 1H), 5.62 (dd, 1H, J=8.2, 2.3 Hz), 4.00-3.81 (m, 2H), 3.73, 3.70 (2s, 3H), 3.51-3.47 (m, 1H), 2.88-2.79 (m, 2H), 2.49-2.41 (m, 1H), 2.14-2.11 (m, 1H), 1.90-1.88 (m, 2H), 1.49-1.40 (m, 2H), 1.29-1.10 (m, 6H), 1.02-0.95 (m, 6H), 0.46 (2d, 3H, J=6.6 Hz); MS (ESI) m/z 660.2 (M++H).
Compound 326 methyl 7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylateMethyl 6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate, which is an intermediate compound, was synthesized, and then Compound 326 (0.21 g, 65%) as white solid foam was obtained according to the same method as the synthesis of compound 285.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (d, 1H, J=5.0 Hz), 7.73 (d, 2H, J=4.5 Hz), 6.67-6.50 (m, 2H), 5.62-5.58 (m, 1H), 4.02-3.90 (m, 2H), 3.72-3.41 (m, 7H), 2.90-1.78 (m, 10H), 1.46 (m, 2H), 1.28 (m, 5H), 1.03-0.96 (m, 6H), 0.45 (t, 1.3; H, J=5.9 Hz), 0.33 (d, 1.7; H, J=6.5 Hz); MS (ESI): 654 (M++H).
Compound 327 7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acidCompound 327 (0.07 g, 38.7%) as white solid foam was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (d, 2H, J=4.3 Hz), 6.67, 6.66 (2d, 1H, J=2.2, 1.6 Hz), 6.56, 6.51, 6.50 (3s, 1H), 5.60 (t, 1H, J=6.6 Hz), 4.02-3.90 (m, 2H), 3.71, 3.69, 3.68 (3s, 3H), 3.62-3.43 (m, 3H), 2.52-1.81 (m, 4H), 1.46 (m, 2H), 1.04, 1.03, 0.99 (3s, 6H), 0.48-0.33 (m, 3H); MS (ESI): 640 (M++H).
Compound 328 methyl 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanoateCompound 328 (1.52 g, 98%) as white solid foam was obtained according to the same method as the synthesis of compound 285.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.76, 7.72 (2s, 2H), 6.67 (dd, 1H, J=16.1, 8.6 Hz), 6.53 (dd, 1H, J=14.7, 11.7 Hz), 5.60 (t, 1H, J=7.4 Hz), 3.98-3.84 (m, 2H), 3.72, 3.70 (2s, 3H), 3.64 (s, 3H), 3.54, 3.44 (2d, 1H, J=14.4 Hz), 2.85-2.72 (m, 2H), 2.47-2.41 (m, 1H), 2.23-2.14 (m, 1H), 2.00-1.91 (m, 2H), 1.52-1.41 (m, 2H), 1.18-1.12 (m, 6H), 1.05-0.98 (m, 6H), 0.41, 0.31 (2d, 3H, J=6.6 Hz); MS (ESI) m/z 674 (M++H).
Compound 329 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanamideCompound 329 (23 mg, 23%) as white solid was obtained according to the same method as the synthesis of compound 299.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (d, 1H, J=7.2 Hz), 6.82 (dd, 1H, J=17.7, 8.6 Hz), 6.54 (dd, 1H, J=15.4, 11.6 Hz), 5.68 (brs, 0.47; H), 5.59 (dd, 1H, J=8.1, 3.0 Hz), 5.55 (brs, 0.13; H), 5.41 (brs, 0.4; H), 4.00-3.86 (m, 2H), 3.73, 3.69 (2s, 3H), 3.53, 3.32 (2d, 1H, J=14.6 Hz), 2.88-2.72 (m, 2H), 2.45-1.97 (m, 2H), 1.89 (brs, 2H), 1.50-1.39 (m, 2H), 1.17 (t, 6H, J=9.9 Hz), 1.00 (dd, 6H, J=5.3, 12.1 Hz), 0.44, 0.31 (2d, 3H, J=6.6 Hz); MS (ESI) m/z 659.1 (M++H).
Compound 330 ethyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenethypcyclobutanecarboxylateCompound 330 (0.03 g, 72.2%) as white solid was obtained according to the same method as the synthesis of compound 285.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.74 (s, 2H), 7.03 (m, 1H), 6.79 (m, 2H), 5.62 (m, 1H), 4.20-3.90 (m, 4H), 3.75 (m, 3H), 3.60 (m, 1H), 2.50-1.83 (m, 13H), 1.50 (m, 2H), 1.30 (m, 5H), 1.05 (m, 6H), 0.44 (2d, 3H, J=6.56, 6.52 Hz).
Compound 331 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenethyl)cyclobutanecarboxylic acidCompound 331 (3 mg, 10.4%) as white solid was obtained according to the same method as the synthesis of compound 286.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.74 (s, 2H), 7.05 (m, 1H), 6.80 (m, 2H), 5.62 (m, 1H), 4.04-3.90 (m, 2H), 3.76 (m, 3H), 3.60 (m, 1H), 2.50-1.83 (m, 13H), 1.50 (m, 2H), 1.30 (m, 5H), 1.05 (m, 6H), 0.46 (m, 3H).
Compound 332 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzonitrileCompound 332 (0.2 g, 56.1%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.88 (s, 1H), 7.75 (m, 2H), 7.59 (m, 1H), 7.29 (m, 1H), 6.95 (m, 1H), 5.66, 5.60 (2d, 1H, J=8.20, 8.08 Hz), 4.01-4.90 (m, 2H), 3.85 (m, 3H), 3.52-3.30 (m, 1H), 2.20-2.04 (m, 2H), 1.52-1.47 (m, 2H), 1.05-0.98 (m, 6H), 1.47 (m, 3H); MS (ESI): 610.1 (M+H)+.
Compound 333 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 333 (0.01 g, 18.6%) as white solid foam was obtained according to the same method as the synthesis of compound 301.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.13 (m, 1H), 7.92-7.72 (m, 4H), 7.03-6.99 (m, 1H), 5.77, 5.62 (2d, 1H, J=8.00, 8.24 Hz), 4.20-4.03 (m, 2H), 3.86 (m, 3H), 3.12 (m, 1H), 2.60-2.04 (m, 2H), 1.54-1.41 (m, 2H), 1.05-0.98 (m, 6H), 1.52, 0.46 (2d, 3H, J=6.56, 6.52 Hz); MS (ESI): 610.1 (M+H)+.
Compound 334 (4R,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneReferring to the published article “Cameron J. Smith et al., J. Med. Chem. 2011 54 4880”, (1R,2R)-2-amino-1-(3,5-bis(trifluoromethyl)phenyl)propane-ol was synthesized, and then Compound 334 (0.11 g, 61.1%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.91 (s, 1H), 7.79 (s, 2H), 6.74-6.78 (m, 2H), 6.54-6.58 (m, 2H), 5.00 (t, 1H, J=5.7 Hz), 3.85-3.94 (m, 1H), 3.66-3.73 (2s, 3H), 3.44-3.60 (m, 1H), 3.34-3.50 (m, 1H), 3.12-3.19 (m, 1H), 2.12-2.40 (m, 2H), 1.85-2.07 (m, 2H), 1.15-1.45 (m, 2H), 1.20-1.38 (m, 6H), 0.95-1.19 (m, 3H), 0.60-1.00 (m, 6H); MS (ESI) m/z 602 (M++H).
Compound 335 (4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneReferring to the published article “Cameron J. Smith et al., J. Med. Chem. 2011 54 4880”, (1S,2S)-2-amino-1-(3,5-bis(trifluoromethyl)phenyl)propane-ol was synthesized, and then Compound 335 (0.16 g, 86%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.89 (s, 1H), 7.78 (s, 2H), 6.75 (dd, 1H, J=5.6, 8.6 Hz), 6.55 (dd, 1H, J=12.2, 3.2 Hz), 4.99 (t, 0H, J=5.6 Hz), 3.93-3.84 (m, 1H), 3.73, 3.65 (2s, 3H), 3.59-3.32 (m, 2H), 3.16-3.11 (m, 1H), 2.34-2.11 (m, 2H), 1.94-1.84 (m, 2H), 1.44-1.25 (m, 2H), 1.22-1.16 (m, 6H), 1.09, 0.98 (2d, 3H, J=6.2 Hz), 0.94 (s, 1.3; H), 0.90 (s, 1.7; H), 0.77 (s, 1.3; H), 0.59 (s, 1.7; H); MS (ESI) m/z 602.1 (M++H). (ratio=1:1.25).
Compound 336 (4R,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneReferring to the published article “Cameron J. Smith et al., J. Med. Chem. 2011 54 4880”, (1S,2R)-2-amino-1-(3,5-bis(trifluoromethyl)phenyppropane-ol was synthesized, and then Compound 336 (0.09 g, 57%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 6.81 (2d, 1H, J=12.64, 12.68 Hz), 6.56 (2d, 1H, J=12.24, 12.12 Hz), 5.63 (m, 1H), 4.01-3.90 (m, 2H), 3.72 (m, 3H), 3.56 (m, 1H), 3.14 (m, 1H), 2.50-2.00 (m, 2H), 1.92 (m, 2H), 1.51-1.47 (m, 2H), 1.20 (m, 6H), 1.04 (m, 6H), 0.40 (m, 3H).
Compound 337 7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxamideCompound 337 (0.03 g, 79.5%) as white solid foam was obtained according to the same method as the synthesis of compound 299.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (d, 2H, J=4.3 Hz), 6.67, 6.66 (2d, 1H, J=2.2, 1.6 Hz), 6.56, 6.51, 6.50 (3s, 1H), 5.60 (t, 1H, J=6.6 Hz), 4.02-3.90 (m, 2H), 3.71, 3.69, 3.68 (3s, 3H), 3.62-3.43 (m, 3H), 2.52-1.81 (m, 4H), 1.46 (m, 2H), 1.04, 1.03 (m, 6H).
Compound 338 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 333 (0.03 g, 0.048 mmol) was dissolved in acetonitrile (10 mL). Potassium carbonate (7 mg) and iodomethane (7 mg) were added to the obtained solution, and then stirred at 100° C. overnight. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was PTLC (SiO2, Hx:EA=1:1, thus obtaining Compound 338 (0.01 g, 39.1%) as colorless oil.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.04 (m, 1H), 7.85-7.71 (m, 4H), 6.99-6.94 (m, 1H), 5.66, 5.54 (2d, 1H, J=8.04, 8.04 Hz), 4.40 (m, 3H), 4.03 (m, 2H), 3.83 (m, 3H), 3.62-3.40 (m, 1H), 2.53-2.05 (m, 2H), 1.95 (m, 2H), 1.50 (m, 2H), 1.06 (m, 6H), 0.38 (m, 3H); MS (ESI): 624.1 (M+H)+.
Compound 339 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1-methyl-1H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 339 (0.01 g, 39.1%) as colorless oil was obtained according to the same method as the synthesis of compound 338.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.75 (m, 2H), 7.65-7.48 (m, 2H), 7.06-7.02 (m, 1H), 5.63, 5.57 (2d, 1H, J=8.24, 8.04 Hz), 4.21 (m, 3H), 4.10-3.95 (m, 2H), 3.90-3.82 (m, 3H), 3.58-3.35 (m, 1H), 2.53-2.05 (m, 2H), 1.95 (m, 2H), 1.50 (m, 2H), 1.06 (m, 6H), 0.48, 0.44 (2d, 1H, J=6.60, 6.62 Hz); MS (ESI): 624.1 (M+H)+.
Compound 340 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 340 (0.04 g, 26.7%) as white solid foam was obtained according to the same method as the synthesis of compound 301.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.00 (s, 1H), 7.86, 7.84 (2s, 1H), 7.73, 7.71 (2s, 1H), 6.72-6.33 (m, 2H), 5.62, 5.50 (2d, 1H, J=8.0 Hz), 4.37-4.04 (m, 2H), 3.80, 3.66 (2s, 3H), 3.10, 2.83 (2d, 1H, J=15, 8.4 Hz), 2.38-1.89 (m, 4H), 1.60-1.31 (m, 8H), 1.03-0.97 (m, 6H), 0.64, 0.38 (2d, 3H, J=6.6 Hz); MS (ESI): 666 (M++H).
Compound 341 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2-methyl-2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 341 (6 mg, 32.6%) as white solid foam was obtained according to the same method as the synthesis of compound 338.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.76, 7.72 (2s, 2H), 6.82-6.79 (m, 1H), 6.68, 6.64 (2d, 1H, J=8.4 Hz), 6.43, 6.41 (2d, 1H, J=2.2 Hz), 5.60, 5.56 (2d, 1H, J=8.2 Hz), 4.27, 4.26 (2s, 3H), 3.93-3.73 (m, 2H), 3.70, 3.68 (2s, 3H), 3.42, 3.35 (2d, 1H, J=14.9 Hz), 3.03-2.85 (m, 2H), 2.48-1.64 (m, 6H), 1.46-1.20 (m, 8H), 1.06-0.98 (m, 6H), 0.38, 0.21 (2d, 3H, J=6.5 Hz); MS (ESI): 680 (M++H).
Compound 342 tert-butyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)acetateCompound 37 (0.1 g, 0.17 mmol) was dissolved in methylene chloride (3 mL). tert-Butyl 2-aminoacetateHCl (37 mg, 0.22 mmol), diisopropylethylamine (0.09 mL, 0.51 mmol) and hydroxybenzotriazole (46 mg, 0.34 mmol) were added dropwise to the obtained solution, and stirred at room temperature 10 minutes. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide (66 mg, 0.34 mmol) was added dropwise to the reaction mixture, and then stirred at room temperature for 1 hour. After the completion of the reaction, the reaction mixture was diluted with methylene chloride, and washed with water and brine. The organic layers were collected, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO2, 20%-30% Hexane/EtOAc), thus obtaining Compound 342 (0.1 g, 87%) as white solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.82 (d, 1H, J=4.7 Hz), 7.73-7.70 (m, 2.5H), 7.65 (dd, 0.5; H, J=8.6, 2.3 Hz), 7.53, 7.47 (2d, 1H, J=2.4 Hz), 6.86 (t, 1H, =8.6 Hz), 6.67-6.60 (m, 1H), 5.56 (dd, 1H, J=16.3, 8.1 Hz), 4.12-4.03 (m, 2H), 3.99-3.92 (m, 2H), 3.80, 3.77 (2s, 3H), 3.47, 3.32 (2d, 1H, J=14.8 Hz), 2.45-2.00 (m, 2H), 1.90 (brs, 2H), 1.48-1.44 (m, 11H), 1.00 (dd, 6H, J=11.0, 2.3 Hz), 0.41, 0.34 (2d, 3H, J=6.5 Hz); MS (ESI) m/z 699.1 (M++H).
Compound 343 tert-butyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylb enzamido)acetateCompound 343 (21 mg, 21%) as white solid was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.74 (s, 2H), 7.41-7.34 (m, 1H), 7.20-7.12 (m, 1H), 6.86-6.83 (m, 1H), 5.62, 6.83 (2d, 1H, J=8.1 Hz), 4.13-3.82 (m, 4H), 3.79, 3.77 (2s, 3H), 3.52-3.34 (m, 1H), 3.05-3.02 (m, 3H), 2.39-2.04 (m, 2H), 1.92 (brs, 2H), 1.51-1.45 (m, 11H), 1.03-1.00 (m, 6H), 0.43, 0.37 (d, 3H, J=6.6 Hz); MS (ESI) m/z 713.1 (M++H).
Compound 344 (R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)-3-methylbutanoateCompound 344 (96 mg, 81%) as white solid was obtained according to the same method as the synthesis of compound 342.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 7.71 (dd, 0.5; H, J=8.6, 2.4 Hz), 7.65 (dd, 0.5; H, J=8.6, 2.4 Hz), 7.53, 7.48 (2d, 1H, J=2.3 Hz), 6.89 (t, 1H, J=8.8 Hz), 6.58-6.54 (m, 1H), 5.55 (dd, 1H, J=19.5, 8.0 Hz), 4.76-4.69 (m, 1H), 4.01-3.93 (m, 2H), 3.83, 3.80 (2s, 3H), 3.77, 3.74 (2s, 3H), 3.50, 3.33 (2d, 1H, J=15.0 Hz), 2.45-2.21 (m, 2H), 1.93 (brs, 2H), 1.52-1.46 (m, 2H), 1.04-0.89 (m, 12H), 0.41 (t, 3H, J=6.7 Hz); MS (ESI) m/z 699.1 (M++H).
Compound 345 (R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylb enzamido)-3-methylbutanoateCompound 345 (50 mg, 55%) as white solid was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.74 (d, 2H, J=8.5 Hz), 7.32 (dd, 1H, J=8.5, 2.2 Hz), 7.12 (dd, 1H, J=10.5, 2.2 Hz), 6.88-6.53 (m, 1H), 5.61 (d, 0.5; H, J=8.4 Hz), 5.46 (d, 0.5; H, J=7.2 Hz), 4.08-3.90 (m, 3H), 3.82-3.73 (m, 6H), 3.68-3.36 (m, 2H), 3.01-2.96 (m, 3H), 2.44-2.19 (m, 2H), 1.96-1.87 (m, 2H), 1.53-1.41 (m, 2H), 1.03-0.75 (m, 12H), 0.41, 0.36 (2d, 3H, J=6.5 Hz); MS (ESI) m/z 713.2 (M++H).
Compound 346 (R)-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)-3-methylbutanoic acidCompound 346 (21 mg, 48%) as white solid was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 7.43-7.37 (m, 1H), 7.22-7.09 (m, 1H), 6.90-6.86 (m, 1H), 5.63-5.48 (m, 1H), 4.23-3.95 (m, 4H), 3.82, 3.80 (2s, 3H), 3.51-3.32 (m, 1H), 3.06 (brs, 3H), 2.56-2.17 (m, 2H), 1.92-1.87 (m, 2H), 1.49-1.41 (m, 2H), 1.10-0.84 (m, 12H), 0.43, 0.38 (2d, 3H, J=6.0 Hz); MS (ESI) m/z 699.1 (M++H).
Compound 347 methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoateCompound 313 (0.03 g, 0.046 mmol) was dissolved in dimethylformamide (3 mL). Potassium carbonate (8.2 mg) and iodomethane (4.0 μL) were added dropwise to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (SiO2, 5%-20% n-hexane/EtOAc), thus obtaining Compound 347 (0.02 g, 75.1%) as white solid foam.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.77, 7.73 (2s, 2H), 6.96-6.93 (m, 1H), 6.76-6.69 (m, 2H), 5.58 (t, 1H, J=8.2 Hz), 3.98-3.84 (m, 2H), 3.72, 3.70 (2s, 3H), 3.63, 3.61 (2s, 3H), 3.55, 3.46 (2d, 1H, J=14.5 Hz), 3.00-2.94 (m, 2H), 2.39-1.81 (m, 11H), 1.46 (m, 2H), 1.03-0.99 (m, 6H), 0.35, 0.25 (2d, 3H, J=6.5 Hz); 668 (M++H).
Compound 348 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)acetic acidCompound 348 (1.4 mg, 8%) as white solid was obtained according to the same method as the synthesis of compound 134.
MS (ESI) m/z 657.1 (M++H).
Compound 349 Methyl 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoateAs shown in reaction scheme 7, Compound 31, an intermediate compound, was synthesized, and then Compound 349 (0.28 g, 69.5%) as white solid foam was obtained according to the similar method to the synthesis of compound 285.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.86 (m, 1H), 7.81, 7.83 (2d, 1H, J=1.77, 1.83 Hz), 7.74-7.75 (m, 2H), 7.02, 7.05 (2d, 1H, J=1.77, 1.77 Hz), 5.60, 5.63 (2d, 1H, J=5.94, 6.00 Hz), 3.91-4.03 (m, 2H), 3.85, 3.88 (2d, 3H), 3.64, 3.65 (2s, 3H), 3.46-3.52 (m, 1H), 2.73-2.80 (m, 2H), 1.90-1.95 (m, 2H), 1.43-1.48 (m, 2H), 1.16-1.20 (m, 6H), 1.01-1.09 (m, 6H), 0.28, 0.49 (2d, 3H, J=4.89, 4.89 Hz); MS (ESI) m/z 657.2 (M++H).
Compound 350 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoic acidCompound 350 (75 mg, 54%) as white solid was obtained according to the same method as the synthesis of compound 134.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.90, 7.90 (2d, 1H, J=2.36, 2.36 Hz), 7.85-7.86 (m, 1H), 7.73-7.74 (2s, 2H), 7.13, 7.15 (2d, 1H, J=2.40, 2.36 Hz), 5.60, 5.64 (2d, 1H, J=8.16, 8.00 Hz), 3.91-4.02 (m, 2H), 3.85-3.88 (2s, 3H), 3.50, 3.55 (2d, 1H, J=14.64, 15.16 Hz), 2.71-2.86 (m, 2H), 2.00-2.53 (m, 2H), 1.86-1.95 (m, 2H), 1.46-1.49 (m, 2H), 1.12-1.18 (m, 6H), 1.00-1.04 (m, 6H), 0.30, 0.52 (2d, 3H, J=6.52, 6.60 Hz); MS (ESI) m/z 643.2 (M++H).
Compound 353 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 353 (1.2 g, 62.6%) as white solid foam was obtained according to the same method as the synthesis of compound 18.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.87 (s, 1H), 7.75 (m, 2H), 7.20-7.17 (m, 1H), 6.96 (m, 1H), 6.81, 6.77 (2d, 1H, J=8.80, 8.80 Hz), 5.65, 5.59 (2d, 1H, J=8.16, 8.24 Hz), 4.01-3.90 (m, 2H), 3.76 (m, 3H), 3.58-3.38 (m, 1H), 2.50-2.00 (m, 2H), 1.92 (m, 2H), 1.50-1.40 (m, 2H), 1.04 (m, 6H), 0.40 (m, 3H); MS (ESI): 576.0 (M+H)+.
Compound 354 tert-butyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylateCompound 353 (0.1 g, 0.174 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (0.05 g, 0.17 mmol), sodium carbonate (0.06 g) and palladium (0.01 g) were dissolved in dimethoxyethane/water (0.8 mL, v/v 3:1). The obtained solution in microwave-reactor was stirred at 120° C. for 30 minutes. After the completion of the reaction, the reaction mixture was cooled down to room temperature, diluted with EtOAc, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (SiO2, 10:1 hexane/EtOAc), thus obtaining Compound 354 (10 mg, 8%) as colorless oil.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 7.24 (m, 1H), 7.00 (m, 1H), 6.85, 6.80 (2d, 1H, J=8.68, 8.68 Hz), 5.90 (m, 1H), 5.59 (m, 1H), 4.10-3.85 (m, 4H), 3.74 (m, 3H), 3.60-3.40 (m, 3H), 2.60-2.03 (m, 5H), 1.92 (m, 2H), 1.44 (m, 9H), 1.03-1.00 (m, 6H), 0.40 (m, 3H).
Compound 355 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 355 (30 mg, 27.7%) as white solid foam was obtained according to the same method as the synthesis of compound 354.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 7.25 (m, 1H), 7.02 (m, 1H), 6.85, 6.81 (2d, 1H, J=8.60, 8.64 Hz), 6.04-5.96 (m, 1H), 5.61 (m, 1H), 4.32-4.26 (m, 1H), 4.00-3.48 (m, 8H), 2.48 (m, 2H), 2.40-2.03 (m, 2H), 1.94 (m, 2H), 1.50 (m, 2H), 1.03-1.00 (m, 6H), 0.40, 0.33 (2d, 3H, J=6.56, 6.52 Hz).
Compound 356 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(hydroxymethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAccording to the same method as the synthesis of Compound 79, the aldehyde compound was synthesized. The obtained aldehyde compound (0.03 g, 0.05 mmol) and (s)-3-fluoropyrrolidine (5 mg) were dissolved in methylene chloride (10 mL). Acetic acid (30 μL) was added dropwise to the obtained solution, and stirred for 1 hour at room temperature. Sodium cyanoborohydride (4 mg) was added dropwise to the reaction mixture. The reaction mixture was stirred overnight, diluted with methylene chloride, washed with saturated sodium hydrogen carbonate solution, water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by PTLC (SiO2, Hx:EA=1:1, thus obtaining “by-product” Compound 356 (0.01 g, 33.2%) as white solid foam.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (m, 2H), 7.24 (m, 1H), 7.06-6.98 (m, 1H), 6.87, 6.82 (2d, 1H, J=8.44, 8.40 Hz), 5.59, 5.51 (2d, 1H, J=7.96, 8.16 Hz), 4.62-4.53 (m, 2H), 4.07-3.92 (m, 2H), 3.79-3.74 (m, 3H), 3.56-3.37 (m, 1H), 2.51-2.05 (m, 2H), 1.93 (m, 2H), 1.53 (m, 2H), 1.05-1.02 (m, 6H), 0.45, 0.34 (2d, 3H, J=6.60, 6.52 Hz).
Compound 357 methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,2,4-oxadiazole-5-carb oxylateCompound 332 (0.03 g, 0.053 mmol) was dissolved in ethanol (20 mL). Sodium carbonate (22 mg) and hydroxylamine (11 mg) were added dropwise to the obtained solution at room temperature, and stirred at 90° C. overnight. After the completion of the reaction, the reaction mixture was cooled down to room temperature, and concentrated under reduced pressure to remove the solvent. The residue was dissolved in pyridine (5 mL). Methyl 2-chloro-2-oxoacetate (20 mg) was added dropwise to the obtained solution at room temperature, and stirred at 40° C. overnight. After the completion of the reaction, the reaction mixture was cooled down to room temperature. The reaction mixture was diluted with EtOAc, washed with saturated ammonium solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (SiO2, Hx:EA=4:1, thus obtaining Compound 357 (5 mg, 45%) as white solid foam.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 8.07 (m, 1H), 7.87 (m, 2H), 7.74 (m, 2H), 7.00, 6.97 (2d, 1H, J=8.64, 8.68 Hz), 5.66, 5.56 (2d, 1H, J=8.12, 8.24 Hz), 4.12 (m, 3H), 4.03 (m, 2H), 3.86 (m, 3H), 3.58-3.36 (m, 1H), 2.45-2.03 (m, 2H), 1.95 (m, 2H), 1.55-1.46 (m, 2H), 1.06-1.01 (m, 6H), 0.39 (m, 3H).
Compound 358 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 354 (0.03 g, 0.042 mmol) was dissolved in methanol/HCl solution. The obtained solution was stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 358 (0.02 g, 77%) as yellow solid.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.99 (m, 1H), 7.92 (m, 2H), 7.40 (m, 1H), 7.20-6.98 (m, 2H), 6.10-6.00 (m, 1H), 5.90-5.80 (m, 1H), 4.20 (m, 1H), 3.82-3.78 (m, 5H), 3.60-3.40 (m, 3H), 2.80 (m, 2H), 2.45-1.85 (m, 4H), 1.55-1.46 (m, 2H), 1.09-1.01 (m, 6H), 0.48, 0.38 (2d, 1H, J=5.64, 6.40 Hz).
Compound 359 methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylateCompound 359 (20 mg, 62.5%) as white solid was obtained according to the same method as the synthesis of compound 110.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 7.24 (m, 1H), 7.00 (m, 1H), 6.85, 6.80 (2d, 1H, J=8.68, 8.64 Hz), 6.00-6.84 (m, 1H), 5.61 (m, 1H), 4.11-3.90 (m, 4H), 3.80-3.44 (m, 9H), 2.52-1.91 (m, 6H), 1.52-1.45 (m, 2H), 1.06-1.01 (m, 6H), 0.39 (2d, 3H); MS (ESI): 681.1 (M+H)+.
Compound 360 (S)-methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyppyrrolidine-2-carboxylateCompound 360 (65 mg, 54%) as colorless oil was obtained according to the same method as the synthesis of compound 356.
MS (ESI) m/z 683.2 (M++H).
Compound 361 (R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzylamino)-3-methylbutanoateCompound 361 (68 mg, 57%) as yellow oil was obtained according to the same method as the synthesis of compound 356.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.72 (s, 2H), 7.16 (dd, 1H, J=8.4, 2.2 Hz), 6.92 (dd, 1H, J=7.4, 2.2 Hz), 6.81-6.74 (m, 1H), 5.60 (dd, 1H, J=3.6, 8.1 Hz), 4.03-3.86 (m, 2.5H), 3.75-3.68 (m, 7H), 3.65-3.41 (m, 2.5H), 3.00-2.94 (m, 1H), 2.45-2.05 (m, 2H), 1.91-1.81 (m, 2H), 1.51-1.42 (m, 2H), 1.03-1.00 (m, 6H), 0.94-0.83 (m, 6H), 0.42, 0.30 (2d, 3H, J=6.6 Hz); MS (ESI) m/z 685.2 (M++H).
Compound 362 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclohex-3-enecarboxylic acidAccording to the same method as the synthesis of Compound 354, the obtained methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclohex-3-enecarboxylate was dissolved in dioxan/water (5 mL, v/v 2:1). Lithium hydroxide (10 mg) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 5 hours. After the completion of the reaction, the reaction mixture was acidified with 2 M HCl solution. The reaction mixture was diluted with EtOAc, was washed with water and brine. The organic layers were collected, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (3:1 hexane:EtOAc), thus obtaining Compound 362 (30 mg, 24%) as white solid foam.
1H NMR (400 MHz, DMSO-d6); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 7.21-7.25 (m, 1H), 6.99-7.00 (m, 1H), 6.78, 6.83 (2d, 1H, J=8.68, 8.68 Hz), 5.94-6.03 (m, 1H), 5.58, 5.61 (2d, 1H, J=8.04, 8.20 Hz), 3.91-4.01 (m, 2H), 3.72-3.78 (m, 3H), 3.49, 3.61 (2d, 1H, J=15.08, 14.68 Hz), 2.10-2.70 (m, 8H), 1.90-1.93 (m, 2H), 1.43-1.53 (m, 2H), 1.01-1.05 (m, 6H), 0.32-0.43 (2d, 3H, J=6.48, 5.76 Hz); MS (ESI) m/z 666 (M++H).
Compound 363 (R)-methyl 2-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)(methyl)amino)-3-methylbutanoateCompound 363 (13 mg, 21%) as colorless oil was obtained according to the same method as the synthesis of compound 112.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (d, 1H, J=4.9 Hz), 7.72 (s, 2H), 7.16 (d, 1H, J=8.4 Hz), 6.90 (d, 1H, J=2.0 Hz), 6.78 (dd, 1H, J=18.2, 8.4 Hz), 5.61-5.57 (m, 1H), 4.03-3.88 (m, 2H), 3.74-3.69 (m, 6H), 3.65-3.30 (m, 3H), 2.79 (dd, 1H, J=7.0, 10.7 Hz), 2.52-2.18 (m, 3H), 2.10-2.01 (m, 3H), 1.92-1.90 (m, 2H), 1.51-1.44 (m, 2H), 1.04-0.95 (m, 9H), 0.87-0.81 (m, 3H), 0.40, 0.27 (2d, 3H, J=6.6 Hz); MS (ESI) m/z 699.2 (M++H).
Compound 364 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(((R)-2-(trifluoromethypp yrrolidin-1-yl)methyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 364 (22 mg, 36%) as colorless oil was obtained according to the same method as the synthesis of compound 356.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (d, 1H, J=4.2 Hz), 7.18 (dd, 0.5; H, J=8.4, 2.1 Hz), 7.10 (dd, 0.5; H, J=8.3, 2.0 Hz), 6.94, 6.88 (2d, 1H, J=2.0 Hz), 6.77 (d, 1H, J=8.4 Hz), 5.60 (dd, 1H, J=14.2, 8.1 Hz), 4.08-3.88 (m, 3H), 3.74, 3.72 (2s, 3H), 3.58, 3.50 (2d, 1H, J=14.8 Hz), 3.42-3.36 (m, 1H), 3.23-3.18 (m, 1H), 2.92-2.70 (m, 1H), 2.47-2.05 (m, 3H), 2.07-1.76 (m, 6H), 1.53-1.43 (m, 2H), 1.03 (d, 6H, J=12.1 Hz), 0.37, 0.29 (2d, 3H, J=6.6 Hz); MS (ESI) m/z 693.1 (M++H).
Compound 366 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-isopropyl-3-methoxypyridin-2-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneAs shown in reaction scheme 8,2-bromopyridin-3-ol, as a starting material, was subjected to the several processes, to synthesize 2-(2-(ethoxycarbonyl)-4,4-dimethylcyclohex-1-enyl)-6-diisopropyl-3-methoxypyridin 1-oxide. The synthesized compound was reacted with diisobutylaluminium hydride (DIBAL-H) and Dess-Martin periodinane (DMP) reagent, thus synthesizing an aldehyde compound. The obtained aldehyde compound was subjected to reductive amination using amino alcohol, thereby an amino alcohol compound was synthesized. 2-(2-(ethoxycarbonyl)-4,4-dimethylcyclohex-1-enyl)-6-diisopropyl-3-methoxypyridin-1-oxide (62 mg, 0.11 mmol), a starting compound, was dissolved in methylene chloride (5 mL). Diisopropylamine (0.11 mL) and triphosgene (0.05 g, 0.16 mmol) were added dropwise to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with EtOAc, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (12 g silica, 3:1=n-hexane:EtOAc, thus obtaining Compound 43 (32 mg, 48.4%) as colorless oil. Compound 43 (32 mg, 0.05 mmol) was dissolved in ethanol (5 mL). Indium (7 mg) and saturated ammonium solution (4 mL) were added dropwise to the obtained solution, and stirred at 80° C. overnight. After the completion of the reaction, the reaction mixture was cooled down to room temperature. The reaction mixture was diluted with EtOAc, washed with water and brine, dried with sodium sulfate anhydrous, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (4 g silica, 1:1=n-hexane:EtOAc, thus obtaining Compound 366 (5 mg, 16.1%) as colorless oil.
1H NMR (400 MHz, DMSO-d6); δ 7.85 (s, 1H), 7.73 (s, 2H), 7.10 (d, 1H, J=8.6 Hz), 7.02 (d, 1H, J=8.5 Hz), 5.54 (d, 1H, J=7.6 Hz), 3.97-4.05 (m, 2H), 3.77 (m, 3H), 3.40 (d, 1H, J=15.0 Hz), 2.94-3.01 (m, 1H), 2.18-2.48 (m, 2H), 1.95 (m, 2H), 1.41-1.55 (m, 2H), 1.20-1.25 (m, 6H), 0.33 (d, 3H, J=6.5 Hz); MS (ESI) m/z 585 (M++H).
Compound 367 (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(((S)-3-fluoropyrrolidin-1-yl)methyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-oneCompound 367 (10 mg, 30%) as white solid foam was obtained according to the same method as the synthesis of compound 356.
1H NMR (400 MHz, CDCl3); atropisomer mixture; δ 7.85 (s, 1H), 7.74 (m, 2H), 7.21-6.95 (m, 2H), 6.82 (2d, 1H, J=8.52, 8.36 Hz), 5.62 (m, 1H), 5.30-5.03 (m, 1H), 4.04-3.91 (m, 2H), 3.76 (m, 3H), 3.70-3.42 (m, 3H), 2.82-2.40 (m, 3H), 2.30-1.98 (m, 4H), 1.94 (m, 2H), 1.53-1.44 (m, 2H), 1.05-1.01 (m, 6H), 0.40 (2d, 1H, J=6.56, 6.52 Hz); MS (ESI): 643.1 (M+H)+.
The chemical structures of compounds 15 to 367 as described above are shown in Tables 1 to 45 below.
Measurement of activities of the compounds of the present invention—experimental protocolsIn order to test the effects of the compounds of formula I of the present invention on the prevention and treatment of arteriosclerosis and hyperlipidemia and the safety thereof, comparative tests were carried out using an existing material as a control.
Experimental Example 1 In Vitro Test for the Ability to Inhibit Cholesteryl Ester Transfer1. Preparation of Cholesteryl Ester Donor
In order to prepare a cholesteryl ester donor to be used in the test, a radiolabeled recombinant HDL containing [3H]-cholesteryl oleate (GE healthcare, TRK886, 3.5 μCi/mg of apoA-1) and apoA-1 was synthesized. Then, rHDL-agarose obtained by immobilizing the recombinant HDL with CNBr-activated Sepharose 4B resin (Amersham Biosciences, Sweden) was used in the test.
2. Cholesteryl Ester Transfer Test
As a source of cholesteryl ester transfer protein, plasma from healthy humans was used, and as cholesteryl ester receptor, LDL from healthy humans was used. Each of test compounds was added to be final concentrations of 16, 80, 400, 2000 and 10000 nM and tested in duplicate. In order to test cholesteryl ester transfer, 20 μl of plasma, 50 μl of LDL (0.25 mg/ml) and 50 μl of rHDL-agarose (0.25 mg/ml) were mixed with each other, and a solution of each test compound was added thereto and reacted thereto at 37° C. Then, the reaction solution was centrifuged at 4° C. for 3 minutes, thereby the reaction was stopped. 150 μl of the supernatant was transferred into a 96-well plate for radioactivity measurement, and the radioactivity thereof was measured with a beta-ray detector.
3. Statistical Processing
The ratio of [3H]-cholesteryl oleate transferred from HDL to LDL was determined, and based on the determined ratio, the IC50 value of each compound was determined using GraphPad Prism 5.0. The results are shown in Table 46 below.
1. Experimental animalsAs Test Animals, 8-Week-Old Male Golden Syrian Hamsters were Purchased and Used in the Experimental.
The animal facility was kept at constant temperature and constant humidity with a 12-hr dark/12-hr light cycle, and the animals were allowed to access food and water ad libitum.
2. Experimental for Anti-Hyperlipidemia Activity in Hamsters
The test animals were used in the test after an acclimation of 1 week. The test animals were divided according to body weight into several groups, each consisting of 5-8 animals. 3 mg/kg of each test compound (CETP inhibitor) was administered orally to the animals. Each test compounds was suspended in a solvent vehicle that is a solution of 5% ethanol, 10% solutol and 85% deionized water (DW), to be used. Each of test compounds suspended in a solvent vehicle was administered orally to the mice for 5 days. To the control group, a solvent vehicle itself was administered. And then, after 4 hours from the last administration, blood was collected through the cardiac puncture. The collected blood was centrifuged at 3000 rpm for 15 minutes, and the concentration of HDL-cholesterol (Biosystem) in the separated serum was measured using a biochemical analyzer (ILab 300 plus, Instrumentation Laboratory).
3. Statistical Processing
All the results were expressed as mean±SEM, and each test group and the control group were compared using one-way ANOVA test (Dunnett's test, p<0.001) in order to determine the effect of each test group. The results are shown in Table 47 below.
Claims
1. Cycloalkenyl aryl derivatives of the following formula 1, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof: —OR7, —CH2OR7, —CH2NR7R8, —SR7, —C(═O)R7, —CH2R7, —CHR7CO2R8, —C(═O)NR7R8, —NR7R8, —NR7C(═O)R8, —NR7CO2R8, —NR7C(═O)NR8R9, —NR7C(═S)NR8R9, Ar or Het; —C1-C6 alkyl, —OC1-C6 alkyl, —C3-C6cycloalkyl, -Ph or
- wherein B1 and B2 are each independently N or C, with the proviso that both B1 and B2 cannot be N at the same time, and if one of B1 and B2 is N, R2 or R5 is absent;
- R1 and R2 are each independently H, —F, —OH, —NH2, —C(═O)H, —CH2OH, —OC1-C6 alkyl, —SC1-C6 alkyl, —CH2OC1-C6 alkyl, —NH(C1-C6 alkyl), —NH(C—O)(C1-C6 alkyl), —N(C1-C6 alkyl)2, or
- R1 and R2 together with the carbon atoms to which they are bonded may form a 5- or 6-membered heterocyclic aromatic or non-aromatic ring compound having 1 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(═O), wherein the heterocyclic aromatic or non-aromatic ring compound may optionally be substituted with R8;
- R3 is —H, —F, —OH, —C1-C6 alkyl, or —OC1-C6 alkyl;
- R4 is —H, halogen, —CN, —NO2, —C1-C6 alkyl, —C2-C6 alkenyl, —C3-C6 cycloalkyl,
- R3 and R4 together with the carbon atoms to which they are bonded may form a 5- or 6-membered cycloalkyl or heterocyclic ring compound having 0 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(═O), wherein the cycloalkyl or heterocyclic ring compound may optionally be substituted with R8;
- Ar is a C6 monocyclic aromatic compound, which is unsubstituted or optionally substituted with one or more selected from the group consisting of halogen, —OH, —NH2, —C1-C6 alkyl and —OC1-C6 alkyl; Het is a 5- or 6-membered heterocyclic ring compound containing 0 to 2 double bonds and having 1 to 4 hetero atoms selected independently from the group consisting of N, O, S, C(═O) and C(═S), and may be unsubstituted or may optionally be substituted with R8;
- R5 is —H, —F, —OH, —CF3, —C1-C6alkyl, or —OC1-C6 alkyl;
- R6 is —H or —C1-C6 alkyl;
- R7 is —H, halogen, —C(═O)(C1-C3 alkyl), —C1-C6 alkyl, —OC1-C6 alkyl, —C3-C6 cycloalkyl, or —OC(═O)(C1-C3 alkyl);
- R8 is —H, halogen, —OH, —CN, —NH2, —NH(C1-C3 alkyl), —C(═O)NH2, —CO2H,
- R9 is —H, —CN, —C1-C6 alkyl, —OC1-C6 alkyl, or —C(═O)(C1-C3 alkyl);
- R10 is —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, or —S(C1-C3 alkyl);
- Z is —CH2—,
- Ra is —H, —Cl or —CF3;
- p is an integer ranging from 0 to 2;
- A1 and A2 are each independently —O—, —(CR11R12)—, or —NR13 wherein R11 and R12 are each independently —H, —F, or —C1-C6 alkyl, or R11 and R12 together form a 3- or 4-membered spirocyclic non-aromatic ring compound, and R13 is —H, —C1-C6 alkyl, —C(═O)(C1-C6 alkyl), —CO2(C1-C6 alkyl), —SO2(C1-C6 alkyl), or —C3-C6 cycloalkyl;
- A3 is —(CH2)n—;
- X is S or O;
- m is an integer ranging from 0 to 3;
- n is an integer ranging from 0 to 2;
- q is an integer ranging from 1 to 3;
- wherein said —C1-C3 alkyl, —C3-C6 cycloalkyl —C1-C6 alkyl or —C2-C6 alkenyl is unsubstituted or substituted with one or more selected from the group consisting of halogen, —OH, —CF3, —CN, —CO2H, —C(═O)CH3, —OC(═O)CH3, —C1-C3alkyl, —OC1-C3alkyl, and -Ph.
2. The cycloalkenyl aryl derivatives of claim 1, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, —N(CH3)2, or —OCH3, —OCH2CH3, —OCH(CH3)2, —OC(CH3)3, —OCF3, —OCH2CF3, —CH2OH, —CH2OCH3, —CH2NR7R8, —SCH3, —C(═O)R7, —CO2R7, —CHR7CO2R8, —C(═O)NR7R8, —NR7R8, —NR7C(═O)R8, —NR7CO2R8, —NR7C(═O)NR8R9, —NR7C(═S)NR8R9, Ar or Het; —C1-C6 alkyl, —OC1-C6 alkyl, —C3-C6 cycloalkyl, -Ph or
- wherein B1 and B2 are each independently N or C, with the proviso that both B1 and B2 cannot be N at the same time, and if any one of B1 and B2 is N, R2 or R5 is absent;
- R is —F, —OH, —NH2, —C(═O)H, —CH2OH, —OCH3, —OCF3, —SCH3, —CH2OCH3, —NHCH3,
- R2 is —H;
- R1 and R2 together with the carbon atoms to which they are bonded may form a 5- or 6-membered heterocyclic aromatic or non-aromatic ring compound having 1 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(═O), wherein the heterocyclic aromatic or non-aromatic ring compound may optionally be substituted with R8;
- R3 is —H, —F, —OH, —CH3, —CF3, —CH2CH3, or —OCH3;
- R4 is —H, —F, —Cl, —CN, —NO2, —CH3, —CH2CH3, —CH(CH3)2, —C(CH3)3, —CF3, —CH(CF3)2, —CH(CH3)(CF3), —C(OCH3)(CF3)2, —CH(OH)CH3, —C(OH)(CH3)2, —C(OH)(CF3)2, —C(═CF2)CF3, -cyclopropyl,
- R3 and R4 together with the carbon atoms to which they are bonded may form a 5- or 6-membered cycloalkyl or heterocyclic ring compound having 0 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(═O), wherein the cycloalkyl or heterocyclic ring compound may optionally be substituted with R8;
- Ar is a C6 monocyclic aromatic compound, which is unsubstituted or optionally substituted with one or more selected from the group consisting of —F, —Cl, —OH, —NH2, —CH3 and —OCH3; Het is selected from
- R5 is —H;
- R6 is —H or —CH3;
- R7 is —H, halogen, —C(═O)(C1-C3 alkyl), —C1-C6 alkyl, —OC1-C6 alkyl, —C3-C6 cycloalkyl, or —OC(═O)(C1-C3 alkyl);
- R8 is —H, halogen, —OH, —CN, —NH2, —NH(C1-C3 alkyl), —C(═O)NH2, —CO2H,
- R9 is —H, —CN, —C1-C6 alkyl, —OC1-C6 alkyl, or —C(═O)(C1-C3 alkyl);
- R10 is —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, or —S(C1-C3 alkyl);
- Z is —CH2—,
- Ra is —H, —Cl or —CF3;
- p is 2;
- A1 is —CH2—, —C(CH3)2—, or —NR13;
- A2 is —O—, —(CR11R12), or —NR13, wherein R11 and R12 are each independently —H, —F, —CH3, —CF3, —CH2CH3, —CH(CH3)2, or —C(CH3)3, or R11 and R12 together form a 3- or 4-membered spirocyclic non-aromatic ring compound, and R13 is —H, —CH3, —CF3, —CH2CH3, —CH(CH3)2, —CH2CF3, —C(═O)CH3, —C(═O)CF3, —CO2C(CH3)3, —SO2CH3, —SO2CF3, or
- A3 is —(CH2)n;
- X is S or O;
- m is an integer ranging from 0 to 3;
- n is an integer ranging from 0 to 2;
- q is an integer ranging from 1 to 3;
- wherein said —C1-C3 alkyl, —C3-C6 cycloalkyl, —C1-C6 alkyl or —C2-C6 alkenyl is unsubstituted or substituted with one or more selected from the group consisting of —F, —Cl, —Br, —OH, —CF3, —CN, —CO2H, —C(═O)CH3, —OC(═O)CH3, —C1-C3 alkyl, —OC1-C3 alkyl, and -Ph.
3. The cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof according to claim 1, wherein the cycloalkenyl aryl derivatives are selected from the group consisting of the following compounds:
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione;
- (4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohept-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclopent-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)cyclopent-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoic acid;
- methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoate;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzoic acid;
- methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzoate;
- (4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(5-isopropyl-2-methoxyphenyl)cyclohept-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-ethyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(hydroxymethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methoxymethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3′-chloro-4,6′-dimethoxybiphenyl-3-yl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(1H-indol-4-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(2-methoxyphenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(dimethylamino)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-5-methoxybenzaldehyde;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(hydroxymethyl)-4-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-methoxy-2-(methoxymethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(quinolin-8-yl)cyclohex-1-enyl)methyl)oxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(1-methyl-1H-indazol-4-yl)cyclohex-1-enyl)methyl)oxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-isopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-morpholinophenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxy-N-methylbenzamide;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-ethyl-4-methoxybenzamide;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxy-N-(2,2,2-trifluoroethyl)benzamide;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxybenzamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)isobutyramide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzaldehyde;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(5-acetyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(2-(trifluoromethoxy)phenyl)cyclohex-1-enyl)methyl)oxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-fluoro-5-(trifluoromethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)ethyl acetate;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramide;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxy-N-methylbenzamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-tert-butyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenypacetamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenypisobutyramide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramide
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(methoxymethyl)-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-tert-butyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)-N-(2,2,2-trifluoroethyl)acetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-acetyl-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenypacetamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluoro-N-methylacetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopyrrolidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopiperidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,5-difluoro-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(methyl)carbamate;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylmethanesulfonamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-N-methylpropanamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1,1,1-trifluoropropan-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetate;
- 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetic acid;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanesulfonamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoromethanesulfonamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylcyclopropanesulfonamide;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylthiourea;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoro-N-methylmethanesulfonamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxoimidazolidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxooxazolidin-3-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(2-amino-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethypphenyl)-4-methyloxazolidin-2-one;
- N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)-N-methylacetamide;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,1-dimethylurea;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methylthio)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,5-dimethyl-2-(2-(methylthio)-5-(trifluoromethoxy)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (Z)-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,1-dimethylguanidine;
- (E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-3-methylguanidine;
- (E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,3,3-trimethylguanidine;
- (Z)-methyl N-3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl-N′-methylcarbamimidothioate;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,3,3-trimethylurea;
- methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1,1,1-trifluoropropan-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(1,1,1-trifluoropropan-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluoroacetamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-bromoacetamide;
- N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)acetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-(methylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(dimethylamino)-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2,2,2-trifluoroacetypphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(perfluoroprop-1-en-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoropropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- tert-butyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(isopropyl)carbamate;
- tert-butyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenykethypcarbamate;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-ethylacetamide;
- (4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(2-methoxy-5-(2,2,2-trifluoro-1-(methoxyimino)ethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-(2-hydroxy-2-methylpropyl)acetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3,3-difluoroazetidine-1-carbonyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(5-acetyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethypphenyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-hydroxyazetidine-1-carbonyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarbonitrile;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarboxamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroacetypphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(cyclopropanecarbonyl)-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(5-amino-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(trifluoromethyl)cyclohex-1-enyl)-4-methoxyphenypacetamide;
- methyl 5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxybenzoate;
- 5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxybenzoic acid;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitro-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(5-amino-2-methoxy-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyptrifluoro-N-methylmethanesulfonamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylacetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(4-(trifluoromethyl)thiazol-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(4-(trifluoromethyl)thiazol-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-N-methylacetamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenypacetamide;
- (4S,5R)-3-((2-(5-amino-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethypphenyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- tert-butyl 3-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-methoxybenzo[d][1,3]dioxol-5-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylisobutyramide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylprop ionamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylmethanesulfonamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-2,2,2-trifluoro-N-methylacetamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)trifluoromethanesulfonamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2,4-dimethoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2,4-dimethoxyphenyl)-N-methylacetamide
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-hydroxy-2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methylamino)-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-ethyl-4-methoxyphenyl)-N-methylacetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((2-hydroxy-2-methylprop yl)(methyl)amino)-2-methoxy-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-cyclopropyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 1-((5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropoxy-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 1-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetate;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-hydroxy-N,2-dimethylpropanamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-4-methyl-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(5-amino-2-methoxy-4-methylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethypphenyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenypacetamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)-N-methylacetamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyptrifluoromethanesulfonamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyptrifluoro-N-methylmethanesulfonamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylethanethioamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(2,2,2-trifluoroacetyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(trifluoromethylsulfonyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((1-acetyl-4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-5-(3,5-bis(trifluoromethypphenyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(methylsulfonyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-isopropyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(2,2,2-trifluoroethyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-thioxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamide;
- methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoate;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoic acid;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-5-isopropyl-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one;
- tert-butyl 6-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-5-methoxyindoline-1-carboxylate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxyindolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(1-acetyl-5-methoxyindolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxy-1-(2,2,2-trifluoroethyl)indolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxy-1-(methylsulfonypindolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- tert-butyl 4-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-3-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((3-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1,2,5,6-tetrahydropyridin-4-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((3-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(2,2,2-trifluoroethyl)-1,2,5,6-tetrahydropyridin-4-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((3-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(trifluoromethylsulfonyl)-1,2,5,6-tetrahydropyridin-4-yl)methyl)-4-methyloxazolidin-2-one;
- methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoate;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoic acid;
- (R)—N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide;
- (S)—N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(2-methoxy-5-nitrophenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((6-(5-amino-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one;
- (R)—N-(3-(5-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide;
- (S)—N-(3-(5-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide;
- (R)—N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-N-methyl-2-phenylpropanamide;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanamide;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanenitrile;
- (4S,5R)-3-((2-(5-(2-(2H-tetrazol-5-yl)ethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3′,5′-difluoro-4-methoxy-4′-(methoxymethoxy)biphenyl-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3′,5′-difluoro-4′-hydroxy-4-methoxybiphenyl-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanamide;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanenitrile;
- methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoate;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoic acid;
- methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutanoate;
- 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutanoic acid;
- ethyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylate;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylic acid;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxamide;
- methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- methyl 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetate;
- 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetic acid;
- 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)-N-methylacetamide;
- 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoic acid;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N,2,2-trimethylpropanamide;
- methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylate;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylic acid;
- 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanoic acid;
- methyl 7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate;
- 7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid;
- methyl 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanoate;
- 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanamide;
- ethyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenethyl)cyclobutanecarboxylate;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenethyl)cyclobutanecarboxylic acid;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzonitrile;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1-methyl-1H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2-methyl-2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- tert-butyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)acetate;
- tert-butyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)acetate;
- (R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)-3-methylbutanoate;
- (R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)-3-methylbutanoate;
- (R)-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)-3-methylbutanoic acid;
- methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoate;
- 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)acetic acid;
- methyl 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoate;
- 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoic acid;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- tert-butyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(hydroxymethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,2,4-oxadiazole-5-carboxylate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate;
- (S)-methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyppyrrolidine-2-carboxylate;
- (R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzylamino)-3-methylbutanoate;
- 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclohex-3-enecarboxylic acid;
- (R)-methyl 2-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)(methyl)amino)-3-methylbutanoate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(((R)-2-(trifluoromethyl)pyrrolidin-1-yl)methyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-isopropyl-3-methoxypyridin-2-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one; and
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(((S)-3-fluoropyrrolidin-1-yl)methyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one.
4. The cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof according to claim 3, wherein the cycloalkenyl aryl derivatives are selected from the group consisting of the following compounds:
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione;
- methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoate;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzaldehyde;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-tert-butyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenypacetamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-tert-butyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,5-difluoro-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(methyl)carbamate;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylmethanesulfonamide;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-N-methylpropanamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1,1,1-trifluoropropan-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoromethanesulfonamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(5-acetyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethypphenyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarbonitrile;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarboxamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroacetypphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(cyclopropanecarbonyl)-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-3-((2-(5-amino-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(trifluoromethyl)cyclohex-1-enyl)-4-methoxyphenypacetamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyptrifluoro-N-methylmethanesulfonamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylacetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(4-(trifluoromethyl)thiazol-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-N-methylacetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-methoxybenzo[d][1,3]dioxol-5-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-2,2,2-trifluoro-N-methylacetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-ethyl-4-methoxyphenyl)-N-methylacetamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-cyclopropyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropoxy-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 1-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetate;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-hydroxy-N,2-dimethylpropanamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)-N-methylacetamide;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyptrifluoro-N-methylmethanesulfonamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(trifluoromethylsulfonyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-isopropyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((4-(4-fluoro-5-isopropyl-2-methoxyphenyl)-1-(2,2,2-trifluoroethyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-methyloxazolidin-2-one;
- methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoate;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoic acid;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-5-isopropyl-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one;
- methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoate;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoic acid;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanenitrile;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one;
- methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoate;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylic acid;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- methyl 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetate;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N,2,2-trimethylpropanamide;
- methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylate;
- 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylic acid;
- 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanamide;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2-methyl-2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one;
- 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoic acid;
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one; and
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-isopropyl-3-methoxypyridin-2-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one.
- (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(((S)-3-fluoropyrrolidin-1-yl)methyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one.
5. Pharmaceutical compositions comprising cycloalkenyl aryl derivatives of formula I, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof according to claim 1 together with pharmaceutically acceptable carriers.
6. The pharmaceutical compositions according to claim 5, wherein the compositions are used for prevention or treatment of dyslipidemia and atherosclerosis associated with dyslipidemia, through increasing of High-density Lipoprotein Cholesterol (HDL-C) and decreasing of Low-density Lipoprotein Cholesterol (LDL-C) by CETP activity inhibition.
7. A method for preparing cycloalkenyl aryl derivatives of formula 1, the method comprising the steps of: subjecting a compound of the following formula 2 to a Vilsmeier reaction to prepare a compound of the following formula 3; subjecting the obtained compound of the formula 3 to a Suzuki reaction with a compound of the following formula 4 in the presence of palladium to prepare a compound of the following formula 5; and wherein, A1, A2, A3, B1, B2, R1, R2, R3, R4, R5, R6, Ra, p and X are came as defined in claim 1; Y is Cl or Br; and Q is —B(OH)2 or
- subjecting the obtained compound of the formula 5 and a compound of the following formula 6 to the reduction to prepare a compound of the following formula 7, and then subjecting the obtained compound of the formula 7 to formation of a ring:
8. A method for preparing cycloalkenyl aryl derivatives of formula 1, the method comprising the steps of: subjecting compound of the following formula 3 and a compound of the following formula 6 to the reduction to prepare a compound of the following formula 8, and then subjecting the obtained compound of the formula 9 to formation of a ring; and wherein, A1, A2, A3, B1, B2, R1, R2, R3, R4, R5, R6, Ra, p and X are same as defined in claim 1; Y is Cl or Br; and Q is —B(OH)2 or
- subjecting the obtained compound of the formula 9 to a Suzuki reaction with a compound of the following formula 4 in the presence of palladium to prepare a compound of the following formula 1:
9. Pharmaceutical compositions comprising cycloalkenyl aryl derivatives of formula I, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof according to claim 3 together with pharmaceutically acceptable carriers.
10. Pharmaceutical compositions comprising cycloalkenyl aryl derivatives of formula I, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof according to claim 2 together with pharmaceutically acceptable carriers.
Type: Application
Filed: Apr 12, 2012
Publication Date: Apr 30, 2015
Patent Grant number: 9371294
Applicant: CHONG KUN DANG PHARMACEUTICAL CORP. (Seoul)
Inventors: SeoHee LEE (Yongin-si), JungTaek OH (Yongin-si), JaeKwang LEE (Yongin-si), JaeWon LEE (Yongin-si), Suyeal BAE (Yongin-si), Nina HA (Yongin-si), Sera LEE (Yongin-si)
Application Number: 14/110,271
International Classification: C07D 263/24 (20060101); C07D 413/08 (20060101); C07D 413/06 (20060101); C07D 417/12 (20060101); C07D 263/16 (20060101);
